Genetic Technologies Limited (GNTLF) F-1/A 12 May 20 Registration statement (foreign) (amended) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Dec. 31, 2019
Cover [Abstract]
Entity Registrant Name	GENETIC TECHNOLOGIES LTD
Entity Central Index Key	0001166272
Amendment Flag	true
Document Type	F-1/A
Amendment Description	Amendment No. 2
Entity Emerging Growth Company	false

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income/ (Loss) - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Revenue from operations
Revenue from contracts with customers	$ 586	$ 18,402
Genetic testing services			$ 25,444	$ 189,254	$ 518,506
Cost of sales of goods	(194,501)	(79,674)	(276,267)	(300,088)	(492,417)
Gross profit (loss) from operations	(193,915)	(61,272)	(250,823)	(110,834)	26,089
Other income	447,756	338,588
Other gains/(losses)	258,078	161,857	(407,482)
General and administrative expenses	(1,747,705)	(1,921,790)	(3,830,198)	(3,015,818)	(3,109,530)
Laboratory, research and development costs	(1,128,124)	(1,401,189)	(2,360,762)	(2,210,498)	(2,366,334)
Selling and marketing expenses	(276,550)	(229,144)	(576,077)	(1,066,404)	(2,721,474)
Operating loss	(2,640,460)	(3,112,950)
Finance expenses	(7,238)	(10,422)	(20,031)	(28,843)	(31,995)
Foreign exchange gains reclassified on liquidation of subsidiary				527,049
Impairment of intangible assets expenses					(544,694)
Non-operating income and expenses			1,019,769	441,476	344,112
Loss before income tax	(2,647,698)	(3,123,372)	(6,425,604)	(5,463,872)	(8,403,826)
Income tax expense
Loss for the period	(2,647,698)	(3,123,372)	(6,425,604)	(5,463,872)	(8,403,826)
Other comprehensive loss
Items that may be reclassified to profit or loss: Exchange gains/(losses) on translation of controlled foreign operations	(381,163)	(54,789)	23,668	(522,966)	(130,655)
Other comprehensive income/(loss) for the year, net of tax	(381,163)		23,668	(522,966)	(130,655)
Total comprehensive loss for the period	(3,028,861)	(3,178,161)	(6,401,936)	(5,986,838)	(8,534,481)
Total comprehensive loss for the period
Owners of Genetic Technologies Limited	$ (3,028,861)	$ (3,178,161)	(6,425,604)	(5,463,872)	(8,403,826)
Non-controlling interests
Total loss for the year			(6,425,604)	(5,463,872)	(8,403,826)
Total comprehensive loss for the year is attributable to:
Owners of Genetic Technologies Limited			(6,401,936)	(5,986,838)	(8,534,481)
Non-controlling interests
Total comprehensive loss for the year			$ (6,401,936)	$ (5,986,838)	$ (8,534,481)
Loss per share for profit from continuing operations attributable to the ordinary equity holders of the company:
Basic earnings per share	$ (0.08)	$ (0.12)
Diluted earnings per share	(0.08)	(0.12)
Loss per share for profit attributable to the ordinary equity holders of the company:
Basic earnings per share	(0.08)	(0.12)
Diluted earnings per share	$ (0.08)	$ (0.12)
Basic and diluted net loss per ordinary share			$ (0.24)	$ (0.22)	$ (0.4)
Weighted-average shares outstanding	3,331,576,766	2,558,004,460	2,635,454,870	2,435,282,724	2,121,638,888

Condensed Consolidated Balance

Condensed Consolidated Balance Sheet - AUD ($)	Dec. 31, 2019		Jun. 30, 2019		Jun. 30, 2018
Current assets
Cash and cash equivalents	$ 3,277,074		$ 2,131,741		$ 5,487,035
Trade and other receivables	440,278		818,766		301,383
Inventories	76,522		31,865		59,007
Other current assets	174,274		213,300
Prepayments and other assets			245,165		202,279
Total current assets	3,968,148		3,195,672		5,990,697
Non-current assets
Right-of-use asset	343,010
Property, plant and equipment	32,448		69,333		175,284
Total non-current assets	375,458		69,333		175,284
Total assets	4,343,606		3,265,005		6,165,981
Current liabilities
Trade and other payables	727,430		1,005,308		945,130
Employee benefit obligations	390,770		487,682
Lease liabilities	224,780
Provisions			487,682		505,583
Total current liabilities	1,342,980		1,492,990		1,450,713
Non-current liabilities
Employee benefit obligations	1,014		809
Lease liabilities	137,307
Provisions			809		3,390
Total non-current liabilities	138,321		809		3,390
Total liabilities	1,481,301		1,493,799		1,454,103
Net assets	2,862,305		1,771,206		4,711,878
EQUITY
Share capital	127,807,987		125,498,824		122,372,662
Other reserves	7,454,278		6,009,932		5,651,162
Retained earnings	(132,399,960)	[1]	(129,737,550)	[1]	(123,311,946)
Total equity	$ 2,862,305		$ 1,771,206		$ 4,711,878
[1]	The group has adopted AASB 16 on 1 July 2019 but has not restated comparatives for the 2019 reporting period, as permitted under the specific transitional provisions in the standard. The reclassifications and the adjustments arising from the new leasing rules are therefore recognised in the opening balance sheet on 1 July 2019.

Condensed Consolidated Statemen

Condensed Consolidated Statement of Changes in Equity - AUD ($)	Issued Capital [Member]	Attributable To Owners of Genetic Technologies Limited Other Reserves [Member]	Retained Earnings [Member]		Parent Interest [Member]	Non-controlling Interests [Member]	Total
Balance at Jun. 30, 2016	$ 115,272,576	$ 6,054,861	$ (109,444,248)		$ 11,883,189		$ 11,883,189
Loss for the year			(8,403,826)		(8,403,826)		(8,403,826)
Other comprehensive income (loss)		(130,655)			(130,655)		(130,655)
Total comprehensive loss		(130,655)	(8,403,826)		(8,534,481)		(8,534,481)
Contributions of equity (net of transaction costs)	6,814,939				6,814,939		6,814,939
Share-based payments		120,287			120,287		120,287
Share facility fee rebate	295,110				295,110		295,110
Transactions with owners in their capacity as owners	7,110,049	120,287			7,230,336		7,230,336
Balance at Jun. 30, 2017	122,382,625	6,044,493	(117,848,074)		10,579,044		10,579,044
Loss for the year			(5,463,872)		(5,463,872)		(5,463,872)
Other comprehensive income (loss)		(522,966)			(522,966)		(522,966)
Total comprehensive loss		(522,966)	(5,463,872)		(5,986,838)		(5,986,838)
Contributions of equity (net of transaction costs)	(9,963)				(9,963)		(9,963)
Share-based payments		129,635			129,635		129,635
Share facility fee rebate
Transactions with owners in their capacity as owners	(9,963)	129,635			119,672		119,672
Balance at Jun. 30, 2018	122,372,662	5,651,162	(123,311,946)		4,711,878		4,711,878
Loss for the year		(54,789)	(3,123,372)				(3,123,372)
Total comprehensive loss		(54,789)	(3,123,372)				(3,178,161)
Contributions of equity (net of transaction costs)	1,346,794						1,346,794
Share-based payments		138,381					138,381
Transactions with owners in their capacity as owners	1,346,794	138,381					1,485,175
Balance at Dec. 31, 2018	123,719,456	5,734,754	(126,435,318)				3,018,892
Balance at Jun. 30, 2018	122,372,662	5,651,162	(123,311,946)		4,711,878		4,711,878
Loss for the year			(6,425,604)				(6,425,604)
Other comprehensive income (loss)		23,668					23,668
Total comprehensive loss		23,668	(6,425,604)				(6,401,936)
Contributions of equity (net of transaction costs)	3,126,162						3,126,162
Share-based payments		341,201					341,201
Reversal of forfeited options		(6,099)					(6,099)
Transactions with owners in their capacity as owners	3,126,162	335,102					3,461,264
Balance at Jun. 30, 2019	125,498,824	6,009,932	(129,737,550)				1,771,206
Balance at Jun. 28, 2019	125,498,824	6,009,932	(129,737,550)				1,771,206
Initial adoption of AASB 16			(14,712)	[1]			(14,712)	[1]
Balance at Jul. 02, 2019	125,498,824	6,009,932	(129,752,262)				1,756,494
Balance at Jun. 30, 2019	125,498,824	6,009,932	(129,737,550)				1,771,206
Loss for the year							(2,647,698)
Other comprehensive income (loss)							(381,163)
Total comprehensive loss							(3,028,861)
Share-based payments							33,771
Issue of options to underwriters							1,873,720
Balance at Dec. 31, 2019	127,807,987	7,454,278	(132,399,960)				2,862,305
Balance at Jul. 02, 2019	125,498,824	6,009,932	(129,752,262)				1,756,494
Loss for the year		(381,163)	(2,647,698)				(3,028,861)
Total comprehensive loss		(381,163)	(2,647,698)				(3,028,861)
Contributions of equity (net of transaction costs)	2,309,163						2,309,163
Share-based payments		33,771					33,771
Reversal of forfeited options		(81,982)					(81,982)
Issue of options to underwriters		1,873,720					1,873,720
Transactions with owners in their capacity as owners	2,309,163	1,825,509					4,134,672
Balance at Dec. 31, 2019	$ 127,807,987	$ 7,454,278	$ (132,399,960)				$ 2,862,305
[1]	See note 1 for details regarding the restatement as a result of a change in accounting policy.

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Cash Flows - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Cash flows from / (used in) operating activities
Receipts from customers	$ 586	$ 156,959	$ 204,768	$ 758,452	$ 964,520
Payments to suppliers and employees	(3,675,822)	(3,875,281)	(6,575,163)	(6,757,243)	(8,077,083)
R&D tax incentive and other grants received	805,231		297,213	362,258	260,159
Interest received	10,754	15,320	25,790	15,218	38,765
Net cash flows from/(used in) operating activities	(2,859,251)	(3,703,002)	(6,073,182)	(5,636,533)	(6,852,404)
Cash flows (used in)/ from investing activities
Repayment of loans by related parties	43,380
Proceeds from the sale of plant and equipment	37,002				52,650
Payments for property, plant and equipment	(2,521)	(3,255)	(50,309)	(2,385)	(234,799)
Interest received			25,849	15,218	38,765
Payments for investments in related parties			(500,000)
Net cash flows (used in)/ from investing activities	77,861	(3,255)	(524,460)	12,833	(143,384)
Cash flows (used in)/ from financing activities
Proceeds from issues of shares and other equity securities	4,499,965	1,350,000	3,557,509		8,049,369
Interest paid	(34,684)
Share issue cost	(317,082)	(3,206)	(431,347)	(9,963)	(1,234,430)
Lease payments	(99,723)
Facility fee rebate					295,110
Net cash flows (used in)/ from financing activities	4,048,476	1,346,794	3,126,162	(9,963)	7,110,049
Net (decrease)/ increase in cash and cash equivalents	1,267,086	(2,359,463)	(3,471,480)	(5,633,663)	114,261
Cash and cash equivalents at the beginning of the financial year	2,131,741	5,487,035	5,487,035	10,988,255	11,179,687
Effects of exchange rate changes on cash and cash equivalents	(121,753)	107,068	116,186	132,443	(305,693)
Cash and cash equivalents at end of the half-year	$ 3,277,074	$ 3,234,640	$ 2,131,741	$ 5,487,035	$ 10,988,255

Basis of Preparation of Half-Ye

Basis of Preparation of Half-Year Report	6 Months Ended
	Dec. 31, 2019
Basis Of Preparation Of Half-year Report
Basis of Preparation of Half-Year Report	1 Basis of preparation of half-year report This condensed consolidated interim financial report for the half-year reporting period ended 31 December 2019 has been prepared in accordance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001. These financial statements also comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), as applicable to interim financial reporting. This interim report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2019 and any public announcements made by Genetic Technologies Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period and the adoption of the new and amended standards as set out below. The Interim Financial Statements have been approved and authorised for issue by the board on 26 February 2020. The Company has prepared the interim financial statements to conform to the requirements and needs of users of the financial statements located in both Australia and the U.S. U.S. users: The Company has prepared the interim financial statements to conform to the requirements of IAS 34 Interim Financial Reporting. Consistent with U.S. domestic registrants, the Company has labelled the interim financial information “unaudited” because the interim financial information is not subject to an audit by our independent registered public accounting firm. The auditor’s independence declaration and independent auditor’s review report are included within this filing to meet the requirements of Australian laws and regulations and are furnished, not filed, for the purposes of incorporation of the related financial statements in any U.S. registration document. Australian users: The Company has prepared the interim financial statements to conform to the requirements of the Corporations Act 2001 and AASB 134 Interim Financial Reporting. A review of the interim financial information has been performed by the Company’s independent auditors to meet the requirements of Australian Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity and users should refer to the auditor’s independence declaration and independent auditor’s review report included within this filing. (a) Going concern For the half-year ended 31 December 2019, the group incurred an operating loss of $2,647,698 (31 December 2018: $3,123,372) and net assets as at 31 December 2019 were $2,862,305 (30 June 2019: $1,771,206). The group’s cash position at 31 December 2019 was $3,277,074 (30 June 2019: $2,131,741). The following matters have been considered by the directors in determining the appropriateness of the going concern basis of preparation: During the 2020 financial year, the Directors expect stable cash outflows from operations as the Company continues to invest resources in expanding the research & development activities in support of the distribution of existing and new products. As a result of these expected cash outflows to support the announcement of the launch of further new genetic testing products, the Directors intend to raise further new equity funding in order to ensure the Company continues to hold adequate levels of available cash resources to meet creditors and other commitments and to deliver on partner expectations in the USA. The Company intends to raise further equity financing in the near future, but there can be no assurance that we will be successful in this regard. In addition to planned equity financing in Australia and the US market through existing and new investors, the group has access to an equity placement facility with Kentgrove Capital Pty Ltd. Under this equity placement facility the group has an opportunity to raise equity funding of up to $20 million in a series of individual placements of up to $1 million(or a higher amount by mutual agreement), expiring 7 April 2020. The Group currently does not have any binding commitments under this facility and the quantum and timing of capital raised will be subject to the market price and trading volumes of our ordinary shares. At the date of this report the group is in negotiations to replace the Kentgrove facility with a new facility from an alternative provider. The continuing viability of the Company and its ability to continue as a going concern and meet its debts and commitments as they fall due is dependent on both the satisfactory completion of planned equity raisings in the next three months, along with the successful commercialisation of existing and new products. In order to progress towards commercialisation and scale-up the operations the Company will require ongoing funding in the near term whilst the products become established in the market. Due to the uncertainty surrounding the timing, quantum or the ability to raise additional equity, there is a material uncertainty that may cast significant doubt on the Group’s ability to continue as a going concern and therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business. However, the Directors believe that the Group will be successful in the above matters and accordingly, have prepared the financial report on a going concern basis. As such no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should the Group not be able to continue as a going concern. References to matters that may cast significant doubt about the Group’s ability to continue as a going concern also raise substantial doubt as contemplated by the Public Company Accounting Oversight Board (“PCAOB”) standards. (b) New and amended standards adopted by the group During the reporting period the following amended standard became applicable for the current reporting period and the group had to change its accounting policies as a result of adopting this standard: • AASB 16 Leases. The impact of the adoption of this standard and the new accounting policy is disclosed below. (c) Impact of new and amended standards adopted by the Company (i) AASB 16 Leases AASB 16 will result in almost all leases being recognised on the balance sheet, as the distinction between operating and finance leases is removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognised. The only exceptions are short-term and low-value leases. On adoption of AASB 16, the group recognised lease liabilities in relation to leases which had previously been classified as ‘operating leases’ under the principles of AASB117 Leases. These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate as of 1 July 2019. The weighted average lessee’s incremental borrowing rate applied to the lease liabilities on 1 July 2019 was 5.37%. The associated right-of use assets were measured at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the balance sheet as at 1 July 2019. There were no onerous lease contracts that would have required an adjustment to the right-of-use assets at the date of initial application. In applying AASB 16 for the first time, the group has used the following practical expedients permitted by the standard: • the use of a single discount rate to a portfolio of leases with reasonably similar characteristics. The group has also elected not to reassess whether a contract is, or contains a lease at the date of initial application. Instead, for contracts entered into before the transition date the group relied on its assessment made applying AASB 117 and interpretation 4 determining whether an arrangement contains a Lease. 31 Dec 2019 Operating lease commitments disclosed as at 30 June 2019 $ 487,837 Discounted using the lessee’s incremental borrowing rate of at the date of initial application $ 461,358 Lease liability recognised as at 1 July 2019 $ 461,358 Of which are: Current lease liabilities $ 209,887 Non-current lease liabilities $ 251,471 Right of use of assets increased by $ 446,645 Lease liabilities increased by $ 461,358 The net impact on retained earnings on 1 July 2019 was a decrease of $ 14,712 Loss per share decreased by 0.03c per share for the six months to 31 December 2019 as a result of the adoption of AASB 16. (d) Accounting policies applied from 1 July 2019 From 1 July 2019, leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: ● fixed payments (including in-substance fixed payments), less any lease incentives receivable ● variable lease payment that are based on an index or a rate ● amounts expected to be payable by the lessee under residual value guarantees ● the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and ● payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be determined, the lessee’s incremental borrowing rate is used, being the rate that the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions. Right-of-use assets are measured at cost comprising the following: ● the amount of the initial measurement of lease liability ● any lease payments made at or before the commencement date less any lease incentives received ● any initial direct costs, and ● restoration costs. Payments associated with short-term leases and leases of low-value assets are recognised on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less.

Corporate Information

Corporate Information	12 Months Ended
	Jun. 30, 2019
CORPORATE INFORMATION
Corporate Information	1. CORPORATE INFORMATION The Financial Report of Genetic Technologies Limited (the “Company”) for the year ended June 30, 2019 was authorized for issue in accordance with a resolution of the Directors dated September 30, 2019. Genetic Technologies Limited is incorporated in Australia and is a company limited by shares. The Directors have the power to amend and reissue the financial statements. The Company’s Ordinary Shares are publicly traded on the Australian Securities Exchange under the symbol GTG and, via Level II American Depositary Receipts, on the Nasdaq Capital Market under the ticker GENE.

Other Income and Expense Items

Other Income and Expense Items	6 Months Ended
	Dec. 31, 2019
Other Income And Expense Items
Other Income and Expense Items	3 Other income and expense items (a) Other income Consolidated entity 31 December 31 December R&D Grant Income (i) 400,000 186,000 Other 47,756 152,588 447,756 338,588 (i) Government grants The group's research and development activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the half year ended 31 December 2019, the group has included an item in other income of $400,000 (2018: $186,000) to recognise income over the period necessary to match the grant on a systematic basis with the costs that they are intended to compensate.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2019
Summary Of Significant Accounting Policies
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of preparation Compliance with International Financial Reporting Standards as issued by the International Accounting Standards Board The Financial Report complies with the International Financial Reporting Standards as issued by the International Accounting Standards Board. Historical cost convention These financial statements have been prepared under the historical cost convention except for financial assets and liabilities (including derivative instruments) which are measured at fair value. Critical accounting estimates The preparation of financial statements requires the use of certain critical accounting estimates. It also requires Management to exercise its judgement in the process of applying the Company’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are critical to the financial statements, are disclosed in Note 3. Going concern For the year ended 30 June 2019, the Company incurred a total comprehensive loss of $6,401,936 (2018: $5,986,838) and net cash outflow from operations of $6,073,182 (2018: $5,636,533). As at 30 June 2019 the Company held total cash and cash equivalents of $2,131,741. During the 2020 financial year, the Directors expect stable cash outflows from operations as the Company continues to invest resources in expanding the research & development activities in support of the distribution of existing and new products. As a result of these expected cash outflows to support the announcement of the launch of further new genetic testing products, the Directors intend to raise further new equity funding in order to ensure the Company continues to hold adequate levels of available cash resources to meet creditors and other commitments and to deliver on partner expectations in China and the USA. The Company intends to raise further equity financing in October 2019, but there can be no assurance that we will be successful in this regard. The Company does not currently have binding commitments from any party to subscribe for shares and any raise will be subject to maintaining active listing on the NASDAQ exchange as well as compliance with the Company’s obligations under ASX Listing Rule 7.1. In addition to the plans to raise capital in the US, the Company has recorded a receivable at 30 June 2019 from the Australian Taxation Office in respect of the 2019 research and development tax incentive claim which the Company expects to receive this in October 2019. The Company also has access to equity placement facility with Kentgrove Capital Pty Ltd whereby it has an opportunity to raise equity funding of up to $20 million in a series of individual placements of up to $1 million (or a higher amount by mutual agreement), expiring 7 April 2020. The Company currently does not have any binding commitments under this facility and the quantum and timing of capital raised will be subject to the market price and trading volumes of our ordinary shares. The continuing viability of the Company and its ability to continue as a going concern and meet its debts and commitments as they fall due is dependent on the satisfactory completion of planned equity raisings in October of 2019. Due to the uncertainty surrounding the timing, quantum or the ability to raise additional equity, there is a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern and therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business. However, the Directors believe that the Company will be successful in the above matters and accordingly, have prepared the financial report on a going concern basis. As such no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should the Company not be able to continue as a going concern. As a U.S. SEC registrant, the Company is required to have its financial statements audited in accordance with Public Company Oversight Board (“PCAOB”) standards. References in these IFRS financial statements to matters that may cast significant doubt about the Company’s ability to continue as a going concern also raise substantial doubt as contemplated by the PCAOB standards. (b) New accounting standards and interpretations Standards and Interpretations affecting amounts reported in the current period (and/or prior period) The Company has applied the following standards and amendments for the first time for their annual reporting period commencing July 1, 2018: IFRS 9 Financial Instruments IFRS 9 Financial Instruments IFRS 9 introduced a new expected loss impairment model that requires entities to account for expected credit losses at the time of recognizing the asset. The adoption of the new standard did not have a material impact on its classification and measurement of the financial assets and liabilities or its results on adoption of the new impairment model. IFRS 15 Revenue from Contracts with Customers IFRS 15 provides a single, principles based five-step model to be applied to all contracts with customers. Guidance is provided on topics such as the point in which revenue is recognized, accounting for variable consideration, costs of fulfilling and obtaining a contract and various related matters. The adoption of this standard applies to the recognition of the sales related to the BREVAGEN plus Other new standards affecting the current reporting period The company also adopted the following standards during the period. ● Classification and Measurement of Share-based Payment Transactions (Amendments to IFRS 2) ● Interpretation 22 Foreign Currency Transactions and Advance Consideration. The adoption of these amendments did not have any impact on the current period or any prior period and is not likely to affect future periods. Certain new accounting standards and interpretations have been published that are not mandatory for June 30, 2019 reporting periods and have not been early adopted by the Company. The Company’s assessment of the impact of these new standards and interpretations is set out below. Standards and interpretations in issue but not yet adopted Title of IFRS 16 Leases Nature of change IFRS 16 was issued in February 2016. It will result in almost all leases being recognised on the consolidated balance sheet by lessees, as the distinction between operating and finance leases is removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognised. The only exceptions are short-term and low-value leases. Impact The Company has reviewed all leasing arrangements in light of the new lease accounting rules in IFRS 16. The standard will affect the accounting for the Company’s operating leases. As at the reporting date, the Company has non-cancellable operating lease commitments of $487,849. The Company expects to recognise at 1 July 2019 right-of-use assets of an amount approximating the nominal value of these non-cancellable operating lease commitments, discounted at the Company’s incremental borrowing rate. A corresponding lease liability will offset the amount recognised as a right-of-use asset at 1 July 2019. Overall net current assets will be $14,712 lower due to the presentation of a portion of the liability as a current liability. In financial year 2020, the operating cash flows will increase and financing cash flows decrease by approximately $221,281 as repayment of the principal portion of the lease liabilities will be classified as cash flows from financing activities. Mandatory application date/Date of adoption by the Company The Company will apply the standard from its mandatory adoption date of July 1, 2019. The Company intends to apply the simplified transition approach and will not restate comparative amounts for the year prior to first adoption. Right-of-use assets for property leases will be measured on transition as if the new rules had always been applied. All other right-of-use assets will be measured at the amount of the lease liability on adoption (adjusted for any prepaid or accrued lease expenses). There are no other new standards and interpretations that are not yet effective and that would be expected to have a material impact on the Company in the current or future reporting periods and on foreseeable future transactions. (c) Principles of consolidation Subsidiaries The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Genetic Technologies Limited (the “Company” or “Parent Entity”) as at June 30, 2019 and the results of all subsidiaries for the year then ended. Genetic Technologies Limited and its subsidiaries together are referred to in this Financial Report as the “Company” or the “Consolidated Entity”. Subsidiaries are all entities (including structured entities) over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement within the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases. Intercompany transactions, balances and unrealized gains / losses on transactions between Company companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the Company’s policies. Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of comprehensive income, consolidated balance sheet and consolidated statements of changes in equity, respectively. (d) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing the performance of the operating segments, has been identified as the Chief Executive Officer. (e) Parent entity financial information The financial information for the parent entity, Genetic Technologies Limited has been prepared on the same basis as the consolidated financial statements, except that investments in subsidiaries are accounted for at cost in the financial statements of Genetic Technologies Limited. Loans to subsidiaries are written down to their recoverable value as at balance date. (f) Foreign currency translation The functional and presentation currency of Genetic Technologies Limited and its Australian subsidiaries is the Australian dollar (AUD). Transactions in foreign currencies are initially recorded in the functional currency at the exchange rates ruling at the date of the transaction. Monetary assets and liabilities which are denominated in foreign currencies are retranslated at the rate of exchange ruling at the balance sheet date. All differences are taken to the statement of comprehensive income. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate ruling at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates ruling at the date when the fair value was determined. The functional currencies of the Company’s two overseas subsidiaries are as follows: GeneType Corporation — United States dollars (USD) Phenogen Sciences Inc. — United States dollars (USD) As at the reporting date, the assets and liabilities of these subsidiaries are translated into the presentation currency of Genetic Technologies Limited at the rate of exchange ruling at the balance sheet date and the statement of comprehensive income is translated at the weighted average exchange rates for the period unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions. The exchange differences arising on the retranslation are recognized in other comprehensive income and taken directly to a separate component of equity. On disposal of a foreign entity, the deferred cumulative amount recognized in equity relating to that particular foreign operation is recognized in the statement of comprehensive income. (g) Earnings per share (“EPS”) Basic EPS is calculated by dividing the profit attributable to owners of the Company, excluding any costs of servicing equity other than Ordinary Shares, by the weighted average number of Ordinary Shares outstanding during the financial year. Diluted EPS adjusts the figures used in the determination of basic EPS to take into account the after income tax effect of interest and other financing costs associated with dilutive potential Ordinary Shares and the weighted average number of Ordinary Shares that would have been outstanding assuming the conversion of all dilutive potential Ordinary Shares. (h) Revenue recognition IFRS 15 supersedes IAS 11 Construction Contracts, IAS18 Revenue and related interpretations and it applies to all revenue arising from contracts with customers, unless those contracts are in the scope of other standards. The new standard has been applied as at 1 July 2018 using the modified retrospective approach and establishes a five-step model to account for revenue arising from contracts with customers. Under IFRS 15, revenue is recognised at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The standard requires entities to exercise judgement, taking into consideration all of the relevant facts and circumstances when applying each step of the model to contracts with their customers. The standard also specifies the accounting for the incremental costs of obtaining a contract and the costs directly related to fulfilling a contract. The adoption of IFRS 15 has not impacted the amounts disclosed within the financial statements. The following recognition criteria must also be met before revenue is recognized: Genetic testing revenues The Company operates facilities which provide genetic testing services. The Company recognises revenue from the provision of these services when the services have been completed. Interest received Income is recognized as the interest accrues using the effective interest method. Government Grants Research and development tax incentive The Australian government replaced the research and development tax concession with research and development (R&D) tax incentive from July 1, 2011. The R&D tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after July 1, 2011. A refundable tax offset is available to eligible companies with an annual aggregate turnover of less than $20 million. Management has assessed the Company’s activities and expenditure to determine which are likely to be eligible under the incentive scheme. The Company accounts for the R&D tax incentive as a government grant. The grant is recognized as other income over the period in which the R&D expense is recognized. Other Other Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received and the company will comply with all attached conditions. (i) Share-based payment and performance rights transactions The fair value of options granted under an Employee Option Plan is recognized as an employee benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognized over the vesting period over which all of the specified vesting conditions are to be satisfied. The fair value at grant date is determined by management with the assistance of an independent valuer, using a Black-Scholes option pricing model or a Monte Carlo simulation analysis. The total amount to be expensed is determined by reference to the fair value of the options granted. ● including any market performance conditions (e.g., the entity’s share price) ● excluding the impact of any service and non-market performance vesting conditions (e.g., remaining an employee over a specified time period) The cumulative employee benefits expense recognized at each reporting date until vesting date reflects (i) the extent to which the vesting period has expired; and (ii) the number of awards that, in the opinion of the Directors of the Company, will ultimately vest. This opinion is formed based on the best information available at balance date. Where the terms of an equity-settled award are modified, as a minimum an expense is recognized as if the terms had not been modified. In addition, an expense is recognized for any increase in the value of the transaction as a result of the modification, as at the date of modification. Where appropriate, the dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share. The Company’s policy is to treat the options of terminated employees as forfeitures. The Performance Rights are not currently quoted on the ASX and as such have no ready market value. The Performance Rights each grant the holder a right of grant of one ordinary Share in the Company upon vesting of the Performance Rights for nil consideration. Accordingly, the Performance Rights may have a present value at the date of their grant. Various factors impact upon the value of Performance Rights including: ● the period outstanding before the expiry date of the Performance Rights; ● the underlying price or value of the securities into which they may be converted; ● the proportion of the issued capital as expanded consequent upon conversion of the Performance Rights into Shares (i.e. whether or not the shares that might be acquired upon exercise of the options represent a controlling or other significant interest); and ● the value of the shares into which the Performance Rights may be converted. There are various formulae which can be applied to determining the theoretical value of options (including the formula known as the Black-Scholes Model valuation formula and the Monte Carlo simulation). With the assistance of an independent valuer, the Company performed a valuation of the Performance Rights. The independent valuer has applied the Monte Carlo simulation in providing the valuation of the Performance Rights. As the Performance Rights have market event hurdles for vesting, the valuation has been provided with a range of underlying share prices. Inherent in the application of the Monte Carlo simulation are a number of inputs, some of which must be assumed. The data relied upon in applying the Monte Carlo simulation was: a) a range of prices analysed from 0.5 cents per share to 1.5 cents per share (being an approximate 50% discount to a 50% premium) from GTG’s current share price of 1.1 cents per share as at October 5, 2018 for all classes of Performance Rights; b) exercise price being 0.0 cents per Performance Right for all classes; c) VWAP hurdle (10 days consecutive share price hurdle) equaling 2.0 cents for Class A and Class B and 3.3 cents for Class C Performance Rights; d) the continuously compounded risk free rate being 2.02% for all classes of Performance Rights (calculated with reference to the RBA quoted Commonwealth Government bonds as at October 8, 2018 of similar duration to that of the expected life of each class of Performance Right); Performance Rights. As the Performance Rights have market event hurdles for vesting, the valuation has been provided with a range of underlying share prices. Inherent in the application of the Monte Carlo simulation are a number of inputs, some of which must be assumed. The data relied upon in applying the Monte Carlo simulation was: e) a range of prices analysed from 0.5 cents per share to 1.5 cents per share (being an approximate 50% discount to a 50%premium) from GTG’s current share price of 1.1 cents per share as at October 5, 2018 for all classes of Performance Rights; f) exercise price being 0.0 cents per Performance Right for all classes; g) VWAP hurdle (10 days consecutive share price hurdle) equaling 2.0 cents for Class A and Class B and 3.3 cents for Class C Performance Rights; h) the continuously compounded risk free rate being 2.02% for all classes of Performance Rights (calculated with reference to the RBA quoted Commonwealth Government bonds as at October 8, 2018 of similar duration to that of the expected life of each class of Performance Right); i) the expected option life of 2.8 years for all classes of Performance Rights; and j) a volatility measure of 80%. (j) Income tax The income tax expense or revenue for the period is the tax payable on the current period’s taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company’s subsidiaries and associates operate and generate taxable income. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in controlled entities where the parent entity is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity. Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively. Tax consolidation legislation Genetic Technologies Limited (“GTG”) and its wholly-owned Australian-resident subsidiaries have implemented the tax consolidation legislation. The head entity, GTG, and the subsidiaries in the tax consolidated Company account for their own current and deferred tax amounts. These tax amounts are measured as if each entity in the tax consolidated Company continues to be a stand-alone taxpayer in its own right. In addition to its own current and deferred tax amounts, GTG also recognizes the current tax assets / liabilities and the deferred tax assets arising from unused tax losses and tax credits assumed from subsidiaries in the tax consolidated Company. Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognized as amounts receivable from or payable to other entities in the Company. Any difference between the amounts assumed and amounts receivable or payable under the tax funding agreements are recognized as a contribution to (or distribution from) wholly-owned tax subsidiaries. (k) Other taxes Revenues, expenses and assets are recognized net of the amount of Goods and Services Tax (GST) except where the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognized as part of the cost of acquisition of the asset or as part of the expense item as applicable; and receivables and payables are stated with the amount of GST included. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet. Cash flows are included in the cash flow statement on a gross basis and the GST component arising from investing and financing activities, which is recoverable from / payable to the taxation authority, are classified as operating cash flows. (l) Withholding tax The Company generates revenues from the granting of licenses to parties resident in overseas countries. Such revenues may, in certain circumstances, be subject to the deduction of local withholding tax. In such cases, revenues are recorded net of any withholding tax deducted. (m) Finance costs Finance costs are recognized using the effective interest rate method. (n) Cash and cash equivalents Cash and cash equivalents in the balance sheet comprise cash at bank and in hand and short-term deposits with an original maturity of 3 months or less. For the purposes of the cash flow statement, cash and cash equivalents consist of cash and cash equivalents as defined above. Cash at bank earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods, depending on the immediate cash requirements of the Company, and earn interest at the respective short-term deposit rates. (o) Trade and other receivables Trade receivables, which are non-interest bearing and generally have terms of between 30 to 90 days, are recognized and carried at original invoice amount less an allowance for any uncollectible amounts. For the comparative periods prior to July 1, 2018, an allowance for doubtful debts is made when there is objective evidence that a receivable is impaired. Such evidence includes an assessment of the debtor’s ability and willingness to pay the amount due. The amount of the allowance/impairment loss is measured as the difference between the carrying amount of the trade receivables and the estimated future cash flows expected to be received from the relevant debtors. The Company has applied IFRS 9 from July 1, 2018. To measure the loss allowance on trade receivables, the Company uses the simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables assets would be grouped based on shared credit risk characteristics and the days past due. (p) Inventories Inventories principally comprise laboratory and other supplies and are valued at the lower of cost and net realizable value. Inventory costs are recognized as the purchase price of items from suppliers plus freight inwards and any applicable landing charges. Costs are assigned on the basis of weighted average cost. (q) Property, plant and equipment Plant and equipment is stated at cost less accumulated depreciation and any impairment in value. Depreciation is calculated on a straight-line basis over the estimated useful life of the respective asset as follows: Laboratory equipment — 3 to 5 years Computer equipment — 3 years Office equipment — 3 to 5 years Leasehold improvements — lease term, being between 1 and 3 years Costs relating to day-to-day servicing of any item of property, plant and equipment are recognized in profit or loss as incurred. The cost of replacing larger parts of some items of property, plant and equipment are capitalized when incurred and depreciated over the period until their next scheduled replacement, with the replacement parts being subsequently written off. (r) Intangible assets Patents Patents held by the Company are used in the licensing, testing and research areas and are carried at cost and amortized on a straight-line basis over their useful lives, being 10 years. External costs incurred in filing and protecting patent applications, for which no future benefit is reasonably assured, are expensed as incurred. Research and development costs Costs relating to research activities are expensed as incurred. An intangible asset arising from development expenditure on an internal project is recognized only when the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the development and the ability to measure reliably the expenditure attributable to the intangible asset during its development. To date, all development costs have been expensed as incurred as their recoverability cannot be regarded as assured. (s) Impairment of assets The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, the Company makes an estimate of the asset’s recoverable amount. An asset’s recoverable amount is the higher of its fair value less costs of disposal or its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset’s value-in-use cannot be estimated to be close to its fair value. In such cases, the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Impairment losses relating to operations are recognized in those expense categories consistent with the function of the impaired asset unless the asset is carried at its revalued amount, in which case the impairment loss is treated as a revaluation decrease. An assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset’s recoverable amount since the last impairment loss was recognized. If so, the carrying amount of the asset is increased to its recoverable amount. The increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in profit or loss unless it reverses a decrement previously charged to equity, in which case the reversal is treated as a revaluation increase. After such a reversal, the depreciation charge is adjusted in future periods to allocate the asset’s revised carrying amount, less any residual value, on a systematic basis over its remaining useful life. (t) Employee benefits (i) Short-term obligations Provision is made for employee benefits accumulated as a result of empl

Critical Accounting Estimates A

Critical Accounting Estimates And Judgements	12 Months Ended
	Jun. 30, 2019
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS
Critical Accounting Estimates and Judgements	3. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS Estimates and judgements are evaluated and based on historical experience and other factors, including expectations of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances. Critical accounting estimates and assumptions The carrying amounts of certain assets and liabilities are often determined based on estimates and assumptions of future events. The key estimates and assumptions that have a significant risk of causing a material adjustment to the carrying value of certain assets and liabilities within the next annual reporting period are set out below. Share-based payments transactions The Company measures the cost of equity-settled transactions with employees by reference to the value of the equity instruments at the date on which they are granted. Management determined the fair value with the assistance of an independent valuer using a Black-Scholes and Monte Carlo simulation options pricing model.

Cost of Sales

Cost of Sales	12 Months Ended
	Jun. 30, 2019
COST OF SALES
Cost of Sales	4. COST OF SALES Consolidated 2019 2018 2017 A$ A$ A$ Inventories used 55,995 93,869 172,070 Direct labour costs 103,601 88,690 152,767 Depreciation expense 55,480 65,853 71,139 Inventories written off (1) 61,191 51,676 96,441 Total cost of sales 276,267 300,088 492,417 (1) Inventories written off include $Nil (2018: $24,506 and 2017: $53,856) of items that expired during the year.

Non Operating Income and Expend

Non Operating Income and Expenditure	12 Months Ended
	Jun. 30, 2019
NON OPERATING INCOME AND EXPENDITURE
Non Operating Income and Expenditure	5. NON OPERATING INCOME AND EXPENDITURE 2019 2018 2017 Net profit on disposal of plant and equipment — — 52,188 Research and development tax incentive 856,707 299,351 253,159 Export Marketing & Development Grant — 126,907 — Interest income 25,794 15,218 38,765 Rental income — — — Other income 137,268 — — Total non operating income and expenditure 1,019,769 441,476 344,112

Foreign Exchange Gain Reclassif

Foreign Exchange Gain Reclassified on Liquidation of Subsidiary	12 Months Ended
	Jun. 30, 2019
FOREIGN EXCHANGE GAIN RECLASSIFIED ON LIQUIDATION OF SUBSIDIARY
Foreign Exchange Gain Reclassified on Liquidation of Subsidiary	6. FOREIGN EXCHANGE GAIN RECLASSIFIED ON LIQUIDATION OF SUBSIDIARY Reclassification of net foreign exchange gains previously recognised in other comprehensive income, reclassified to profit or loss Nil Total gain on liquidation of subsidiary Nil Total gain is attributable to the liquidation of GeneType AG, a dormant subsidiary, that was completed on 13 December 2017

Other Gains _ (Losses)

Other Gains / (Losses)	12 Months Ended
	Jun. 30, 2019
OTHER GAINS / (LOSSES)
Other Gains / (Losses)	7. OTHER GAINS / (LOSSES) Consolidated 2019 2018 2017 A$ A$ A$ Net foreign exchange gains/(losses) 92,518 — — Net impairment losses(1) (500,000 ) — — Total other gains / (losses) (407,482 ) — — (1) In August 2018, the Company invested $250,000 into Swisstec towards the proposed joint venture to enable the Company and Swisstec to collaborate to develop a medical and health service platform using blockchain technology. The Company has recorded an impairment against the investment during the financial year ended June 30, 2019, due to cessation of activities in relation to the joint venture. (1) In December 2018, Genetic Technologies Limited entered and invested $250,000 into a Joint Venture agreement with Blockshine Health Pty Ltd. with an ownership of 49%. The Company has recorded an impairment against the investment during the financial year ended June 30, 2019, due to the cancellation of the project.

Expenses

Expenses	12 Months Ended
	Jun. 30, 2019
Expenses by nature [abstract]
Expenses	8. EXPENSES Consolidated 2019 2018 2017 A$ A$ A$ Amortization of intangible assets — — 63,783 Depreciation of fixed assets 156,248 303,749 307,828 Employee benefits expenses 2,414,408 2,657,232 3,594,936 Operating lease expenses 312,956 326,192 310,413 Research and development expenses 310,703 459,026 418,598

Income Tax

Income Tax	12 Months Ended
	Jun. 30, 2019
Major components of tax expense (income) [abstract]
Income Tax	9. INCOME TAX Consolidated 2019 2018 2017 A$ A$ A$ Reconciliation of income tax expense to prima facie tax payable Loss before income tax expense (6,425,604 ) (5,463,872 ) (8,403,826 ) Tax at the Australian tax rate of 27.50% (2018: 27.50% and 2017: 28.50%) (1,767,041 ) (1,502,565 ) (2,311,052 ) Tax effect amounts which are not deductible/(taxable) in calculating taxable income Share-based payments expense 92,153 35,650 33,079 Research and development tax incentive 541,596 148,346 108,163 Other non-deductible items 590 1,509 1,257 Other assessable items — — 81,155 (1,132,702 ) (1,317,060 ) (2,087,398 ) Difference in overseas tax rates 41,009 67,557 (96,775 ) Under /(over) provision 1,126,722 (268,092 ) (75,054 ) Temporary differences not recognized (121,965 ) — — Research and development tax credit (238,084 ) (82,322 ) (69,619 ) Tax losses not recognized 325,020 1,599,917 2,328,846 Income tax expense — — — Net deferred tax assets Deferred tax assets not recognized Property, plant and equipment 863 1,381 2,802 Capital raising costs 232,328 347,370 320,417 Applera settlement — — — Intangible assets 1,893,220 1,949,601 2,003,505 Provisions 187,958 201,492 333,103 Other — — — Total deferred tax assets 2,314,369 2,499,844 2,659,827 Deferred tax liabilities not recognized Prepayments — — — Total deferred tax liabilities — — — Net deferred tax assets on temporary differences not brought to account (2,314,369 ) (2,499,844 ) (2,659,827 ) Total net deferred tax assets — — — Consolidated 2019 2018 2017 A$ A$ A$ Tax losses Unused tax losses for which no deferred tax asset has been recognized 90,254,547 87,970,140 80,706,629 Potential tax benefit 27.50% (2016: 28.50%) 23,104,882 22,596,182 22,194,323 Subject to the Company continuing to meet the relevant statutory tests, the tax losses are available for offset against future taxable income. At June 30, 2019, the Company had a potential tax benefit related to tax losses carried forward of $23,104,882 (2018:22,596,182). Such amount includes net losses of $5,541,152 (2018:$5,155,038) related to subsidiaries in the United States (U.S.). The Tax Cuts and Jobs Act (TCJA) enacted by Congress in the U.S. on December 22, 2017 cut the top corporate income tax rate from 35% to 21%. For tax years beginning after December 31, 2017, the graduated corporate tax rate structure is eliminated and corporate taxable income will be taxed at 21-percent flat rate. Additionally, the previous 20-year limitation on carry forward net operating losses (NOL’s) has been removed, allowing the NOL’s to be carried forward indefinitely. The remaining tax losses carried forward of $ 17,563,730 (2018:17,441,144) are indefinite and are attributable to the Company’s operations in Australia. As such the total unused tax losses available to the Company, equal $23,104,882 (2018:$22,596,182). As at balance date, there are unrecognized tax losses with a benefit of approximately $23,104,882 (2018: $22,596,182 and 2017: $22,194,323) that have not been recognized as a deferred tax asset to the Company. These unrecognized deferred tax assets will only be obtained if: (a) The Company companies derive future assessable income of a nature and amount sufficient to enable the benefits to be realized; (b) The Company companies continue to comply with the conditions for deductibility imposed by the law; and (c) No changes in tax legislation adversely affect the Company companies from realizing the benefit. Tax consolidation legislation Genetic Technologies Limited and its wholly-owned Australian subsidiaries implemented the tax consolidation legislation as from July 1, 2003. The accounting policy in relation to this legislation is set out in Note 2(j). The entities in the tax consolidated Company have entered into a Tax Sharing Agreement which, in the opinion of the Directors, limits the joint and several liabilities of the wholly-owned entities in the case of a default by the head entity, Genetic Technologies Limited. The entities have also entered into a Tax Funding Agreement under which the wholly-owned entities fully compensate Genetic Technologies Limited for any current tax payable assumed and are compensated by Genetic Technologies Limited for any current tax receivable and deferred tax assets relating to unused tax losses or unused tax credits that are transferred to Genetic Technologies Limited under the tax consolidation legislation. The funding amounts are determined by reference to the amounts recognized in the respective subsidiaries’ financial statements. The amounts receivable or payable under the Tax Funding Agreement are due upon receipt of the funding advice from the head entity, which is issued as soon as practicable after the end of each financial year. As at June 30, 2019, there are no unrecognised temporary differences associated with the Company’s investments in subsidiaries, as the Company has no liability for additional taxation should unremitted earnings be remitted (2017: $nil).

Loss Per Share

Loss Per Share	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Loss per share for profit attributable to the ordinary equity holders of the company:
Loss Per Share	5 Loss per share (a) Basic/diluted loss per share Consolidated entity 31 December 31 December From continuing operations (0.08 ) (0.12 ) (b) Reconciliation of earnings used in calculating earnings per share Consolidated entity 31 December 31 December Basic earnings per share Loss attributable to the ordinary equity holders of the company used in calculating basic/diluted earnings per share: From continuing operations 2,647,698 3,123,372 (c) Weighted average number of shares used as denominator Consolidated entity 31 December 31 December Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share 3,331,576,766 2,558,004,460	10. LOSS PER SHARE The following reflects the income and share data used in the calculations of basic and diluted loss per share: 2019 2018 2017 Loss for the year attributable to the owners of Genetic Technologies Limited (6,425,604 ) (5,463,872 ) (8,403,826 ) Weighted average number of Ordinary Shares used in calculating loss per share 2,635,454,870 2,435,282,724 2,121,638,888 Note: None of the 114,250,000 (2018: 55,102,778 and 2017: 75,102,778) options/performance rights over the Company’s Ordinary Shares that were outstanding as at the reporting date are considered to be dilutive for the purposes of calculating diluted earnings per share.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Jun. 30, 2019
Cash and cash equivalents [abstract]
Cash And Cash Equivalents	11. CASH AND CASH EQUIVALENTS Consolidated 2019 2018 2017 A$ A$ A$ Reconciliation of cash and cash equivalents Cash at bank and on hand 2,131,741 5,487,035 10,988,255 Total cash and cash equivalents 2,131,741 5,487,035 10,988,255 Reconciliation of loss for the year Reconciliation of loss for the year after income tax to net cash flows used in operating activities is as follows: Loss for the year after income tax (6,425,604 ) (5,463,872 ) (8,403,826 ) Adjust for non-cash items Amortization and depreciation expenses 156,260 303,749 371,611 Impairment of intangible assets — 544,694 Impairment of investments 500,000 Share-based payments expense 335,102 129,635 120,287 interest classified as investing cash flows (25,850 ) 15,219 — Net (profit) / loss on disposal of plant and equipment — — (52,188 ) Net (gains) / losses on liquidation of subsidiary — (527,049 ) — Net foreign exchange (gains) / losses (92,518 ) (128,360 ) 175,038 Adjust for changes in assets and liabilities (Increase) / decrease in trade and other receivables (517,383 ) 124,889 204,501 (Increase) / decrease in prepayments and other assets (42,885 ) 14,843 103,488 Increase / (decrease) in trade and other payables 60,178 47,027 60,120 Increase / (decrease) in provisions (20,482 ) (122,176 ) 62,636 Net cash flows from / (used in) operating activities (6,073,182 ) (5,636,533 ) (6,813,639 ) Financing facilities available As at June 30, 2019, the following financing facilities had been negotiated and were available: Total facilities Credit cards 95,714 183,770 306,128 Facilities used as at reporting date Credit cards (6,516 ) (12,031 ) (12,428 ) Facilities unused as at reporting date Credit cards 89,198 171,739 293,700

Trade and Other Receivables (Cu

Trade and Other Receivables (Current)	12 Months Ended
	Jun. 30, 2019
Trade and other current receivables [abstract]
Trade and Other Receivables (Current)	12. TRADE AND OTHER RECEIVABLES (CURRENT) Consolidated 2019 2018 A$ A$ Trade receivables 16,529 10,503 Less: 2019: Impairment allowance / 2018: provision for doubtful debts — — Net trade receivables 16,529 10,503 Other receivables* 802,237 290,880 Total net current trade and other receivables 818,766 301,383 ● Other receivables majorly consists of R&D income grant receivable. Note: Trade and other receivables for the Company include amounts due in US dollars of USD Nil (2018: USD 7,114). Refer Note 28 for details of aging, interest rate and credit risks applicable to trade and other receivables for which, due to their short-term nature, their carrying value approximates their fair value.

Prepayments and Other Assets (C

Prepayments and Other Assets (Current)	12 Months Ended
	Jun. 30, 2019
PREPAYMENTS AND OTHER ASSETS (CURRENT)
Prepayments and Other Assets (Current)	13. PREPAYMENTS AND OTHER ASSETS (CURRENT) 2019 2018 Prepayments 159,844 139,767 Inventories at the lower of cost and net realizable value 31,865 59,007 Performance bond and deposits 53,456 3,505 Total current prepayments and other assets 245,165 202,279

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jun. 30, 2019
Disclosure of detailed information about property, plant and equipment [abstract]
Property, Plant and Equipment	14. PROPERTY, PLANT AND EQUIPMENT Consolidated 2019 2018 A$ A$ Laboratory equipment, at cost 1,451,389 1,451,389 Less: accumulated depreciation (1,410,877 ) (1,355,397 ) Net laboratory equipment 40,512 95,992 Computer equipment, at cost 609,550 609,550 Add: additions during the year 47,715 — Less: accumulated depreciation (628,868 ) (563,208 ) Net computer equipment 28,397 46,342 Office equipment, at cost 167,564 167,564 Less: accumulated depreciation (167,564 ) (166,807 ) Net office equipment — 757 Equipment under hire purchase, at cost 594,626 594,626 Less: accumulated depreciation (594,626 ) (594,626 ) Net equipment under hire purchase — — Leasehold improvements, at cost 462,797 462,797 Add: additions during the year 2,583 Less: accumulated depreciation (464,956 ) (430,604 ) Net leasehold improvements 424 32,193 Total net property, plant and equipment 69,333 175,284 Reconciliation of property, plant and equipment Opening gross carrying amount 3,285,926 3,283,541 Add: additions purchased during the year 50,297 2,385 Less: disposals made during the year — — Closing gross carrying amount 3,336,223 3,285,926 Opening accumulated depreciation and impairment losses (3,110,642 ) (2,806,893 ) Add: disposals made during the year — — Less: depreciation expense charged (156,248 ) (303,749 ) Closing accumulated depreciation and impairment losses (3,266,890 ) (3,110,642 ) Total net property, plant and equipment 69,333 175,284 Reconciliation of movements in property, plant and equipment by asset category Opening Closing net carrying Additions Disposals Depreciation net amount during year during year expense amount Asset category A$ A$ A$ A$ A$ Laboratory equipment 95,992 — — (55,480 ) 40,512 Computer equipment 46,342 47,714 — (66,416 ) 28,397 Leasehold improvements 32,193 2,583 — (34,352 ) 424 Totals 175,284 50,297 — (156,248 ) 69,333

Trade and Other Payables (Curre

Trade and Other Payables (Current)	12 Months Ended
	Jun. 30, 2019
Trade and other payables [abstract]
Trade and Other Payables (Current)	15. TRADE AND OTHER PAYABLES (CURRENT) Consolidated 2019 2018 A$ A$ Trade payables 590,231 535,924 Other payables 68,423 222,502 Accrued expenses 346,654 186,704 Total current trade and other payables 1,005,308 945,130 Note: Trade payables for the Company include amounts due in US dollars of USD 126,829 (2018: USD 116,063) and Swiss francs of CHF 0 (2017: CHF 380). Refer Note 28 for details of management of interest rate, foreign exchange and liquidity risks applicable to trade and other payables for which, due to their short-term nature, their carrying value approximates their fair value.

Provisions (Current and Non-Cur

Provisions (Current and Non-Current)	12 Months Ended
	Jun. 30, 2019
Provisions [abstract]
Provisions (Current and Non-Current)	16. PROVISIONS (CURRENT AND NON-CURRENT) 2019 2018 A$ A$ Current provisions Annual leave 152,352 145,449 Long service leave 243,740 268,544 Make good * 91,590 91,590 Total current provisions 487,682 505,583 Non-current provisions Long service leave 809 3,390 Make good * — — Total non-current provisions 809 3,390 Total provisions 488,491 508,973 * Make good provision Genetic Technologies Limited is required to restore the leased premises situated in Fitzroy, Melbourne to their original condition at the end of the lease terms. A provision has been recognized for the present value of the estimated expenditure required to remove any leasehold improvements. These costs have been capitalized as part of the cost of leasehold improvements and are amortized over the shorter of the term of the lease or the useful life of the assets. See Note 2 (u) for the Company’s other accounting policies relevant to provisions. Consolidated 2019 2018 A$ A$ Reconciliation of annual leave provision Balance at the beginning of the financial year 145,499 239,821 Add: obligation accrued during the year 91,106 155,967 Less: utilized during the year (84,253 ) (250,289 ) Balance at the end of the financial year 152,352 145,499 Reconciliation of long service leave provision Balance at the beginning of the financial year 271,933 299,739 (Less)/ Add: obligation accrued during the year 10,226 (27,806 ) Less: utilized during the year (37,610 ) — Balance at the end of the financial year 244,549 271,933 Note: The current provisions for annual leave and long service leave include a total amount of $335,655 (2018: $325,421) in respect of obligations which, based on historical evidence, the Company estimates will be settled more than 12 months from balance date.

Equity

Equity	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Disclosure of classes of share capital [abstract]
Equity	4 Equity 31 December 31 December 30 June 30 June Fully paid 4,063,134,143 127,807,987 2,938,134,143 125,498,824 (a) Share capital (i) Movements in ordinary shares Details Number of $ Balance at 1 July 2019 2,938,134,143 125,498,824 Rights issue* 1,125,000,000 4,499,965 Less: transaction costs arising on share issue - (2,190,802 ) Balance at 31 December 2019 4,063,134,143 127,807,987 *On 11 October 2019, the company invited its shareholders to subscribe to a fully underwritten rights issue of 1,125,000,000 ordinary shares at an issue price of $0.4 cents per share on the basis of 1 new share for every 2 fully paid ordinary shares held. (ii) Rights of each type of share Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the group in proportion to the number of shares held. On a show of hands every holder of ordinary shares present at a meeting or by proxy, is entitled to one vote. Upon a poll every holder is entitled to one vote per share held. The ordinary shares have no par value. (b) Other reserves Consolidated entity Share- based Foreign Total Balance at 1 July 2018 4,885,232 765,930 5,651,162 Currency translation differences - 23,668 23,668 Other comprehensive income for the period - 23,668 23,668 Transactions with owners in their capacity as owners Share-based payment expenses 341,201 - 341,201 Reversal of forfeited options (6,099 ) (6,099 ) At 30 June 2019 5,220,334 789,598 6,009,932 Consolidated entity Share- based Foreign Total Balance at 1 July 2019 5,220,334 789,598 6,009,932 Currency translation differences - (381,163 ) (381,163 ) Other comprehensive income for the period - (381,163 ) (381,163 ) Transactions with owners in their capacity as owners Share-based payment expenses 33,771 - 33,771 Reversal of forfeited performance rights (81,982 ) - (81,982 ) Issue of options to underwriters 1,873,720 - 1,873,720 At 31 December 2019 7,045,843 470,648 7,516,491 Details Number of Number of Total Balance at 1 July 2019 76,250,000 38,000,000 5,220,334 Reversal of forfeited performance rights (61,250,000 ) - (81,982 ) Issue of Options to underwriters - 500,000,000 1,873,720 Share based payment expense - - 33,771 Balance 31 December 2019 15,000,000 538,000,000 7,045,843 The following are the valuation details towards the options issued to underwriters for the capital raise in October 2019. 2019 Grant Date 30 Oct 2019 Options issued 250,000,000 Dividend yield - Historic volatility and expected volatility 136 % Option exercise price $ 0.008 Fair value of options at grant date $ 0.003 Weighted average exercise price $ 0.008 Risk-free interest rate 0.78 % Expected life of an option 3 years Model used Black-Scholes 2019 Grant Date 20 Dec 2019 Options issued 250,000,000 Dividend yield - Historic volatility and expected volatility 136 % Option exercise price $ 0.008 Fair value of options at grant date $ 0.004 Weighted average exercise price $ 0.008 Risk-free interest rate 0.85 % Expected life of an option 3 years Model used Black-Scholes	17. CONTRIBUTED EQUITY Consolidated 2019 2018 A$ A$ Issued and paid-up capital Fully paid Ordinary Shares 125,498,824 122,372,662 Total contributed equity 125,498,824 122,372,662 Movements in shares on issue Year ended June 30, 2018 Shares $ Balance at the beginning of the financial year 2,435,282,724 122,382,625 Less: transaction costs arising on share issue — (9,963 ) Balance at the end of the financial year 2,435,282,724 122,372,662 Year ended June 30, 2019 Shares $ Balance at the beginning of the financial year 2,435,282,724 122,372,662 Shares issued during the year 502,851,419 3,557,509 Less: transaction costs arising on share issue (431,347 ) Balance at the end of the financial year 2,938,134,143 125,498,824 Terms and conditions of contributed equity Ordinary shares have the right to receive dividends as declared and, in the event of winding up the Company, to participate in the proceeds from the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares, which have no par value, entitle their holder to one vote, either in person or by proxy, at a meeting of the Company. Capital management When managing capital, Management’s objective is to ensure that the Company continues as a going concern as well as to provide returns for shareholders and benefits for other stakeholders. Management also aims to maintain a capital structure to reduce the entity’s cost of capital.

Reserves

Reserves	12 Months Ended
	Jun. 30, 2019
Disclosure of reserves within equity [abstract]
Reserves	18. RESERVES Consolidated 2019 2018 A$ A$ Foreign currency translation 789,598 765,930 Share-based payments 5,220,334 4,885,232 Total reserves 6,009,932 5,651,162 Reconciliation of foreign currency translation reserve Balance at the beginning of the financial year 765,930 1,288,896 Add: net currency translation gain / (loss) 23,668 (522,966 ) Balance at the end of the financial year 789,598 765,930 Reconciliation of share-based payments reserve Balance at the beginning of the financial year 4,885,232 4,755,597 Add: share-based payments expense 341,201 129,635 Less: Reversal of forfeited/lapsed options (6,099 ) Balance at the end of the financial year 5,220,334 4,885,232 Nature and purpose of reserves Foreign currency translation reserve This reserve is used to record exchange differences arising from the translation of the financial statements of foreign subsidiaries. Share-based payments reserve This reserve is used to record the value of share-based payments provided to employees and others providing similar services as part of their remuneration.

Accumulated Losses

Accumulated Losses	12 Months Ended
	Jun. 30, 2019
ACCUMULATED LOSSES
Accumulated Losses	19. ACCUMULATED LOSSES Balance at the beginning of the financial year (123,311,946 ) (117,848,074 ) Add: net loss attributable to owners of Genetic Technologies Limited (6,425,604 ) (5,463,872 ) Balance at the end of the financial year (129,737,550 ) (123,311,946 )

Options

Options	12 Months Ended
	Jun. 30, 2019
Options
Options	20. OPTIONS The fair value of options granted under an Employee Option Plan is recognised as an employee benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognized over the vesting period over which all of the specified vesting conditions are to be satisfied. The fair value at grant date is determined by management with the assistance of an independent valuer, using a Black-Scholes option pricing model or a Monte Carlo simulation analysis. The total amount to be expensed is determined by reference to the fair value of the options granted; · · The cumulative employee benefits expense recognised at each reporting date until vesting date reflects (i) the extent to which the vesting period has expired; and (ii) the number of awards that, in the opinion of the Directors of the Company, will ultimately vest. This opinion is formed based on the best information available at balance date. Where the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any increase in the value of the transaction as a result of the modification, as at the date of modification. Where appropriate, the dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share. The Company’s policy is to treat the options of terminated employees as forfeitures. On November 30, 2001, the Directors of the Company established a Staff Share Plan. On November 19, 2008, the shareholders of the Company approved the introduction of a new Employee Option Plan. Under the terms of the respective Plans, the Directors may, at their discretion, grant options over the ordinary shares in the Genetic Technologies Limited to executives, consultants, employees, and former Non-Executive Directors, of the Company. During the year 16,000,000 options over ordinary shares were granted pursuant the Employee Option Plan. The following information relates to ordinary shares granted pursuant to the Employee Option Plan at no cost for year ended 30 June 2019; Set out below are summaries of all listed and unlisted options, including ESOP: Ave. exercise price per option Number of options and performance rights As at 1 July $ 0.017 55,102,778 Granted to KentGrove Capital $ 0.015 12,500,000 Granted to employees during the year $ 0.010 16,000,000 Lapsed during the year $ 0.020 (19,236,111 ) Forfeited during the year $ 0.001 (6,000,000 ) Lapse of unlisted options attached to convertible notes $ 0.015 (20,366,667 ) As at 30 June $ 0.015 38,000,000 Note: On August 8, 2018, the Company announced that it issued the following securities to Kentgrove Capital Pty Ltd: · · · Fair value of options granted The options granted to Kentgrove Capital Pty Ltd were valued based on the following: 2019 Grant Date 08 Aug 2018 Options issued 12,500,000 Dividend yield — Historic volatility and expected volatility 80 % Option exercise price $ 0.0153 Weighted average exercise price $ 0.0153 Risk-free interest rate 2.02 % Expected life of an option 3 years Model used Black-Scholes Fair value of options at grant date $ 0.0040 As at June 30, 2019, the following options over Ordinary Shares in the Company were outstanding. 2019 Weighted ave. exercise price 2018 Weighted ave. exercise price Unlisted employee options (refer below) 25,500,000 $ 0.015 34,736,111 $ 0.017 Unlisted options attached to convertible notes — — 20,366,667 $ 0.015 Unlisted options granted to KentGrove Capital 12,500,000 $ 0.015 — — 38,000,000 $ 0.015 55,102,778 $ 0.016 On November 30, 2001, the Directors of the Company established a Staff Share Plan. On November 19, 2008, the shareholders of the Company approved the introduction of a new Employee Option Plan. Under the terms of the respective Plans, the Directors of the Company may grant options over Ordinary Shares in Genetic Technologies Limited to executives, consultants and employees of the Company. The options, which are granted at nil cost, are not transferable and are not quoted on the ASX. As at June 30, 2019, there was 1 executive and 12 employees who held options that had been granted under the Plans. Options granted under the Plans carry no rights to dividends and no voting rights. The movements in the number of options granted under the Plans are as follows: 2019 Weighted ave. exercise price 2018 Weighted ave. exercise price Unlisted employee options Balance at the beginning of the financial year 34,736,111 $ 0.017 54,736,111 $ 0.016 Add: options granted during the year 16,000,000 $ 0.010 — — Less: options lapsed during the year (19,236,111 ) $ 0.020 — — Less: options forfeited during the year (6,000,000 ) $ 0.010 (20,000,000 ) $ 0.014 Balance at the end of the financial year 25,500,000 $ 0.015 34,736,111 $ 0.017 There were no options exercised under the Employee Option Plan during the year ended June 30, 2019 (2018: Nil). The numbers of options outstanding as at June 30, 2019 by ASX code, including the respective dates of expiry and exercise prices, are tabled below (refer Note 23 for further information). The options tabled below are not listed on ASX. Option description 2019 Weighted ave. exercise price 2018 Weighted ave. exercise price Unlisted employee options Options to Kentgrove (expiring August 8, 2021) 12,500,000 $ 0.015 — — GTGAD (expiring September 14, 2020) — — — — GTGAD (expiring November 24, 2020) — — 19,236,111 $ 0.020 GTGAD (expiring March 31, 2021) 5,000,000 $ 0.020 5,000,000 $ 0.020 GTGAD (expiring February 16, 2022) 5,500,000 $ 0.010 10,500,000 $ 0.010 ESOP options (expiring December 11, 2021) 15,000,000 $ 0.010 — — Balance at the end of financial year 38,000,000 $ 0.015 34,736,111 $ 0.017 Unlisted options attached to convertible notes GTGAC (expiring December 2, 2018) — — 20,366,667 $ 0.015 Balance at the end of the financial year 38,000,000 $ 0.015 55,102,778 $ 0.016 Exercisable at the end of the financial year 38,000,000 $ 0.015 48,102,778 $ 0.017 The weighted average remaining contractual life of options outstanding as at June 30, 2019 was 2.16 years (2018: 1.94 years).

Segment Information

Segment Information	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Disclosure of operating segments [abstract]
Segment Information	2 Segment information (a) Description of segments and principal activities The company has identified a sole operating segment as reported that is consistent with the internal reporting provided to the chief operating decision maker and is aligned to the one major revenue stream. (b) Business Segments The segment information for the reportable segment for the half-year 31 December 2019 is as follows: Consolidated entity Sales Other Totals Profit /(loss) Operations 586 447,756 448,342 (2,647,698 ) December 2018 Operations 18,402 338,588 356,990 (3,123,372 ) Consolidated entity Assets Liabilities Amortisation/ Purchases Operations 4,343,606 (1,481,301 ) (39,561 ) 2,521 June 2019 Operations 3,265,005 (1,493,799 ) (156,248 ) 5,353 (c) Geographic information · Australia: · USA: · Switzerland: The segment information for the reportable segment for the half-year 31 December 2019 and 2018 is as follows: Consolidated entity Sales Other Totals Profit/(loss) Australia - 447,756 447,756 (2,418,577 ) U.S. 586 - 586 (229,121 ) Total 586 447,756 448,342 (2,647,698 ) December 2018 Australia - 338,588 338,588 (1,580,663 ) U.S. 18,402 - 18,402 (1,542,709 ) Total 18,402 338,588 356,990 (3,123,372 ) Genetic Technologies recognises expenses per the Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income by function. To assist with the readers understanding of the nature of such expenses, the following costs have been included within the respective line items Within General and administrative expenses, depreciation amounting to $12,156 (2018: $12,199) has been recognised in respect of Property, plant and equipment at 31 December 2019, whilst an amount of $103,635 has been recognised for Leased Assets following the adoption of the new AASB 16 Leasing standard. An amount of $27,405 (2018: $28,408) has been included in Cost of goods sold reflecting the depreciation for laboratory specific equipment in the six-month period. Employee expenses of $675,822 (2018: $1,100,509) have been included within Laboratory and Research and Development for the 6 month period, with a proportion of the total employee expenses, $109,581 (2018: 32,670), being allocated to Cost of goods sold -representing the wages incurred by the laboratory specific employees. (d) Segment assets The internal management reporting presented to key business decision makers report total assets on the basis consistent with that of the consolidated financial statements. These reports do not allocate assets based on the operations of each segment or by geographical location. Under the current management reporting framework, total assets are not reviewed to a specific reporting segment or geographical location. (e) Segment liabilities The internal management reporting presented to key business decision makers report total liabilities on the basis consistent with that of the consolidated financial statements. Under the current management reporting framework, total liabilities are not reviewed to a specific reporting segment or geographical location. (f) Segment products and locations The principal geographical segment in Australia, with the company's headquarters being located in Melbourne in the State of Victoria, however the key sales activities take place in the U.S. (g) Major customers During the period ended 31 December 2019 and 31 December 2018 there was no customer from whom the company generated revenues representing more than 10% of the total consolidated revenue from operations or outstanding receivables. (h) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operation decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing the performance of the operating segments, has been identified as the Chief Executive Officer.	21. SEGMENT INFORMATION Identification of reportable segments The Company has identified a sole operating segment as reported that is consistent with the internal reporting provided to the chief operating decision maker and is aligned to the one major revenue stream. The Company’s operating segment is summarized as follows: Business segments Revenues and income Segment Sales Other Totals Profit / (loss) A$ A$ A$ A$ Operations 2019 25,444 1,019,769 1,045,213 (6,425,604 ) 2018 189,254 441,476 630,730 (5,463,872 ) 2017 518,506 344,112 862,618 (8,403,826 ) Amortization Purchases of Segment Assets Liabilities /depreciation equipment A$ A$ A$ A$ Operations 2019 3,265,005 (1,493,799 ) (156,248 ) 5,353 2018 6,165,981 (1,454,103 ) (303,749 ) 2,385 2017 12,108,297 (1,529,253 ) (371,611 ) 234,799 Geographic information Australia U.S. Switzerland Geographic information Revenues and income Sales Other Totals Profit/(Loss) A$ A$ A$ A$ Australia 2019 5,247 1,019,769 1,025,016 (5,791,950 ) 2018 — 441,476 441,476 (3,504,098 ) 2017 18,215 344,112 362,327 (7,000,994 ) U.S. 2019 20,197 — 20,197 (633,654 ) 2018 189,254 — 189,254 (1,959,774 ) 2017 500,291 — 500,291 (1,371,001 ) Other 2019 — — — — 2018 — — — — 2017 — — — (31,831 ) Totals 2019 25,444 1,019,769 1,045,213 (6,425,604 ) 2018 189,254 441,476 630,730 (5,463,872 ) 2017 518,506 344,112 862,618 (8,403,826 ) Segment assets: The internal management reporting presented to key business decision makers report total assets on the basis consistent with that if the consolidated financial statements. These reports do not allocate assets based on the operations of each segment or by geographical location. Under the current management reporting framework, total assets are not reviewed to a specific reporting segment or geographical location. Segment Liabilities: The internal management reporting presented to key business decision makers report total liabilities on the basis consistent with that if the consolidated financial statements. Under the current management reporting framework, total liabilities are not reviewed to a specific reporting segment or geographical location. Other revenues and income Expenses Included in the above figures are the following intersegment balances and transactions: Consolidated 2019 2018 2017 A$ A$ A$ Foreign exchange gain (U.S.) and foreign exchange loss (Australia) 291,542 981,141 776,295 Cost of sales (U.S.) and sales (Australia) 9,708 38,352 74,762 Segment products and locations The principal geographic segment is Australia, with the Company’s headquarters being located in Melbourne in the State of Victoria however the key sales activities take place in the U.S.. Major customers During the years ended June 30, 2019 and June 30, 2018 there was no customer from whom the Company generated revenues representing more than 10% of the total consolidated revenue from operations or outstanding receivables.

Share Based Payments

Share Based Payments	12 Months Ended
	Jun. 30, 2019
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Share Based Payments	22. SHARE BASED PAYMENTS (a) Employee option plan On November 30, 2001, the Directors of the Company established a Staff Share Plan. On November 19, 2008, the shareholders of the Company approved the introduction of a new Employee Option Plan. Under the terms of the respective Plans, the Directors may, at their discretion, grant options over the Ordinary Shares in the Genetic Technologies Limited to executives, consultants, employees, and former Non-Executive Directors, of the Company. During the year 16,000,000 options over Ordinary Shares were granted pursuant the Employee Option Plan. The following information relates to Ordinary Shares granted pursuant to the Employee Option Plan at no cost for year ended 30 June 2019; i. 16,000,000 unlisted options (Expiring on December 11, 2021 with an exercise price of $0.01 vesting on 30 June 2019) over Ordinary Shares pursuant to the Employee Option Plan were granted. The fair value of each option granted is estimated by an external valuer using a Black-Scholes option-pricing model, with assumptions as follows: 2019 Grant Date 12 Dec 2018 Options issued 16,000,000 Dividend yield — Historic volatility and expected volatility 80 % Option exercise price $ 0.010 Weighted average exercise price $ 0.030 Risk-free interest rate 2.02 % Expected life of an option 2.8 years Model used Black-Scholes Fair value of options at grant date $ 0.0051 As at 30 June 2019, there were 14 employee who held options that had been granted under the Plan. During the financial year 2018 no options over ordinary shares were granted pursuant the Employee Option Plan. The following information relates to ordinary shares granted pursuant to the Employee Option Plan at no cost for year ended 30 June 2017; The following information relates to Ordinary Shares granted pursuant to the Employee Option Plan at no cost for year ended 30 June 2017; i. 1,250,000 options to a number of employees of the Company’s US Subsidiary, Phenogen Sciences Inc. The options vest based on non-market performance conditions (requirement to remain employed by the Company) in three tranches commencing on the date of the 2017 Annual General Meeting (AGM) of the Company and then at each of the 12 and 24 month anniversaries thereafter. The fair value of each option granted is estimated by an external valuer using a Black-Scholes option-pricing model, with assumptions as follows 2017 Grant Date 17 Feb 2017 Options issued 1,250,000 Dividend yield — Historic volatility and expected volatility 60 % Option exercise price $ 0.010 Weighted average exercise price $ 0.010 Risk-free interest rate 2.19 % Expected life of an option 4.5 years Model used Black-Scholes Fair value of options at grant date $ 0.0050 As at 30 June 2019, there was 1 employee (2018: 1) who held options that had been granted under the Plan. ii. 21,500,000 options to a number of KMP. The options vest based on non-market performance conditions (requirement to remain employed by the Company) in three tranches commencing on the date of the 2017 Annual General Meeting (AGM) of the Company and then at each of the 12 and 24 month anniversaries thereafter. The fair value of each option granted is estimated by an external valuer using a Black-Scholes option-pricing model, with assumptions as follows 2017 Grant Date 17 Feb 2017 Options issued 21,500,000 Dividend yield — Historic volatility and expected volatility 60 % Option exercise price $ 0.010 Weighted average exercise price $ 0.010 Risk-free interest rate 2.19 % Expected life of an option 4.5 years Model used Black-Scholes Fair value of options at grant date $ 0.0050 iii. 1,250,000 options (2016: 2,000,000 options) to a number of employees of the Company’s US Subsidiary, Phenogen Sciences Inc. The options vest based on non-market performance conditions (requirement to remain employed by the Company) in three tranches commencing on the date of the 2017 Annual General Meeting (AGM) of the Company and then at each of the 12 and 24 month anniversaries thereafter (2016: three equal tranches after 12 months, 24 months, and 36 months from date of grant, respectively). The fair value of each option granted is estimated by an external valuer using a Black-Scholes option-pricing model, with assumptions as follows 2017 2016 Grant Date 17 Feb 2017 1 April 2016 25 Nov 2015 Options issued 1,250,000 500,000 1,500,000 Dividend yield — — — Historic volatility and expected volatility 60% 80% 80% Option exercise price $0.010 $0.039 $0.058 Fair value of options at grant date $0.0050 $0.0065 $0.0139 Weighted average exercise price $0.010 $0.039 $0.058 Risk-free interest rate 2.19% 1.93% 2.22% Expected life of an option 4.5 years 4.3 years 4.5 years Model used Black-Scholes Black-Scholes Black-Scholes (b) Performance Rights Issuance After receiving requisite shareholder approval on November 29, 2018, the Company has issued 76,250,000 performance rights to Directors of the Company as follows: 7,500,000 Class A Performance Rights, 25,000,000 Class B Performance Rights and 25,000,000 Class C performance Rights to Dr Paul Kasian 3,750,000 Class A Performance Rights to Dr Lindsay Wakefield 6,250,000 Class A Performance Rights to Dr Jerzy Muchnicki 5,000,000 Class A Performance Rights to Mr Peter Rubinstein 3,750,000 Class A Performance Rights to Mr Xue Lee Further detail around each tranche of performance rights has been detailed within the explanatory memorandum accompanying the Notice of Meeting lodged with the ASX on October 30, 2018. The Company has accounted for these performance rights in accordance with its accounting policy for share-based payment transactions and has recorded $104,441 of associated expense in the current year-end. Valuation of Performance Rights The Performance Rights are not currently quoted on the ASX and as such have no ready market value. The Performance Rights each grant the holder a right of grant of one ordinary Share in the Company upon vesting of the Performance Rights for nil consideration. Accordingly, the Performance Rights may have a present value at the date of their grant. Various factors impact upon the value of Performance Rights including: · the period outstanding before the expiry date of the Performance Rights; · the underlying price or value of the securities into which they may be converted; · the proportion of the issued capital as expanded consequent upon conversion of the Performance Rights into Shares (i.e. whether or not the shares that might be acquired upon exercise of the options represent a controlling or other significant interest); and · the value of the shares into which the Performance Rights may be converted. There are various formulae which can be applied to determining the theoretical value of options (including the formula known as the Black-Scholes Model valuation formula and the Monte Carlo simulation). The Company has commissioned an independent valuation of the Performance Rights. The independent valuer has applied the Monte Carlo simulation in providing the valuation of the Performance Rights. Inherent in the application of the Monte Carlo simulation are a number of inputs, some of which must be assumed. The data relied upon in applying the Monte Carlo simulation was: a) exercise price being 0.0 cents per Performance Right for all classes; b) VWAP hurdle (10 days consecutive share price hurdle) equaling 2.0 cents for Class A and Class B and 3.3cents for Class C Performance Rights; c) the continuously compounded risk-free rate being 2.02% for all classes of Performance Rights (calculated with reference to the RBA quoted Commonwealth Government bonds as at October 8,2018 of similar duration to that of the expected life of each class of Performance Right); d) the expected option life of 2.8 years for all classes of Performance Rights; and e) a volatility measure of 80%. Based on the independent valuation of the performance rights, the company agrees that the total value of the performance rights to be issued to each director (depending on the share price at issue) is as follows: Valuation of Class A Performance Rights Number of Performance Rights issued Valuation per Class A (cents) Total fair value of Class A Performance Rights Expense accounted for during the year Dr Paul Kasian 7,500,000 0.77 $ 57,750 $ 11,229 Dr Lindsay Wakefield 3,750,000 0.77 $ 28,875 $ 5,614 Dr Jerzy Muchnicki 6,250,000 0.77 $ 48,125 $ 9,358 Mr Peter Rubinstein 5,000,000 0.77 $ 38,500 $ 7,486 Mr Sam Lee 3,750,000 0.77 $ 28,875 $ 5,614 Valuation of Class B Performance Rights Number of Performance Rights issued Valuation per Class B (cents) Class B Performance Rights Expense accounted for during the year Dr Paul Kasian 25,000,000 0.77 $ 192,500 $ 37,431 Valuation of Class C Performance Rights Number of Performance Rights issued Valuation per Class C (cents) Class C Performance Rights Expense accounted for during the year Dr Paul Kasian 25,000,000 0.57 $ 142,500 $ 27,708 (b) Expenses arising from share-based payment transactions Total expenses arising from share-based payment transactions recognized during the period as part of employee benefit expense were as follows: Consolidated 2019 2018 2017 Kentgrove options issued 15,278 — — Performance rights issued 104,441 — 120,287 Options issued under employee option plan 215,383 129,635 120,287 Total expenses arising from share-based payments 335,102 129,635 120,287

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2019
Disclosure of contingent liabilities [abstract]
Commitments and Contingencies	23. COMMITMENTS AND CONTINGENCIES Consolidated 2019 2018 2017 Operating lease expenditure commitments A$ A$ A$ Minimum operating lease payments - not later than one year 250,068 41,625 227,992 - later than one year but not later than five years 266,560 — 35,676 - later than five years — — — Total minimum operating lease payments 516,628 41,625 263,668 As at June 30, 2019, the above operating leases related to the following premises that are currently occupied by the Company: Location Landlord Use Date of expiry of lease Minimum payments ($) 60-66 Hanover Street Crude Pty. Ltd. Office / laboratory August 31, 2021 487,837 1300 Baxter Street, Suite 157, Charlotte, North Carolina Mid-Town Partners LLC Office Month to month 28,791 Total 516,628 Apart from the above, there were no other commitments or contingencies as at June 30, 2019. On July 3, 2018 the lease agreement for the Fitzroy premises in Melbourne was extended for 3 years from September 1, 2018 to August 31, 2021. In addition, Phenogen Sciences Inc. has vacated the Harris Corners Parkway office in Charlotte and entered into a lease agreement effective July 23, 2018 for premises situated at 1300 Baxter Street, Suite 157, Charlotte, North Carolina.

Auditors' Remuneration

Auditors' Remuneration	12 Months Ended
	Jun. 30, 2019
Auditor's remuneration [abstract]
Auditors' Remuneration	24. AUDITORS’ REMUNERATION Consolidated 2019 2018 2017 A$ A$ A$ Audit and assurance services PricewaterhouseCoopers in respect of: Audit(1) 288,000 288,200 325,972 Audit related — — 107,451 Other audit firms in respect of: Audit of the Financial Reports of subsidiaries — — 4,070 Total remuneration in respect of audit services 288,000 288,200 437,493 (1) Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Disclosure of transactions between related parties [abstract]
Related Party Transactions	6 Related party transactions Parent entities (i) Ultimate parent Genetic Technologies Limited is the ultimate Australian parent company. As at the date of this Report, no shareholder controls more than 50% of the issued capital of the company (ii) Transactions within the group and with other related parties During the half year ended 31 December 2019, the only transactions between entities within the group and other related parties occurred, are as listed below. Except where noted, all amounts were charged on similar to market terms and at commercial rates. (iii) Blockchain Global Limited As announced by the company on 15 February 2018, a non-binding terms sheet with Blockchain Global Limited (BCG) was entered to provide a framework for continuing discussions between the two companies, with the proposed transaction being subject to shareholder approval (by non-associated Shareholders); and as announced by the company on 2 August 2018, a framework agreement with BCG was entered formalizing the non-binding terms sheet and providing a framework for a strategic alliance between the company and BCG, with the agreement became binding on 29 November 2019 upon receiving the requisite shareholder approval. To date no shares have been issued under the framework agreements and no milestones have been achieved. Any rights to the 486 million milestone shares lapse between 27th Dec 2019 and 27 June 2020. The company has accounted for these share issuances in accordance with its accounting policy for share-based payment transactions and has not recorded any associated expense in the current half-year given performance conditions have not been met and are not currently considering any Blockchain related projects. A number of directors of the company presently or previously have had involvement with BCG. Mr Sam Lee has a direct and indirect share interest in BCG of 21% and is a director of BCG. Mr Peter Rubinstein has a direct and indirect share interest in BCG of 8%. Dr George Muchnicki has a direct and indirect share interest in BCG of 3.4%. Dr Paul Kasian was previously a director of BCG until July 2018. (iv) Lodge Corporate Dr. Kasian was a director of corporate finance and corporate advisor from December 2017 to February 2019 with Lodge Corporate. During the period, the company engaged in corporate advisory services with Lodge Corporate and had transactions worth $121,225 which also included $88,000 that related to 2% of the underwriting of the capital raise during the half year end 31 December 2019. (v) Mr. Phillip Hains (Chief Financial Officer) On July 11, 2019, the Company announced that it had appointed Mr. Phillip Hains (MBA, CA) as the Chief Financial Officer who has over 30 years of extensive experience in roles with a portfolio of ASX and NASDAQ listed companies and provides CFO services through his firm The CFO Solution. Prior to this point the Company had a similar arrangement with The CFO Solution, where it would engage and provided services of overall CFO, accounting and other finance related activities. During the reporting period, the company had transactions valued at $251,170 with The CFO Solution towards provision of overall CFO, accounting and other finance related activities. (vi) Issuance of options to directors towards underwriting the capital raise As announced on 4 October 2019, the Company undertook an underwritten non-renounceable pro-rata entitlement offer at an Issue Price of 0.4 cents per new share. On 11 October 2019, the Company updated the market to advise that the offer was from that time agreed to be underwritten by Lodge Corporate Pty Ltd and that two of the Company’s directors (Peter Rubinstein and Dr. George Muchnicki), had agreed to sub-underwrite the offer. Both directors, in conjunction with the underwriter Lodge Corporate Pty Ltd, subsequently agreed amongst themselves to alter the respective sub-underwritten amounts, but the total to be sub-written between them ($2 million) remained same, as did the total underwritten amount (of $4 million). Accordingly, the underwritten offer subsequently was sub-underwritten by Peter Rubinstein and Dr. George Muchnicki (each as up to $1 million) in conjunction with a consortium of non-associated wholesale investors (also as sub-underwriters) who in aggregate equate to the underwritten amount of $4 million, each in accordance with the terms of their separate sub-underwriting agreements with Lodge Corporate Pty Ltd (each a Sub-Underwriting Agreement). Dr. Muchnicki and Mr. Rubinstein reflecting the amount of their sub-writing commitment were to be granted on the same terms as all options to be granted to the relevant sub-underwriters. The number of options issued to both directors was calculated as 1 Option for every 2 Shares being sub-underwritten and were issued a total of 125,000,000 unlisted options to each of the directors. As announced on October 11, 2019, within the rights issue offer document, upon exercise each such option converts into 1 fully paid share on terms consistent with the ASX Listing Rules; with a 3-year expiry date from grant and with an exercise price per underwriter option equal to the lower of: • 0.008 cents; and • The implicit price per share at which any raise done by Aegis capital within 3 months from the company’s shareholder meeting. but in any event with a floor exercise price equal to 0.004 cents. (vii) Performance rights issuance After receiving requisite shareholder approval on 29 November 2018, the company has issued 76,250,000 performance rights to directors of the company as follows: • 7,500,000 Class A Performance Rights, 25,000,000 Class B Performance Rights and 25,000,000 Class C Performance Rights to Dr Paul Kaisian • 3,750,000 Class A Performance Rights to Dr Lindsay Wakefield • 6,250,000 Class A Performance Rights to Dr George Muchnicki • 5,000,000 Class A Performance Rights to Mr Peter Rubinstein • 3,750,000 Class A Performance Rights to Mr Xue Lee The company has accounted for these performance rights in accordance with its accounting policy for share-based payment transactions and has recorded $33,771 of associated expense in the current period end. 3,750,000 performance rights of the issued to Mr. Xue Lee that have been previously expensed off as at June 30, 2019 were cancelled during the half year ended 31 December 2019. Additionally, 57,500,000 performance rights issued to Dr. Paul Kasian were reversed in the current period for any expense recognised in the prior reporting year since they were forfeited. Due to the forfeiture of performance rights, a reversal amounting to $ 81,983 relating to prior period expense recognition was accounted for during the current reporting period. (viii) Blockshine Health Joint Venture The company, via its subsidiary Gene Ventures Pty Ltd, entered into a joint venture with Blockshine Technology Corporation (BTC). The joint venture company, called Blockshine Health, was to pursue and develop blockchain opportunities in the biomedical sector. Blockshine Health would have had as per the agreement full access to BTC’s technology (royalty free) as well as all of its opportunities in the biomedical sector. The company invested $250,000 into the joint venture and have a 49% equity stake. During the year ended 30 June 2019, the Company determined that the $250,000 investment in the Joint Venture agreement was fully impaired. On 6 August 2019 the Company announced the Joint Venture agreement was cancelled. Subsequent to the announcement, the company managed to recover $43,380 from the investment in BTC. Dr George Muchnicki is currently the director of both the company and Blockshine Health. At this time, no directors fees are payable to Dr Muchnicki by the joint venture company Blockshine Health. (ix) Genetic Technologies HK Limited and Aocheng Genetic Technologies Co. Ltd - Joint Venture In August 2018, the company announced a Heads of Agreement had been reached with Representatives of the Hainan Government - Hainan Ecological Smart City Group (“HESCG”), a Chinese industrial park development and operations company have formally invited Genetic Technologies Limited (“GTG”) to visit the Hainan Medical Pilot Zone to conduct a formal review and discuss opportunities for market entry into China via the Hainan Free Trade Zone initiative. The invitation was extended to GTG via Beijing Zishan Health Consultancy Limited (“Zishan”), demonstrating the potential for growth presented by the proposed Joint Venture between the parties (as announced to the market on 14 August 2018). Participants in the Hainan Medical Pilot Zone gain access to the Chinese healthcare market with an estimated value in excess of US$800B. Discussions with HESCG form part of an official review process to evaluate the feasibility of offering GTG’s suite of genetic risk assessment tests into China through the Hainan Medical Pilot Zone. Subsequently, the company announced the official formation of Genetic Technologies HK Limited and Aocheng Genetic Technologies Co. Ltd in Hong Kong to the market on March 27, 2019. With a growing clinical market and increased government investment in health-related technology, China is poised to become one of the largest global markets for genomic testing. The invitation from representatives of the Hainan Government represents a significant opportunity for GTG to advance the adoption of genetic risk assessment tests in the region. There were no transactions with parties related to Key Management Personnel during the period other than that disclosed above. Details of Directors and Key Management Personnel as at balance date. Directors • Dr Lindsay Wakefield (Non-Executive) • Dr Jerzy Muchnicki (Executive Director and Interim Chief Executive Officer) • Mr Peter Rubinstein (Non-Executive) • Mr. Nicholas Burrows (Non-Executive) • Dr. Paul Kasian (Former Chief Executive Officer) (resigned on 24 September 2019) Executives • Dr Richard Allman (Scientific Director) • Mr Phillip Hains (Chief Financial Officer) • Mr Paul Viney (Former Chief Financial Officer, Chief Operating Officer and Company Secretary) (appointed on December 15, 2018 and resigned on July 15, 2019)	25. RELATED PARTY DISCLOSURES Ultimate parent Genetic Technologies Limited is the ultimate Australian parent company. As at the date of this Report, no shareholder controls more than 50% of the issued capital of the Company. Transactions within the Group and with other related parties During the year ended 31 December 2019, the only transactions between entities within the Group and other related parties occurred, are as listed below. Except where noted, all amounts were charged on similar to market terms and at commercial rates. Debt convertible notes During the year ended 30 June 2015, the Company finalised the raising of $2,150,000 via the issue of unlisted secured (debt) notes to existing and new Australian institutional and wholesale investors. The debt notes carried a 10.0% coupon rate, and as approved at the Annual General Meeting, held on 25 November 2014, became convertible notes which could convert into ordinary shares (at a 10.0% discount to the 5 day VWAP). These convertible notes also carry free attached options to purchase further shares in the Company. Of these convertible notes, $125,000 were issued to a holder associated with Dr Lindsay Wakefield, a Company director at the time of issue, on the same terms and conditions as other note holders, all of which were converted during the year ended 30 June 2015. The 8,333,333 share options attached to these convertible notes expired during the year ended 30 June 2019. Dr Muchnicki and Mr Rubinstein, both of whom were elected as Directors of the Company on 31 January 2018, also participated in the debt convertible notes raising, during the year ended 30 June 2019 associated options indirectly held of 6,666,667 and 5,000,000 respectively expired. Blockchain Global Limited As announced by the Company on 15 February 2018, a non-binding terms sheet with Blockchain Global Limited(BCG) was entered to provide a framework for continuing discussions between the two companies, with the proposed transaction being subject to shareholder approval (by non-associated Shareholders); and as announced by the Company on 2 August 2018, a framework agreement with BCG was entered formalizing the non-binding terms sheet and providing a framework for a strategic alliance between the Company and BCG, with the agreement became binding on 29 November 2018 upon receiving the requisite shareholder approval. The agreement proposed the issue of 486 million shares to BCG in 3 tranches subject to the achievement of certain milestones. To date no shares have been issued under the framework agreements and no milestones have been achieved. Any rights to the 486 million milestone shares lapse between 27th December 2019 and 27 June 2020. The company has accounted for these share issuances in accordance with its accounting policy for share-based payment transactions and has not recorded any associated expense in the current year given performance conditions have not been met and are not currently considering any Blockchain related projects. A number of Directors of the Company presently or previously have had involvement with BCG. Mr Sam Lee has a direct and indirect share interest and was a CEO and managing director of BCG. Mr Peter Rubinstein held a minority shareholding in the entity and was also a director in BCG. Dr Jerzy Muchnicki has a direct and indirect interest in BCG. Dr Paul Kasian was previously a director of BCG until July 2018. Performance Rights Issuance After receiving requisite shareholder approval on 29 November 2018, the Company has issued 76,250,000 performance rights to Directors of the Company as follows: · · · · · The Company has accounted for these performance rights in accordance with its accounting policy for share-based payment transactions and has recorded $104,441 of associated expense in the current year. Valuation of Performance Rights The Performance Rights are not currently quoted on the ASX and as such have no ready market value. The Performance Rights each grant the holder a right of grant of one ordinary Share in the Company upon vesting of the Performance Rights for nil consideration. Accordingly, the Performance Rights may have a present value at the date of their grant. Various factors impact upon the value of Performance Rights including: · · · · Blockshine Health Joint Venture The Company, via its subsidiary Gene Ventures Pty Ltd, entered into a joint venture with Blockshine Technology Corporation (BTC). The joint venture company, called Blockshine Health, will pursue and develop blockchain opportunities in the biomedical sector. Blockshine Health will have full access to BTC’s technology (royalty free) as well as all of its opportunities in the biomedical sector. The Company invested $250,000 into the joint venture for a 49% equity stake. The Company has recorded an impairment against the investment during the financial year ended June 30, 2019, due to the cancellation of the project. Dr Jerzy Muchnicki (GTG’s nominee for directorship) is currently the director of both the Company and Blockshine Health. At this time, no Directors fees are payable to Dr Muchnicki by the joint venture company Blockshine Health. There were no transactions with parties related to Key Management Personnel during the year other than that disclosed above. Genetic Technologies HK Limited and Aocheng Genetic Technologies Co. Ltd - Joint Venture In August 2018, the Company announced a Heads of Agreement had been reached with Representatives of the Hainan Government - Hainan Ecological Smart City Group (“HESCG”), a Chinese industrial park development & operations company have formally invited Genetic Technologies Limited (“GTG”) to visit the Hainan Medical Pilot Zone to conduct a formal review and discuss opportunities for market entry into China via the Hainan Free Trade Zone initiative. The invitation was extended to GTG via Beijing Zishan Health Consultancy Limited (“Zishan”), demonstrating the potential for growth presented by the proposed Joint Venture between the parties (as announced to the market on 14 August 2018). Participants in the Hainan Medical Pilot Zone gain access to the Chinese healthcare market with an estimated value in excess of US$800B. Discussions with HESCG form part of an official review process to evaluate the feasibility of offering GTG’s suite of genetic risk assessment tests into China through the Hainan Medical Pilot Zone. Subsequently, the Company announced the official formation of Genetic Technologies HK Limited and Aocheng Genetic Technologies Co. Ltd in Hong Kong to the market on March 27, 2019, With a growing clinical market and increased government investment in health-related technology, China is poised to become one of the largest global markets for genomic testing. The invitation from representatives of the Hainan Government represents a significant opportunity for GTG to advance the adoption of genetic risk assessment tests in the region. GTG’s Chairman, Dr Paul Kasian has been named in the formation Heads of Agreement document to be the Chairman of the Joint Venture entity. At this time, no Directors fees or emoluments have been paid to Dr Kasian, nor have agreements regarding fees been reached. Lodge Corporate Dr. Kasian was a director of corporate finance and corporate advisor from December 2017 to February 2019 with Lodge Corporate. During the year, the company engaged in corporate advisory services with Lodge Corporate and had transactions worth $67,000 during the financial year end 2019. Mr. Phillip Hains (Chief Financial Officer) Subsequent to the financial year end 2019, on July 11, 2019, the Company announced that it had appointed Mr. Phillip Hains (MBA, CA) as the Chief Financial Officer who has over 30 years of extensive experience in roles with a portfolio of ASX and NASDAQ listed companies and provides CFO services through his firm The CFO Solution. The Company had a similar arrange with The CFO Solution, where it would engage and provided services of overall CFO, accounting and other finance related activities. During the financial year 2019, the company had transactions valued at $45,459 with The CFO Solution towards provision of overall CFO, accounting and other finance related activities. Details of Directors and Key Management Personnel as at balance date Directors • Dr Paul Kasian (Former Chairman and Interim CEO) (resigned September 24, 2019) • Dr Lindsay Wakefield (Non-Executive) • Dr Jerzy Muchnicki (Executive Director and Interim CEO) (appointed on September 24, 2019) • Mr Peter Rubinstein (Non-Executive) • Mr Xue Lee (Non-Executive) (resigned on July 9, 2019) Executives • Dr Richard Allman (Scientific Director) • Mr Paul Viney (Chief Financial Officer, Chief Operating Officer and Company Secretary) (appointed on December 15, 2018 and resigned on July 15, 2019) • Kevin Fischer (Chief Financial Officer) (resigned on December 31, 2018) Consolidated 2019 2018 2017 A$ A$ A$ Remuneration of Key Management Personnel Short-term employee benefits 964,162 1,215,632 1,533,457 Post-employment benefits 86,130 96,315 101,320 Share-based payments 157,886 130,385 121,269 Other long-term benefits 734 2,371 61,594 Termination benefits — 164,760 — Total remuneration of Key Management Personnel 1,208,912 1,609,463 1,817,640

Subsidiaries

Subsidiaries	12 Months Ended
	Jun. 30, 2019
Disclosure of subsidiaries [abstract]
Subsidiaries	26. SUBSIDIARIES The following diagram is a depiction of the Company structure as at June 30, 2019. Company interest (%) Net carrying value ($) Name of Company Incorporation details 2019 2018 2019 2018 Entities held directly by parent GeneType Pty. Ltd. September 5, 1990 100 % 100 % — — Genetic Technologies Corporation Pty. Ltd. October 11, 1996 100 % 100 % 2 2 Gene Ventures Pty. Ltd. * March 7, 2001 100 % 100 % 10 10 GeneType AG ** February 13, 1989 — — — — GeneType Corporation December 18, 1989 100 % 100 % — — Phenogen Sciences Inc. (BREVAGen TM ) June 28, 2010 100 % 100 % 11,006 11,006 Genetic Technologies HK Ltd March 18, 2019 100 % N/A — — Total carrying value 11,018 11,018 * On 26 April 2018, the name of RareCellect Pty Ltd (ACN 096 135 9847) was changed to Gene Ventures Pty Ltd (ACN 096 135 947) ** Liquidation of GeneType AG was completed on 13 December 2017

Financial Risk Management

Financial Risk Management	12 Months Ended
	Jun. 30, 2019
Disclosure of detailed information about financial instruments [abstract]
Financial Risk Management	27. FINANCIAL RISK MANAGEMENT The Company’s activities expose it to a variety of financial risks such as credit risk, market risk (including foreign currency risk and interest rate risk) and liquidity risk. The Company’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the financial performance of the Company. The Company uses different methods to measure the different types of risk to which it is exposed. These methods include sensitivity analysis in the case of foreign exchange, interest rate and aging analysis for credit risk. Risk management is managed by the Executive under guidance provided by the Board of Directors via its Audit Committee, which provides guidance for overall risk management, as well as policies covering specific areas, such as credit risk, foreign exchange risk and interest rate risk. The Committee identifies and evaluates financial risks in close cooperation with the Company’s executive management. The Company’s principal financial instruments comprise cash and cash equivalents. The Company also has other financial assets and liabilities, such as trade receivables and payables, which arise directly from its operations. The Company does not typically enter into derivative transactions, such as interest rate swaps or forward currency contracts. It is, and has been throughout the period under review, the Company’s policy that no trading in financial instruments shall be undertaken. The main risks arising from the Company’s financial instruments are credit risk exposures, foreign currency risk, interest rate risk and liquidity risk. The policies for managing each of these risks are summarized below. Details of the significant accounting policies and methods adopted, including the criteria for recognition, the basis of measurement and the basis on which income and expenses are recognized, in respect of each class of financial asset, financial liability and equity instrument are disclosed in Note 2. The Company holds the following financial instruments: Consolidated 2019 2018 A$ A$ Financial assets Cash at bank / on hand 2,131,741 5,487,035 Trade and other receivables 818,766 301,383 Performance bond and deposits 53,456 3,505 Total financial assets 3,003,963 5,791,923 Financial liabilities Trade and other payables 1,005,308 945,130 Total financial liabilities 1,005,308 945,130 Credit risk The Company’s credit risk is managed on a Company basis. Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions, as well as credit exposures to customers, including outstanding receivables and committed transactions. Other receivables represent amounts accrued for which reimbursement will be applied for from the Australian Taxation Authority under the Governments Research & Development grant. The maximum exposures to credit risk at June 30, 2019 in relation to each class of recognized financial asset is the carrying amount of those assets, as indicated in the balance sheet. Financial assets included on the balance sheet that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and trade receivables. In accordance with the guidelines of the Company’s Short Term Investment Policy, the Company minimizes this concentration of risk by placing its cash and cash equivalents with financial institutions that maintain superior credit ratings in order to limit the degree of credit exposure. For banks and financial institutions, only independently-rated parties with a minimum rating of “A-1” are accepted. The Company has also established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. The Company does not require collateral to provide credit to its customers. The Company has not entered into any transactions that qualify as a financial derivative instrument. The trade receivables balance is reflective of historical collection rates which are monitored on an ongoing basis and adjusted accordingly based on changing collection and test data. As at June 30, 2019, the balance of the Company’s total accrued net trade receivables was $16,529 (2018: $10,503 (refer Note 12)). Credit risk further arises in relation to financial guarantees given by the Company to certain parties in respect of obligations of its subsidiaries. Such guarantees are only provided in exceptional circumstances. An analysis of the aging of trade and other receivables s is provided below: Consolidated 2019 2018 A$ A$ Net trade and other receivables Current (less than 30 days) 802,237 294,454 31 days to 60 days 11,159 3142 61 days to 90 days (note) — 783 Greater than 90 days (note) 5,370 3004 Total net trade and other receivables (Note 12) 818,766 301,383 Market risk Foreign currency risk The Company operates internationally and is exposed to foreign currency exchange risk, primarily with respect to the US dollar, through financial assets and liabilities. It is the Company’s policy not to hedge these transactions as the exposure is considered to be minimal from a consolidated operations perspective. Further, as the Company incurs expenses which are payable in US dollars, the financial assets that are held in US dollars provide a natural hedge for the Company. Foreign exchange risk arises from planned future commercial transactions and recognized assets and liabilities denominated in a currency that is not the entity’s functional currency and net investments in foreign operations. The risk is measured using sensitivity analysis and cash flow forecasting. The Company has a Foreign Exchange Management Policy which was developed to establish a formal framework and procedures for the efficient management of the financial risks that impact on Genetic Technologies Limited through its activities outside of Australia, predominantly in the United States. The policy governs the way in which the financial assets and liabilities of the Company that are denominated in foreign currencies are managed and any risks associated with that management are identified and addressed. Under the policy, which is updated on a regular basis as circumstances dictate, the Company generally retains in foreign currency only sufficient funds to meet the expected expenditures in that currency. Surplus funds are converted into Australian dollars as and when deemed appropriate by the Board in consultation with the CFO. As at June 30, 2019, the Company held the following financial assets and liabilities that were denominated in foreign currencies: Consolidated Year USD EUR CHF Financial assets Cash at bank / on hand 2019 201,737 27,052 — 2018 2,154,291 28,952 — Bonds and deposits 2019 1,986 — — 2018 3,505 — — Total financial assets 2019 203,723 27,052 — 2018 2,157,796 28,952 — Financial liabilities Trade and other payables 2019 117,992 1,900 — 2018 116,063 — — Total financial liabilities 2019 117,992 1,900 — 2018 116,063 — — Notes: USD EUR CHF During the year ended June 30, 2019, the Australian dollar / US dollar exchange rate weakened by 5.13%, from 0.7403 at the beginning of the year to 0.7023 at the end of the year. Based on the financial instruments held at June 30, 2019, had the Australian dollar weakened/ strengthened by 10% against the US dollar with all other variables held constant, the Company’s loss for the year would have been $11,851 lower/ $9,696 higher (2018: 306,000 lower/ $250,000 higher), mainly as a result of changes in the values of cash and cash equivalents which are denominated in US dollars, as detailed in the above tables. Interest rate risk The Company’s main interest rate risk arises in relation to its short-term deposits with various financial institutions. If rates were to decrease, the Company may generate less interest revenue from such deposits. However, given the relatively short duration of such deposits, the associate risk is relatively minimal. The Company has a Short Term Investment Policy which was developed to manage the Company’s surplus cash and cash equivalents. In this context, the Company adopts a prudent approach that is tailored to cash forecasts rather than seeking high returns that may compromise access to funds as and when they are required. Under the policy, the Company deposits its surplus cash in a range of deposits / securities over different time frames and with different institutions in order to diversify its portfolio and minimize risk. On a monthly basis, Management provides the Board with a detailed list of all cash and cash equivalents, showing the periods over which the cash has been deposited, the name and credit rating of the institution holding the deposit and the interest rate at which the funds have been deposited. At June 30, 2019, if interest rates had changed by +/- 50 basis points from the year-end rates, with all other variables held constant, the Company’s loss for the year would have been $8,969 lower / higher (2018: loss $12,000 lower / higher), as a result of higher / lower interest income from cash and cash equivalents. The exposure to interest rate risks and the effective interest rates of financial assets and liabilities, both recognized and unrealized, for the Company is as follows: Floating rate Fixed rate Carrying amount Weighted ave. effective rate Ave. maturity Period Consolidated Year A$ A$ A$ % Days Financial assets Cash at bank / on hand 2019 2,131,741 2,131,741 1.74 % At call 2018 2,394,754 — 2,394,754 1.74 % At call Performance bond / deposits 2019 53,456 53,456 — At call 2018 — 3,505 3,505 — At call Totals 2019 2,131,741 53,456 2,131,741 2018 2,394,754 3,505 2,398,259 Financial liabilities Financial liabilities at fair value through profit or loss 2019 — — — — — 2018 — — — — — Totals 2019 — — — 2018 — — — Note The Company holds the balance of its cash in non-interest bearing bank accounts. Liquidity risk Prudent liquidity risk management implies maintaining sufficient cash and cash equivalents and the availability of funding through an adequate amount of committed credit facilities, such as its hire purchase and credit card facilities. The Company manages liquidity risk by continuously monitoring forecast and actual cash flows and, wherever possible, matching the maturity profiles of financial assets and liabilities. Due to the dynamic nature of the underlying businesses, Management aims to maintain flexibility in funding by keeping committed credit lines available. Surplus funds are generally only invested in instruments that are tradeable in highly liquid markets. Refer note 2(a) for further information on the material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. A balanced view of cash inflows and outflows affecting the Company is summarized in the table below: < 6 months 6 to 12 months 1 to 5 years > 5 years Totals Consolidated Year A$ A$ A$ A$ A$ Financial assets Cash at bank / on hand 2019 2,131,741 2,131,741 2018 5,487,035 — — — 5,487,035 Trade and other receivables 2019 818,766 818,766 2018 301,383 — — — 301,383 Performance bond and deposits 2019 53,456 53,456 2018 3,505 — — — 3,505 Total financial assets 2019 3,003,963 3,003,963 2018 5,791,923 — — — 5,791,923 Financial liabilities Trade and other payables 2019 1,005,308 1,005,308 2018 945,130 — — — 945,130 Total financial liabilities 2019 1,005,308 1,005,308 2018 945,130 — — — 945,130 Net maturity 2019 (1,998,655 ) (1,998,655 ) 2018 4,846,793 — — — 4,846,793 The Company had access to the following undrawn borrowing facility as at June 30, 2019: Facility limit Amount used Amount available A$ A$ A$ Nature of facility Credit card facility 95,714 -6,516 89,198

Events Occurring After The Repo

Events Occurring After The Reporting Period	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Disclosure of non-adjusting events after reporting period [abstract]
Events Occurring After The Reporting Period	7 Events occurring after the reporting period No matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those operations or the state of affairs of the group or economic entity in subsequent financial periods.	28. SUBSEQUENT EVENTS Significant events after balance date The following significant events have occurred after balance date; · The Company appointed Mr. Nick Burrows as Non- Executive Independent Director to the board on September 2, 2019. · On August 15, 2019, the Company announced a ratio change on the ADR program from 1 ADS representing 150 Ordinary Shares to a new ratio of 1 ADS representing 600 Ordinary Shares. The ratio change will result in a reverse split on Genetic Technologies ADSs on the basis of 1 ADS for 4 old ADS held. The Ordinary Shares of Genetic Technologies Limited will not be affected by this change in the ADS to ordinary shares ratio. · On July 11, 2019, the Company announced the appointment of a new Company Secretary in form of Mr. Justyn Stedwell and appointed a new Chief Financial Officer of the Company in form of Mr. Phillip Hains. These appointments replace roles performed by Mr. Paul Viney due to his departure which was announced during the same month. · On September 24, 2019, the Company announced resignation of Dr. Paul Kasian (current Chairman and interim Chief Executive Officer) with immediate effect with Dr. Jerzy Muchnicki taking up the role of the interim Chief Executive Officer. · On September 23, 2019, the Company announced the signing of a three-year collaboration agreement with Translational Genomics Research Institute (TGen) of Phoenix, Arizona USA. The agreement includes cooperation in the design feasibility analysis of clinical research studies to support the clinical application of GTG’s polygenic risk tests and identification of appropriate clinical partners to participate in the studies.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2019
Summary Of Significant Accounting Policies
Basis of Preparation	(a) Basis of preparation Compliance with International Financial Reporting Standards as issued by the International Accounting Standards Board The Financial Report complies with the International Financial Reporting Standards as issued by the International Accounting Standards Board. Historical cost convention These financial statements have been prepared under the historical cost convention except for financial assets and liabilities (including derivative instruments) which are measured at fair value. Critical accounting estimates The preparation of financial statements requires the use of certain critical accounting estimates. It also requires Management to exercise its judgement in the process of applying the Company’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are critical to the financial statements, are disclosed in Note 3. Going concern For the year ended 30 June 2019, the Company incurred a total comprehensive loss of $6,401,936 (2018: $5,986,838) and net cash outflow from operations of $6,073,182 (2018: $5,636,533). As at 30 June 2019 the Company held total cash and cash equivalents of $2,131,741. During the 2020 financial year, the Directors expect stable cash outflows from operations as the Company continues to invest resources in expanding the research & development activities in support of the distribution of existing and new products. As a result of these expected cash outflows to support the announcement of the launch of further new genetic testing products, the Directors intend to raise further new equity funding in order to ensure the Company continues to hold adequate levels of available cash resources to meet creditors and other commitments and to deliver on partner expectations in China and the USA. The Company intends to raise further equity financing in October 2019, but there can be no assurance that we will be successful in this regard. The Company does not currently have binding commitments from any party to subscribe for shares and any raise will be subject to maintaining active listing on the NASDAQ exchange as well as compliance with the Company’s obligations under ASX Listing Rule 7.1. In addition to the plans to raise capital in the US, the Company has recorded a receivable at 30 June 2019 from the Australian Taxation Office in respect of the 2019 research and development tax incentive claim which the Company expects to receive this in October 2019. The Company also has access to equity placement facility with Kentgrove Capital Pty Ltd whereby it has an opportunity to raise equity funding of up to $20 million in a series of individual placements of up to $1 million (or a higher amount by mutual agreement), expiring 7 April 2020. The Company currently does not have any binding commitments under this facility and the quantum and timing of capital raised will be subject to the market price and trading volumes of our ordinary shares. The continuing viability of the Company and its ability to continue as a going concern and meet its debts and commitments as they fall due is dependent on the satisfactory completion of planned equity raisings in October of 2019. Due to the uncertainty surrounding the timing, quantum or the ability to raise additional equity, there is a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern and therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business. However, the Directors believe that the Company will be successful in the above matters and accordingly, have prepared the financial report on a going concern basis. As such no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should the Company not be able to continue as a going concern. As a U.S. SEC registrant, the Company is required to have its financial statements audited in accordance with Public Company Oversight Board (“PCAOB”) standards. References in these IFRS financial statements to matters that may cast significant doubt about the Company’s ability to continue as a going concern also raise substantial doubt as contemplated by the PCAOB standards.
New Accounting Standards and Interpretations	(b) New accounting standards and interpretations Standards and Interpretations affecting amounts reported in the current period (and/or prior period) The Company has applied the following standards and amendments for the first time for their annual reporting period commencing July 1, 2018: IFRS 9 Financial Instruments IFRS 9 Financial Instruments IFRS 9 introduced a new expected loss impairment model that requires entities to account for expected credit losses at the time of recognizing the asset. The adoption of the new standard did not have a material impact on its classification and measurement of the financial assets and liabilities or its results on adoption of the new impairment model. IFRS 15 Revenue from Contracts with Customers IFRS 15 provides a single, principles based five-step model to be applied to all contracts with customers. Guidance is provided on topics such as the point in which revenue is recognized, accounting for variable consideration, costs of fulfilling and obtaining a contract and various related matters. The adoption of this standard applies to the recognition of the sales related to the BREVAGEN plus Other new standards affecting the current reporting period The company also adopted the following standards during the period. ● Classification and Measurement of Share-based Payment Transactions (Amendments to IFRS 2) ● Interpretation 22 Foreign Currency Transactions and Advance Consideration. The adoption of these amendments did not have any impact on the current period or any prior period and is not likely to affect future periods. Certain new accounting standards and interpretations have been published that are not mandatory for June 30, 2019 reporting periods and have not been early adopted by the Company. The Company’s assessment of the impact of these new standards and interpretations is set out below. Standards and interpretations in issue but not yet adopted Title of IFRS 16 Leases Nature of change IFRS 16 was issued in February 2016. It will result in almost all leases being recognised on the consolidated balance sheet by lessees, as the distinction between operating and finance leases is removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognised. The only exceptions are short-term and low-value leases. Impact The Company has reviewed all leasing arrangements in light of the new lease accounting rules in IFRS 16. The standard will affect the accounting for the Company’s operating leases. As at the reporting date, the Company has non-cancellable operating lease commitments of $487,849. The Company expects to recognise at 1 July 2019 right-of-use assets of an amount approximating the nominal value of these non-cancellable operating lease commitments, discounted at the Company’s incremental borrowing rate. A corresponding lease liability will offset the amount recognised as a right-of-use asset at 1 July 2019. Overall net current assets will be $14,712 lower due to the presentation of a portion of the liability as a current liability. In financial year 2020, the operating cash flows will increase and financing cash flows decrease by approximately $221,281 as repayment of the principal portion of the lease liabilities will be classified as cash flows from financing activities. Mandatory application date/Date of adoption by the Company The Company will apply the standard from its mandatory adoption date of July 1, 2019. The Company intends to apply the simplified transition approach and will not restate comparative amounts for the year prior to first adoption. Right-of-use assets for property leases will be measured on transition as if the new rules had always been applied. All other right-of-use assets will be measured at the amount of the lease liability on adoption (adjusted for any prepaid or accrued lease expenses). There are no other new standards and interpretations that are not yet effective and that would be expected to have a material impact on the Company in the current or future reporting periods and on foreseeable future transactions.
Principles of Consolidation	(c) Principles of consolidation Subsidiaries The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Genetic Technologies Limited (the “Company” or “Parent Entity”) as at June 30, 2019 and the results of all subsidiaries for the year then ended. Genetic Technologies Limited and its subsidiaries together are referred to in this Financial Report as the “Company” or the “Consolidated Entity”. Subsidiaries are all entities (including structured entities) over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement within the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases. Intercompany transactions, balances and unrealized gains / losses on transactions between Company companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the Company’s policies. Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of comprehensive income, consolidated balance sheet and consolidated statements of changes in equity, respectively.
Segment Reporting	(d) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing the performance of the operating segments, has been identified as the Chief Executive Officer.
Parent Entity Financial Information	(e) Parent entity financial information The financial information for the parent entity, Genetic Technologies Limited has been prepared on the same basis as the consolidated financial statements, except that investments in subsidiaries are accounted for at cost in the financial statements of Genetic Technologies Limited. Loans to subsidiaries are written down to their recoverable value as at balance date.
Foreign Currency Translation	(f) Foreign currency translation The functional and presentation currency of Genetic Technologies Limited and its Australian subsidiaries is the Australian dollar (AUD). Transactions in foreign currencies are initially recorded in the functional currency at the exchange rates ruling at the date of the transaction. Monetary assets and liabilities which are denominated in foreign currencies are retranslated at the rate of exchange ruling at the balance sheet date. All differences are taken to the statement of comprehensive income. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate ruling at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates ruling at the date when the fair value was determined. The functional currencies of the Company’s two overseas subsidiaries are as follows: GeneType Corporation — United States dollars (USD) Phenogen Sciences Inc. — United States dollars (USD) As at the reporting date, the assets and liabilities of these subsidiaries are translated into the presentation currency of Genetic Technologies Limited at the rate of exchange ruling at the balance sheet date and the statement of comprehensive income is translated at the weighted average exchange rates for the period unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions. The exchange differences arising on the retranslation are recognized in other comprehensive income and taken directly to a separate component of equity. On disposal of a foreign entity, the deferred cumulative amount recognized in equity relating to that particular foreign operation is recognized in the statement of comprehensive income.
Earnings Per Share ("EPS")	(g) Earnings per share (“EPS”) Basic EPS is calculated by dividing the profit attributable to owners of the Company, excluding any costs of servicing equity other than Ordinary Shares, by the weighted average number of Ordinary Shares outstanding during the financial year. Diluted EPS adjusts the figures used in the determination of basic EPS to take into account the after income tax effect of interest and other financing costs associated with dilutive potential Ordinary Shares and the weighted average number of Ordinary Shares that would have been outstanding assuming the conversion of all dilutive potential Ordinary Shares.
Revenue Recognition	(h) Revenue recognition IFRS 15 supersedes IAS 11 Construction Contracts, IAS18 Revenue and related interpretations and it applies to all revenue arising from contracts with customers, unless those contracts are in the scope of other standards. The new standard has been applied as at 1 July 2018 using the modified retrospective approach and establishes a five-step model to account for revenue arising from contracts with customers. Under IFRS 15, revenue is recognised at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The standard requires entities to exercise judgement, taking into consideration all of the relevant facts and circumstances when applying each step of the model to contracts with their customers. The standard also specifies the accounting for the incremental costs of obtaining a contract and the costs directly related to fulfilling a contract. The adoption of IFRS 15 has not impacted the amounts disclosed within the financial statements. The following recognition criteria must also be met before revenue is recognized: Genetic testing revenues The Company operates facilities which provide genetic testing services. The Company recognises revenue from the provision of these services when the services have been completed. Interest received Income is recognized as the interest accrues using the effective interest method. Government Grants Research and development tax incentive The Australian government replaced the research and development tax concession with research and development (R&D) tax incentive from July 1, 2011. The R&D tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after July 1, 2011. A refundable tax offset is available to eligible companies with an annual aggregate turnover of less than $20 million. Management has assessed the Company’s activities and expenditure to determine which are likely to be eligible under the incentive scheme. The Company accounts for the R&D tax incentive as a government grant. The grant is recognized as other income over the period in which the R&D expense is recognized. Other Other Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received and the company will comply with all attached conditions.
Share-based Payment and Performance Rights Transactions	(i) Share-based payment and performance rights transactions The fair value of options granted under an Employee Option Plan is recognized as an employee benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognized over the vesting period over which all of the specified vesting conditions are to be satisfied. The fair value at grant date is determined by management with the assistance of an independent valuer, using a Black-Scholes option pricing model or a Monte Carlo simulation analysis. The total amount to be expensed is determined by reference to the fair value of the options granted. ● including any market performance conditions (e.g., the entity’s share price) ● excluding the impact of any service and non-market performance vesting conditions (e.g., remaining an employee over a specified time period) The cumulative employee benefits expense recognized at each reporting date until vesting date reflects (i) the extent to which the vesting period has expired; and (ii) the number of awards that, in the opinion of the Directors of the Company, will ultimately vest. This opinion is formed based on the best information available at balance date. Where the terms of an equity-settled award are modified, as a minimum an expense is recognized as if the terms had not been modified. In addition, an expense is recognized for any increase in the value of the transaction as a result of the modification, as at the date of modification. Where appropriate, the dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share. The Company’s policy is to treat the options of terminated employees as forfeitures. The Performance Rights are not currently quoted on the ASX and as such have no ready market value. The Performance Rights each grant the holder a right of grant of one ordinary Share in the Company upon vesting of the Performance Rights for nil consideration. Accordingly, the Performance Rights may have a present value at the date of their grant. Various factors impact upon the value of Performance Rights including: ● the period outstanding before the expiry date of the Performance Rights; ● the underlying price or value of the securities into which they may be converted; ● the proportion of the issued capital as expanded consequent upon conversion of the Performance Rights into Shares (i.e. whether or not the shares that might be acquired upon exercise of the options represent a controlling or other significant interest); and ● the value of the shares into which the Performance Rights may be converted. There are various formulae which can be applied to determining the theoretical value of options (including the formula known as the Black-Scholes Model valuation formula and the Monte Carlo simulation). With the assistance of an independent valuer, the Company performed a valuation of the Performance Rights. The independent valuer has applied the Monte Carlo simulation in providing the valuation of the Performance Rights. As the Performance Rights have market event hurdles for vesting, the valuation has been provided with a range of underlying share prices. Inherent in the application of the Monte Carlo simulation are a number of inputs, some of which must be assumed. The data relied upon in applying the Monte Carlo simulation was: a) a range of prices analysed from 0.5 cents per share to 1.5 cents per share (being an approximate 50% discount to a 50% premium) from GTG’s current share price of 1.1 cents per share as at October 5, 2018 for all classes of Performance Rights; b) exercise price being 0.0 cents per Performance Right for all classes; c) VWAP hurdle (10 days consecutive share price hurdle) equaling 2.0 cents for Class A and Class B and 3.3 cents for Class C Performance Rights; d) the continuously compounded risk free rate being 2.02% for all classes of Performance Rights (calculated with reference to the RBA quoted Commonwealth Government bonds as at October 8, 2018 of similar duration to that of the expected life of each class of Performance Right); Performance Rights. As the Performance Rights have market event hurdles for vesting, the valuation has been provided with a range of underlying share prices. Inherent in the application of the Monte Carlo simulation are a number of inputs, some of which must be assumed. The data relied upon in applying the Monte Carlo simulation was: e) a range of prices analysed from 0.5 cents per share to 1.5 cents per share (being an approximate 50% discount to a 50%premium) from GTG’s current share price of 1.1 cents per share as at October 5, 2018 for all classes of Performance Rights; f) exercise price being 0.0 cents per Performance Right for all classes; g) VWAP hurdle (10 days consecutive share price hurdle) equaling 2.0 cents for Class A and Class B and 3.3 cents for Class C Performance Rights; h) the continuously compounded risk free rate being 2.02% for all classes of Performance Rights (calculated with reference to the RBA quoted Commonwealth Government bonds as at October 8, 2018 of similar duration to that of the expected life of each class of Performance Right); i) the expected option life of 2.8 years for all classes of Performance Rights; and j) a volatility measure of 80%.
Income Tax	(j) Income tax The income tax expense or revenue for the period is the tax payable on the current period’s taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company’s subsidiaries and associates operate and generate taxable income. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in controlled entities where the parent entity is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity. Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively. Tax consolidation legislation Genetic Technologies Limited (“GTG”) and its wholly-owned Australian-resident subsidiaries have implemented the tax consolidation legislation. The head entity, GTG, and the subsidiaries in the tax consolidated Company account for their own current and deferred tax amounts. These tax amounts are measured as if each entity in the tax consolidated Company continues to be a stand-alone taxpayer in its own right. In addition to its own current and deferred tax amounts, GTG also recognizes the current tax assets / liabilities and the deferred tax assets arising from unused tax losses and tax credits assumed from subsidiaries in the tax consolidated Company. Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognized as amounts receivable from or payable to other entities in the Company. Any difference between the amounts assumed and amounts receivable or payable under the tax funding agreements are recognized as a contribution to (or distribution from) wholly-owned tax subsidiaries.
Other Taxes	(k) Other taxes Revenues, expenses and assets are recognized net of the amount of Goods and Services Tax (GST) except where the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognized as part of the cost of acquisition of the asset or as part of the expense item as applicable; and receivables and payables are stated with the amount of GST included. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet. Cash flows are included in the cash flow statement on a gross basis and the GST component arising from investing and financing activities, which is recoverable from / payable to the taxation authority, are classified as operating cash flows.
Withholding Tax	(l) Withholding tax The Company generates revenues from the granting of licenses to parties resident in overseas countries. Such revenues may, in certain circumstances, be subject to the deduction of local withholding tax. In such cases, revenues are recorded net of any withholding tax deducted.
Finance Costs	(m) Finance costs Finance costs are recognized using the effective interest rate method.
Cash and Cash Equivalents	(n) Cash and cash equivalents Cash and cash equivalents in the balance sheet comprise cash at bank and in hand and short-term deposits with an original maturity of 3 months or less. For the purposes of the cash flow statement, cash and cash equivalents consist of cash and cash equivalents as defined above. Cash at bank earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods, depending on the immediate cash requirements of the Company, and earn interest at the respective short-term deposit rates.
Trade and Other Receivables	(o) Trade and other receivables Trade receivables, which are non-interest bearing and generally have terms of between 30 to 90 days, are recognized and carried at original invoice amount less an allowance for any uncollectible amounts. For the comparative periods prior to July 1, 2018, an allowance for doubtful debts is made when there is objective evidence that a receivable is impaired. Such evidence includes an assessment of the debtor’s ability and willingness to pay the amount due. The amount of the allowance/impairment loss is measured as the difference between the carrying amount of the trade receivables and the estimated future cash flows expected to be received from the relevant debtors. The Company has applied IFRS 9 from July 1, 2018. To measure the loss allowance on trade receivables, the Company uses the simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables assets would be grouped based on shared credit risk characteristics and the days past due.
Inventories	(p) Inventories Inventories principally comprise laboratory and other supplies and are valued at the lower of cost and net realizable value. Inventory costs are recognized as the purchase price of items from suppliers plus freight inwards and any applicable landing charges. Costs are assigned on the basis of weighted average cost.
Property, Plant and Equipment	(q) Property, plant and equipment Plant and equipment is stated at cost less accumulated depreciation and any impairment in value. Depreciation is calculated on a straight-line basis over the estimated useful life of the respective asset as follows: Laboratory equipment — 3 to 5 years Computer equipment — 3 years Office equipment — 3 to 5 years Leasehold improvements — lease term, being between 1 and 3 years Costs relating to day-to-day servicing of any item of property, plant and equipment are recognized in profit or loss as incurred. The cost of replacing larger parts of some items of property, plant and equipment are capitalized when incurred and depreciated over the period until their next scheduled replacement, with the replacement parts being subsequently written off.
Intangible Assets	(r) Intangible assets Patents Patents held by the Company are used in the licensing, testing and research areas and are carried at cost and amortized on a straight-line basis over their useful lives, being 10 years. External costs incurred in filing and protecting patent applications, for which no future benefit is reasonably assured, are expensed as incurred. Research and development costs Costs relating to research activities are expensed as incurred. An intangible asset arising from development expenditure on an internal project is recognized only when the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the development and the ability to measure reliably the expenditure attributable to the intangible asset during its development. To date, all development costs have been expensed as incurred as their recoverability cannot be regarded as assured.
Impairment of Assets	(s) Impairment of assets The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, the Company makes an estimate of the asset’s recoverable amount. An asset’s recoverable amount is the higher of its fair value less costs of disposal or its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset’s value-in-use cannot be estimated to be close to its fair value. In such cases, the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Impairment losses relating to operations are recognized in those expense categories consistent with the function of the impaired asset unless the asset is carried at its revalued amount, in which case the impairment loss is treated as a revaluation decrease. An assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset’s recoverable amount since the last impairment loss was recognized. If so, the carrying amount of the asset is increased to its recoverable amount. The increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in profit or loss unless it reverses a decrement previously charged to equity, in which case the reversal is treated as a revaluation increase. After such a reversal, the depreciation charge is adjusted in future periods to allocate the asset’s revised carrying amount, less any residual value, on a systematic basis over its remaining useful life.
Employee Benefits	(t) Employee benefits (i) Short-term obligations Provision is made for employee benefits accumulated as a result of employees rendering services up to the reporting date. These benefits include wages and salaries, annual leave and long service leave. Liabilities arising in respect of wages and salaries, expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled. Expenses for non-accumulating sick leave are recognized when the leave is taken during the year and are measured at rates paid or payable. ii) Other long-term employee benefit obligations The liabilities for long service leave and annual leave are not expected to be settled wholly within 12 months after the end of the reporting period in which the employee renders the related service. They are therefore recognized in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. (iii) Retirement benefit obligations The Company does not have any defined benefit funds. Statutory contributions to defined contribution superannuation funds are recognized as an expense as they become payable. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. Statutory contributions are legally enforceable in Australia.
Provisions	(u) Provisions Provisions for legal claims, service claims and make good obligations are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects some or all of a provision to be reimbursed, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of comprehensive income net of any reimbursement. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects market assessments of the time value of money and, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.
Trade and Other Payables	(v) Trade and other payables Trade payables and other payables are carried at amortized cost and represent liabilities for goods and services provided to the Company prior to the end of the financial year that are unpaid and arise when the Company becomes obliged to make future payments in respect of the purchase of these goods and services. Trade payables and other payables generally have terms of between 30 and 60 days.
Contributed Equity	(w) Contributed equity Issued and paid up capital is recognized at the fair value of the consideration received by the Company. Transaction costs arising on the issue of Ordinary Shares are recognized directly in equity as a deduction, net of tax, of the proceeds received. The Company has a share-based payment option plan under which options to subscribe for the Company’s shares have been granted to certain executives and other employees.

Basis of Preparation of Half-_2

Basis of Preparation of Half-Year Report (Table)	6 Months Ended
	Dec. 31, 2019
Basis Of Preparation Of Half-year Report
Schedule of Operating Lease Liability	31 Dec 2019 Operating lease commitments disclosed as at 30 June 2019 $ 487,837 Discounted using the lessee's incremental borrowing rate of at the date of initial application $ 461,358 Lease liability recognised as at 1 July 2019 $ 461,358 Of which are: Current lease liabilities $ 209,887 Non-current lease liabilities $ 251,471 Right of use of assets increased by $ 446,645 Lease liabilities increased by $ 461,358 The net impact on retained earnings on 1 July 2019 was a decrease of $ 14,712

Other Income and Expense Items

Other Income and Expense Items (Tables)	6 Months Ended
	Dec. 31, 2019
Other Income And Expense Items
Schedule of Other income	(a) Other income Consolidated entity 31 December 31 December R&D Grant Income (i) 400,000 186,000 Other 47,756 152,588 447,756 338,588 (i) Government grants The group's research and development activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the half year ended 31 December 2019, the group has included an item in other income of $400,000 (2018: $186,000) to recognise income over the period necessary to match the grant on a systematic basis with the costs that they are intended to compensate.

Cost of Sales (Tables)

Cost of Sales (Tables)	12 Months Ended
	Jun. 30, 2019
COST OF SALES
Schedule of Cost of Sales	Consolidated 2019 2018 2017 A$ A$ A$ Inventories used 55,995 93,869 172,070 Direct labour costs 103,601 88,690 152,767 Depreciation expense 55,480 65,853 71,139 Inventories written off (1) 61,191 51,676 96,441 Total cost of sales 276,267 300,088 492,417 (1) Inventories written off include $Nil (2018: $24,506 and 2017: $53,856) of items that expired during the year.

Non Operating Income and Expe_2

Non Operating Income and Expenditure (Tables)	12 Months Ended
	Jun. 30, 2019
NON OPERATING INCOME AND EXPENDITURE
Schedule of Non Operating Income and Expenditure	2019 2018 2017 Net profit on disposal of plant and equipment — — 52,188 Research and development tax incentive 856,707 299,351 253,159 Export Marketing & Development Grant — 126,907 — Interest income 25,794 15,218 38,765 Rental income — — — Other income 137,268 — — Total non operating income and expenditure 1,019,769 441,476 344,112

Foreign Exchange Gain Reclass_2

Foreign Exchange Gain Reclassified on Liquidation of Subsidiary (Tables)	12 Months Ended
	Jun. 30, 2019
FOREIGN EXCHANGE GAIN RECLASSIFIED ON LIQUIDATION OF SUBSIDIARY
Schedule of Foreign Exchange Gain Reclassified On Liquidation of Subsidiary	Reclassification of net foreign exchange gains previously recognised in other comprehensive income, reclassified to profit or loss Nil Total gain on liquidation of subsidiary Nil

Other Gains _ (Losses) (Tables)

Other Gains / (Losses) (Tables)	12 Months Ended
	Jun. 30, 2019
OTHER GAINS / (LOSSES)
Schedule of Other Gains / (losses)	Consolidated 2019 2018 2017 A$ A$ A$ Net foreign exchange gains/(losses) 92,518 — — Net impairment losses(1) (500,000 ) — — Total other gains / (losses) (407,482 ) — — (1) In August 2018, the Company invested $250,000 into Swisstec towards the proposed joint venture to enable the Company and Swisstec to collaborate to develop a medical and health service platform using blockchain technology. The Company has recorded an impairment against the investment during the financial year ended June 30, 2019, due to cessation of activities in relation to the joint venture. (1) In December 2018, Genetic Technologies Limited entered and invested $250,000 into a Joint Venture agreement with Blockshine Health Pty Ltd. with an ownership of 49%. The Company has recorded an impairment against the investment during the financial year ended June 30, 2019, due to the cancellation of the project.

Expenses (Tables)

Expenses (Tables)	12 Months Ended
	Jun. 30, 2019
Expenses by nature [abstract]
Schedule of Expenses	Consolidated 2019 2018 2017 A$ A$ A$ Amortization of intangible assets — — 63,783 Depreciation of fixed assets 156,248 303,749 307,828 Employee benefits expenses 2,414,408 2,657,232 3,594,936 Operating lease expenses 312,956 326,192 310,413 Research and development expenses 310,703 459,026 418,598

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Jun. 30, 2019
Major components of tax expense (income) [abstract]
Schedule of Income Tax Expense	Consolidated 2019 2018 2017 A$ A$ A$ Reconciliation of income tax expense to prima facie tax payable Loss before income tax expense (6,425,604 ) (5,463,872 ) (8,403,826 ) Tax at the Australian tax rate of 27.50% (2018: 27.50% and 2017: 28.50%) (1,767,041 ) (1,502,565 ) (2,311,052 ) Tax effect amounts which are not deductible/(taxable) in calculating taxable income Share-based payments expense 92,153 35,650 33,079 Research and development tax incentive 541,596 148,346 108,163 Other non-deductible items 590 1,509 1,257 Other assessable items — — 81,155 (1,132,702 ) (1,317,060 ) (2,087,398 ) Difference in overseas tax rates 41,009 67,557 (96,775 ) Under /(over) provision 1,126,722 (268,092 ) (75,054 ) Temporary differences not recognized (121,965 ) — — Research and development tax credit (238,084 ) (82,322 ) (69,619 ) Tax losses not recognized 325,020 1,599,917 2,328,846 Income tax expense — — —
Schedule of Net Deferred Tax Assets	Net deferred tax assets Deferred tax assets not recognized Property, plant and equipment 863 1,381 2,802 Capital raising costs 232,328 347,370 320,417 Applera settlement — — — Intangible assets 1,893,220 1,949,601 2,003,505 Provisions 187,958 201,492 333,103 Other — — — Total deferred tax assets 2,314,369 2,499,844 2,659,827 Deferred tax liabilities not recognized Prepayments — — — Total deferred tax liabilities — — — Net deferred tax assets on temporary differences not brought to account (2,314,369 ) (2,499,844 ) (2,659,827 ) Total net deferred tax assets — — —
Schedule of Tax Losses	Consolidated 2019 2018 2017 A$ A$ A$ Tax losses Unused tax losses for which no deferred tax asset has been recognized 90,254,547 87,970,140 80,706,629 Potential tax benefit 27.50% (2016: 28.50%) 23,104,882 22,596,182 22,194,323

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Loss per share for profit attributable to the ordinary equity holders of the company:
Schedule of Loss Per Share	(a) Basic/diluted loss per share Consolidated entity 31 December 31 December From continuing operations (0.08 ) (0.12 )
Schedule of Reconciliation of Earnings Used in Calculating Earnings Per Share	(b) Reconciliation of earnings used in calculating earnings per share Consolidated entity 31 December 31 December Basic earnings per share Loss attributable to the ordinary equity holders of the company used in calculating basic/diluted earnings per share: From continuing operations 2,647,698 3,123,372
Schedule of Weighted Average Number of Shares Used as Denominator	(c) Weighted average number of shares used as denominator Consolidated entity 31 December 31 December Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share 3,331,576,766 2,558,004,460	The following reflects the income and share data used in the calculations of basic and diluted loss per share: 2019 2018 2017 Loss for the year attributable to the owners of Genetic Technologies Limited (6,425,604 ) (5,463,872 ) (8,403,826 ) Weighted average number of Ordinary Shares used in calculating loss per share 2,635,454,870 2,435,282,724 2,121,638,888

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Jun. 30, 2019
Cash and cash equivalents [abstract]
Schedule of Cash and Cash Equivalents	Consolidated 2019 2018 2017 A$ A$ A$ Reconciliation of cash and cash equivalents Cash at bank and on hand 2,131,741 5,487,035 10,988,255 Total cash and cash equivalents 2,131,741 5,487,035 10,988,255 Reconciliation of loss for the year Reconciliation of loss for the year after income tax to net cash flows used in operating activities is as follows: Loss for the year after income tax (6,425,604 ) (5,463,872 ) (8,403,826 ) Adjust for non-cash items Amortization and depreciation expenses 156,260 303,749 371,611 Impairment of intangible assets — 544,694 Impairment of investments 500,000 Share-based payments expense 335,102 129,635 120,287 interest classified as investing cash flows (25,850 ) 15,219 — Net (profit) / loss on disposal of plant and equipment — — (52,188 ) Net (gains) / losses on liquidation of subsidiary — (527,049 ) — Net foreign exchange (gains) / losses (92,518 ) (128,360 ) 175,038 Adjust for changes in assets and liabilities (Increase) / decrease in trade and other receivables (517,383 ) 124,889 204,501 (Increase) / decrease in prepayments and other assets (42,885 ) 14,843 103,488 Increase / (decrease) in trade and other payables 60,178 47,027 60,120 Increase / (decrease) in provisions (20,482 ) (122,176 ) 62,636 Net cash flows from / (used in) operating activities (6,073,182 ) (5,636,533 ) (6,813,639 ) Financing facilities available As at June 30, 2019, the following financing facilities had been negotiated and were available: Total facilities Credit cards 95,714 183,770 306,128 Facilities used as at reporting date Credit cards (6,516 ) (12,031 ) (12,428 ) Facilities unused as at reporting date Credit cards 89,198 171,739 293,700

Trade and Other Receivables (_2

Trade and Other Receivables (Current) (Tables)	12 Months Ended
	Jun. 30, 2019
Trade and other current receivables [abstract]
Schedule of Trade and Other Receivables (current)	Consolidated 2019 2018 A$ A$ Trade receivables 16,529 10,503 Less: 2019: Impairment allowance / 2018: provision for doubtful debts — — Net trade receivables 16,529 10,503 Other receivables* 802,237 290,880 Total net current trade and other receivables 818,766 301,383 ● Other receivables majorly consists of R&D income grant receivable.

Prepayments and Other Assets _2

Prepayments and Other Assets (Current) (Tables)	12 Months Ended
	Jun. 30, 2019
PREPAYMENTS AND OTHER ASSETS (CURRENT)
Schedule of Prepayments and Other Assets (Current)	2019 2018 Prepayments 159,844 139,767 Inventories at the lower of cost and net realizable value 31,865 59,007 Performance bond and deposits 53,456 3,505 Total current prepayments and other assets 245,165 202,279

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jun. 30, 2019
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of Property, Plant and Equipment	Consolidated 2019 2018 A$ A$ Laboratory equipment, at cost 1,451,389 1,451,389 Less: accumulated depreciation (1,410,877 ) (1,355,397 ) Net laboratory equipment 40,512 95,992 Computer equipment, at cost 609,550 609,550 Add: additions during the year 47,715 — Less: accumulated depreciation (628,868 ) (563,208 ) Net computer equipment 28,397 46,342 Office equipment, at cost 167,564 167,564 Less: accumulated depreciation (167,564 ) (166,807 ) Net office equipment — 757 Equipment under hire purchase, at cost 594,626 594,626 Less: accumulated depreciation (594,626 ) (594,626 ) Net equipment under hire purchase — — Leasehold improvements, at cost 462,797 462,797 Add: additions during the year 2,583 Less: accumulated depreciation (464,956 ) (430,604 ) Net leasehold improvements 424 32,193 Total net property, plant and equipment 69,333 175,284 Reconciliation of property, plant and equipment Opening gross carrying amount 3,285,926 3,283,541 Add: additions purchased during the year 50,297 2,385 Less: disposals made during the year — — Closing gross carrying amount 3,336,223 3,285,926 Opening accumulated depreciation and impairment losses (3,110,642 ) (2,806,893 ) Add: disposals made during the year — — Less: depreciation expense charged (156,248 ) (303,749 ) Closing accumulated depreciation and impairment losses (3,266,890 ) (3,110,642 ) Total net property, plant and equipment 69,333 175,284
Schedule of Reconciliation of Movements in Property, Plant and Equipment by Asset Category	Reconciliation of movements in property, plant and equipment by asset category Opening Closing net carrying Additions Disposals Depreciation net amount during year during year expense amount Asset category A$ A$ A$ A$ A$ Laboratory equipment 95,992 — — (55,480 ) 40,512 Computer equipment 46,342 47,714 — (66,416 ) 28,397 Leasehold improvements 32,193 2,583 — (34,352 ) 424 Totals 175,284 50,297 — (156,248 ) 69,333

Trade and Other Payables (Cur_2

Trade and Other Payables (Current) (Tables)	12 Months Ended
	Jun. 30, 2019
Trade and other payables [abstract]
Schedule of Trade and Other Payables	Consolidated 2019 2018 A$ A$ Trade payables 590,231 535,924 Other payables 68,423 222,502 Accrued expenses 346,654 186,704 Total current trade and other payables 1,005,308 945,130

Provisions (Current and Non-C_2

Provisions (Current and Non-Current) (Tables)	12 Months Ended
	Jun. 30, 2019
Provisions [abstract]
Schedule of Current and Non-current Provisions	2019 2018 A$ A$ Current provisions Annual leave 152,352 145,449 Long service leave 243,740 268,544 Make good * 91,590 91,590 Total current provisions 487,682 505,583 Non-current provisions Long service leave 809 3,390 Make good * — — Total non-current provisions 809 3,390 Total provisions 488,491 508,973 * Make good provision
Schedule of Reconciliation of Provision	Consolidated 2019 2018 A$ A$ Reconciliation of annual leave provision Balance at the beginning of the financial year 145,499 239,821 Add: obligation accrued during the year 91,106 155,967 Less: utilized during the year (84,253 ) (250,289 ) Balance at the end of the financial year 152,352 145,499 Reconciliation of long service leave provision Balance at the beginning of the financial year 271,933 299,739 (Less)/ Add: obligation accrued during the year 10,226 (27,806 ) Less: utilized during the year (37,610 ) — Balance at the end of the financial year 244,549 271,933

Equity (Tables)

Equity (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Disclosure of classes of share capital [abstract]
Schedule of Issued and Paid-Up Capital	31 December 31 December 30 June 30 June Fully paid 4,063,134,143 127,807,987 2,938,134,143 125,498,824	Consolidated 2019 2018 A$ A$ Issued and paid-up capital Fully paid Ordinary Shares 125,498,824 122,372,662 Total contributed equity 125,498,824 122,372,662
Schedule of Movements in Shares On Issue	(a) Share capital (i) Movements in ordinary shares Details Number of $ Balance at 1 July 2019 2,938,134,143 125,498,824 Rights issue* 1,125,000,000 4,499,965 Less: transaction costs arising on share issue - (2,190,802 ) Balance at 31 December 2019 4,063,134,143 127,807,987 *On 11 October 2019, the company invited its shareholders to subscribe to a fully underwritten rights issue of 1,125,000,000 ordinary shares at an issue price of $0.4 cents per share on the basis of 1 new share for every 2 fully paid ordinary shares held.	Year ended June 30, 2018 Shares $ Balance at the beginning of the financial year 2,435,282,724 122,382,625 Less: transaction costs arising on share issue — (9,963 Balance at the end of the financial year 2,435,282,724 122,372,662 Year ended June 30, 2019 Shares $ Balance at the beginning of the financial year 2,435,282,724 122,372,662 Shares issued during the year 502,851,419 3,557,509 Less: transaction costs arising on share issue (431,347 Balance at the end of the financial year 2,938,134,143 125,498,824
Schedule of Other Reserves	(b) Other reserves Consolidated entity Share- based Foreign Total Balance at 1 July 2018 4,885,232 765,930 5,651,162 Currency translation differences - 23,668 23,668 Other comprehensive income for the period - 23,668 23,668 Transactions with owners in their capacity as owners Share-based payment expenses 341,201 - 341,201 Reversal of forfeited options (6,099 ) (6,099 ) At 30 June 2019 5,220,334 789,598 6,009,932 Consolidated entity Share- based Foreign Total Balance at 1 July 2019 5,220,334 789,598 6,009,932 Currency translation differences - (381,163 ) (381,163 ) Other comprehensive income for the period - (381,163 ) (381,163 ) Transactions with owners in their capacity as owners Share-based payment expenses 33,771 - 33,771 Reversal of forfeited performance rights (81,982 ) - (81,982 ) Issue of options to underwriters 1,873,720 - 1,873,720 At 31 December 2019 7,045,843 470,648 7,516,491 Details Number of Number of Total Balance at 1 July 2019 76,250,000 38,000,000 5,220,334 Reversal of forfeited performance rights (61,250,000 ) - (81,982 ) Issue of Options to underwriters - 500,000,000 1,873,720 Share based payment expense - - 33,771 Balance 31 December 2019 15,000,000 538,000,000 7,045,843
Schedule of Option Issued	The following are the valuation details towards the options issued to underwriters for the capital raise in October 2019. 2019 Grant Date 30 Oct 2019 Options issued 250,000,000 Dividend yield - Historic volatility and expected volatility 136 % Option exercise price $ 0.008 Fair value of options at grant date $ 0.003 Weighted average exercise price $ 0.008 Risk-free interest rate 0.78 % Expected life of an option 3 years Model used Black-Scholes 2019 Grant Date 20 Dec 2019 Options issued 250,000,000 Dividend yield - Historic volatility and expected volatility 136 % Option exercise price $ 0.008 Fair value of options at grant date $ 0.004 Weighted average exercise price $ 0.008 Risk-free interest rate 0.85 % Expected life of an option 3 years Model used Black-Scholes

Reserves (Tables)

Reserves (Tables)	12 Months Ended
	Jun. 30, 2019
Disclosure of reserves within equity [abstract]
Schedule of Reserves	Consolidated 2019 2018 A$ A$ Foreign currency translation 789,598 765,930 Share-based payments 5,220,334 4,885,232 Total reserves 6,009,932 5,651,162 Reconciliation of foreign currency translation reserve Balance at the beginning of the financial year 765,930 1,288,896 Add: net currency translation gain / (loss) 23,668 (522,966 ) Balance at the end of the financial year 789,598 765,930 Reconciliation of share-based payments reserve Balance at the beginning of the financial year 4,885,232 4,755,597 Add: share-based payments expense 341,201 129,635 Less: Reversal of forfeited/lapsed options (6,099 ) Balance at the end of the financial year 5,220,334 4,885,232

Accumulated Losses (Tables)

Accumulated Losses (Tables)	12 Months Ended
	Jun. 30, 2019
ACCUMULATED LOSSES
Schedule of Accumulated Losses	Balance at the beginning of the financial year (123,311,946 ) (117,848,074 ) Add: net loss attributable to owners of Genetic Technologies Limited (6,425,604 ) (5,463,872 ) Balance at the end of the financial year (129,737,550 ) (123,311,946 )

Options (Tables)

Options (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of Number and Weighted Average Exercise Prices of Share Options		Ave. exercise price per option Number of options and performance rights As at 1 July $ 0.017 55,102,778 Granted to KentGrove Capital $ 0.015 12,500,000 Granted to employees during the year $ 0.010 16,000,000 Lapsed during the year $ 0.020 (19,236,111 ) Forfeited during the year $ 0.001 (6,000,000 ) Lapse of unlisted options attached to convertible notes $ 0.015 (20,366,667 ) As at 30 June $ 0.015 38,000,000
Schedule of Fair Value of Each Option Granted by an External Valuer	The following are the valuation details towards the options issued to underwriters for the capital raise in October 2019. 2019 Grant Date 30 Oct 2019 Options issued 250,000,000 Dividend yield - Historic volatility and expected volatility 136 % Option exercise price $ 0.008 Fair value of options at grant date $ 0.003 Weighted average exercise price $ 0.008 Risk-free interest rate 0.78 % Expected life of an option 3 years Model used Black-Scholes 2019 Grant Date 20 Dec 2019 Options issued 250,000,000 Dividend yield - Historic volatility and expected volatility 136 % Option exercise price $ 0.008 Fair value of options at grant date $ 0.004 Weighted average exercise price $ 0.008 Risk-free interest rate 0.85 % Expected life of an option 3 years Model used Black-Scholes
Summary of Options Over Ordinary Shares Outstanding		As at June 30, 2019, the following options over Ordinary Shares in the Company were outstanding. 2019 Weighted ave. exercise price 2018 Weighted ave. exercise price Unlisted employee options (refer below) 25,500,000 $ 0.015 34,736,111 $ 0.017 Unlisted options attached to convertible notes — — 20,366,667 $ 0.015 Unlisted options granted to KentGrove Capital 12,500,000 $ 0.015 — — 38,000,000 $ 0.015 55,102,778 $ 0.016
Schedule of Number of Options Granted Under the Plans		The movements in the number of options granted under the Plans are as follows: 2019 Weighted ave. exercise price 2018 Weighted ave. exercise price Unlisted employee options Balance at the beginning of the financial year 34,736,111 $ 0.017 54,736,111 $ 0.016 Add: options granted during the year 16,000,000 $ 0.010 — — Less: options lapsed during the year (19,236,111 ) $ 0.020 — — Less: options forfeited during the year (6,000,000 ) $ 0.010 (20,000,000 ) $ 0.014 Balance at the end of the financial year 25,500,000 $ 0.015 34,736,111 $ 0.017
Schedule of Members of Options Outstanding by Asx Code		The options tabled below are not listed on ASX. Option description 2019 Weighted ave. exercise price 2018 Weighted ave. exercise price Unlisted employee options Options to Kentgrove (expiring August 8, 2021) 12,500,000 $ 0.015 — — GTGAD (expiring September 14, 2020) — — — — GTGAD (expiring November 24, 2020) — — 19,236,111 $ 0.020 GTGAD (expiring March 31, 2021) 5,000,000 $ 0.020 5,000,000 $ 0.020 GTGAD (expiring February 16, 2022) 5,500,000 $ 0.010 10,500,000 $ 0.010 ESOP options (expiring December 11, 2021) 15,000,000 $ 0.010 — — Balance at the end of financial year 38,000,000 $ 0.015 34,736,111 $ 0.017 Unlisted options attached to convertible notes GTGAC (expiring December 2, 2018) — — 20,366,667 $ 0.015 Balance at the end of the financial year 38,000,000 $ 0.015 55,102,778 $ 0.016 Exercisable at the end of the financial year 38,000,000 $ 0.015 48,102,778 $ 0.017
Kentgrove Capital Pty Ltd [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of Fair Value of Each Option Granted by an External Valuer		The options granted to Kentgrove Capital Pty Ltd were valued based on the following: 2019 Grant Date 08 Aug 2018 Options issued 12,500,000 Dividend yield — Historic volatility and expected volatility 80 % Option exercise price $ 0.0153 Weighted average exercise price $ 0.0153 Risk-free interest rate 2.02 % Expected life of an option 3 years Model used Black-Scholes Fair value of options at grant date $ 0.0040

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Disclosure of operating segments [abstract]
Summary of Reportable Segments Financial Information	The segment information for the reportable segment for the half-year 31 December 2019 is as follows: Consolidated entity Sales Other Totals Profit /(loss) Operations 586 447,756 448,342 (2,647,698 ) December 2018 Operations 18,402 338,588 356,990 (3,123,372 ) Consolidated entity Assets Liabilities Amortisation/ Purchases Operations 4,343,606 (1,481,301 ) (39,561 ) 2,521 June 2019 Operations 3,265,005 (1,493,799 ) (156,248 ) 5,353	The Company’s operating segment is summarized as follows: Business segments Revenues and income Segment Sales Other Totals Profit / (loss) A$ A$ A$ A$ Operations 2019 25,444 1,019,769 1,045,213 (6,425,604 ) 2018 189,254 441,476 630,730 (5,463,872 ) 2017 518,506 344,112 862,618 (8,403,826 ) Amortization Purchases of Segment Assets Liabilities /depreciation equipment A$ A$ A$ A$ Operations 2019 3,265,005 (1,493,799 ) (156,248 ) 5,353 2018 6,165,981 (1,454,103 ) (303,749 ) 2,385 2017 12,108,297 (1,529,253 ) (371,611 ) 234,799
Summary of Geographical Information	The segment information for the reportable segment for the half-year 31 December 2019 and 2018 is as follows: Consolidated entity Sales Other Totals Profit/(loss) Australia - 447,756 447,756 (2,418,577 ) U.S. 586 - 586 (229,121 ) Total 586 447,756 448,342 (2,647,698 ) December 2018 Australia - 338,588 338,588 (1,580,663 ) U.S. 18,402 - 18,402 (1,542,709 ) Total 18,402 338,588 356,990 (3,123,372 )	Geographic information Revenues and income Sales Other Totals Profit/(Loss) A$ A$ A$ A$ Australia 2019 5,247 1,019,769 1,025,016 (5,791,950 ) 2018 — 441,476 441,476 (3,504,098 ) 2017 18,215 344,112 362,327 (7,000,994 ) U.S. 2019 20,197 — 20,197 (633,654 ) 2018 189,254 — 189,254 (1,959,774 ) 2017 500,291 — 500,291 (1,371,001 ) Other 2019 — — — — 2018 — — — — 2017 — — — (31,831 ) Totals 2019 25,444 1,019,769 1,045,213 (6,425,604 ) 2018 189,254 441,476 630,730 (5,463,872 ) 2017 518,506 344,112 862,618 (8,403,826 )
Summary of Intersegment Balances and Transactions		Included in the above figures are the following intersegment balances and transactions: Consolidated 2019 2018 2017 A$ A$ A$ Foreign exchange gain (U.S.) and foreign exchange loss (Australia) 291,542 981,141 776,295 Cost of sales (U.S.) and sales (Australia) 9,708 38,352 74,762

Share Based Payments (Tables)

Share Based Payments (Tables)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of Fair Value of Each Option Granted by an External Valuer	The following are the valuation details towards the options issued to underwriters for the capital raise in October 2019. 2019 Grant Date 30 Oct 2019 Options issued 250,000,000 Dividend yield - Historic volatility and expected volatility 136 % Option exercise price $ 0.008 Fair value of options at grant date $ 0.003 Weighted average exercise price $ 0.008 Risk-free interest rate 0.78 % Expected life of an option 3 years Model used Black-Scholes 2019 Grant Date 20 Dec 2019 Options issued 250,000,000 Dividend yield - Historic volatility and expected volatility 136 % Option exercise price $ 0.008 Fair value of options at grant date $ 0.004 Weighted average exercise price $ 0.008 Risk-free interest rate 0.85 % Expected life of an option 3 years Model used Black-Scholes
Schedule of Independent Valuation of Performance Rights Granted		Valuation of Class A Performance Rights Number of Performance Rights issued Valuation per Class A (cents) Total fair value of Class A Performance Rights Expense accounted for during the year Dr Paul Kasian 7,500,000 0.77 $ 57,750 $ 11,229 Dr Lindsay Wakefield 3,750,000 0.77 $ 28,875 $ 5,614 Dr Jerzy Muchnicki 6,250,000 0.77 $ 48,125 $ 9,358 Mr Peter Rubinstein 5,000,000 0.77 $ 38,500 $ 7,486 Mr Sam Lee 3,750,000 0.77 $ 28,875 $ 5,614 Valuation of Class B Performance Rights Number of Performance Rights issued Valuation per Class B (cents) Class B Performance Rights Expense accounted for during the year Dr Paul Kasian 25,000,000 0.77 $ 192,500 $ 37,431 Valuation of Class C Performance Rights Number of Performance Rights issued Valuation per Class C (cents) Class C Performance Rights Expense accounted for during the year Dr Paul Kasian 25,000,000 0.57 $ 142,500 $ 27,708
Schedule of Expenses Arising from Share-based Payment Transactions Recognized Part of Employee Benefit Expense		Consolidated 2019 2018 2017 Kentgrove options issued 15,278 — — Performance rights issued 104,441 — 120,287 Options issued under employee option plan 215,383 129,635 120,287 Total expenses arising from share-based payments 335,102 129,635 120,287
Employee Stock Option [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of Fair Value of Each Option Granted by an External Valuer		2019 Grant Date 12 Dec 2018 Options issued 16,000,000 Dividend yield — Historic volatility and expected volatility 80 % Option exercise price $ 0.010 Weighted average exercise price $ 0.030 Risk-free interest rate 2.02 % Expected life of an option 2.8 years Model used Black-Scholes Fair value of options at grant date $ 0.0051
Subsidiaries [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of Fair Value of Each Option Granted by an External Valuer		2017 Grant Date 17 Feb 2017 Options issued 1,250,000 Dividend yield — Historic volatility and expected volatility 60 % Option exercise price $ 0.010 Weighted average exercise price $ 0.010 Risk-free interest rate 2.19 % Expected life of an option 4.5 years Model used Black-Scholes Fair value of options at grant date $ 0.0050
Subsidiaries [Member] | Employee Stock Option [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of Fair Value of Each Option Granted by an External Valuer		2017 2016 Grant Date 17 Feb 2017 1 April 2016 25 Nov 2015 Options issued 1,250,000 500,000 1,500,000 Dividend yield — — — Historic volatility and expected volatility 60% 80% 80% Option exercise price $0.010 $0.039 $0.058 Fair value of options at grant date $0.0050 $0.0065 $0.0139 Weighted average exercise price $0.010 $0.039 $0.058 Risk-free interest rate 2.19% 1.93% 2.22% Expected life of an option 4.5 years 4.3 years 4.5 years Model used Black-Scholes Black-Scholes Black-Scholes
Key Management Personnel Of Entity Or Parent [Member] | Employee Stock Option [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of Fair Value of Each Option Granted by an External Valuer		Grant Date 17 Feb 2017 Options issued 21,500,000 Dividend yield — Historic volatility and expected volatility 60 % Option exercise price $ 0.010 Weighted average exercise price $ 0.010 Risk-free interest rate 2.19 % Expected life of an option 4.5 years Model used Black-Scholes Fair value of options at grant date $ 0.0050

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2019
Disclosure of contingent liabilities [abstract]
Schedule of Operating Lease Expenditure Commitments	Consolidated 2019 2018 2017 Operating lease expenditure commitments A$ A$ A$ Minimum operating lease payments - not later than one year 250,068 41,625 227,992 - later than one year but not later than five years 266,560 — 35,676 - later than five years — — — Total minimum operating lease payments 516,628 41,625 263,668
Schedule of Operating Lease Payments	As at June 30, 2019, the above operating leases related to the following premises that are currently occupied by the Company: Location Landlord Use Date of expiry of lease Minimum payments ($) 60-66 Hanover Street Crude Pty. Ltd. Office / laboratory August 31, 2021 487,837 1300 Baxter Street, Suite 157, Charlotte, North Carolina Mid-Town Partners LLC Office Month to month 28,791 Total 516,628

Auditors' Remuneration (Tables)

Auditors' Remuneration (Tables)	12 Months Ended
	Jun. 30, 2019
Auditor's remuneration [abstract]
Schedule of Auditor's Remuneration	Consolidated 2019 2018 2017 A$ A$ A$ Audit and assurance services PricewaterhouseCoopers in respect of: Audit(1) 288,000 288,200 325,972 Audit related — — 107,451 Other audit firms in respect of: Audit of the Financial Reports of subsidiaries — — 4,070 Total remuneration in respect of audit services 288,000 288,200 437,493 (1) Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2019
Disclosure of transactions between related parties [abstract]
Schedule of Remuneration of Key Management Personnel	Consolidated 2019 2018 2017 A$ A$ A$ Remuneration of Key Management Personnel Short-term employee benefits 964,162 1,215,632 1,533,457 Post-employment benefits 86,130 96,315 101,320 Share-based payments 157,886 130,385 121,269 Other long-term benefits 734 2,371 61,594 Termination benefits — 164,760 — Total remuneration of Key Management Personnel 1,208,912 1,609,463 1,817,640

Subsidiaries (Tables)

Subsidiaries (Tables)	12 Months Ended
	Jun. 30, 2019
Disclosure of subsidiaries [abstract]
Schedule of Subsidiary Undertakings	Company interest (%) Net carrying value ($) Name of Company Incorporation details 2019 2018 2019 2018 Entities held directly by parent GeneType Pty. Ltd. September 5, 1990 100 % 100 % — — Genetic Technologies Corporation Pty. Ltd. October 11, 1996 100 % 100 % 2 2 Gene Ventures Pty. Ltd. * March 7, 2001 100 % 100 % 10 10 GeneType AG ** February 13, 1989 — — — — GeneType Corporation December 18, 1989 100 % 100 % — — Phenogen Sciences Inc. (BREVAGen TM ) June 28, 2010 100 % 100 % 11,006 11,006 Genetic Technologies HK Ltd March 18, 2019 100 % N/A — — Total carrying value 11,018 11,018 * On 26 April 2018, the name of RareCellect Pty Ltd (ACN 096 135 9847) was changed to Gene Ventures Pty Ltd (ACN 096 135 947) ** Liquidation of GeneType AG was completed on 13 December 2017

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
	Jun. 30, 2019
Disclosure of detailed information about financial instruments [abstract]
Schedule of Financial Instruments	The Company holds the following financial instruments: Consolidated 2019 2018 A$ A$ Financial assets Cash at bank / on hand 2,131,741 5,487,035 Trade and other receivables 818,766 301,383 Performance bond and deposits 53,456 3,505 Total financial assets 3,003,963 5,791,923 Financial liabilities Trade and other payables 1,005,308 945,130 Total financial liabilities 1,005,308 945,130
Schedule of Analysis of Aging of Trade and Other Receivables	An analysis of the aging of trade and other receivables s is provided below: Consolidated 2019 2018 A$ A$ Net trade and other receivables Current (less than 30 days) 802,237 294,454 31 days to 60 days 11,159 3142 61 days to 90 days (note) — 783 Greater than 90 days (note) 5,370 3004 Total net trade and other receivables (Note 12) 818,766 301,383
Schedule of Financial Assets and Liabilities That Were Denominated in Foreign Currencies	As at June 30, 2019, the Company held the following financial assets and liabilities that were denominated in foreign currencies: Consolidated Year USD EUR CHF Financial assets Cash at bank / on hand 2019 201,737 27,052 — 2018 2,154,291 28,952 — Bonds and deposits 2019 1,986 — — 2018 3,505 — — Total financial assets 2019 203,723 27,052 — 2018 2,157,796 28,952 — Financial liabilities Trade and other payables 2019 117,992 1,900 — 2018 116,063 — — Total financial liabilities 2019 117,992 1,900 — 2018 116,063 — —
Schedule of Exposure to Interest Rate Risks and Effective Interest Rates of Financial Assets and Liabilities	The exposure to interest rate risks and the effective interest rates of financial assets and liabilities, both recognized and unrealized, for the Company is as follows: Floating rate Fixed rate Carrying amount Weighted ave. effective rate Ave. maturity Period Consolidated Year A$ A$ A$ % Days Financial assets Cash at bank / on hand 2019 2,131,741 2,131,741 1.74 % At call 2018 2,394,754 — 2,394,754 1.74 % At call Performance bond / deposits 2019 53,456 53,456 — At call 2018 — 3,505 3,505 — At call Totals 2019 2,131,741 53,456 2,131,741 2018 2,394,754 3,505 2,398,259 Financial liabilities Financial liabilities at fair value through profit or loss 2019 — — — — — 2018 — — — — — Totals 2019 — — — 2018 — — —
Schedule of Liquidity Risk	A balanced view of cash inflows and outflows affecting the Company is summarized in the table below: < 6 months 6 to 12 months 1 to 5 years > 5 years Totals Consolidated Year A$ A$ A$ A$ A$ Financial assets Cash at bank / on hand 2019 2,131,741 2,131,741 2018 5,487,035 — — — 5,487,035 Trade and other receivables 2019 818,766 818,766 2018 301,383 — — — 301,383 Performance bond and deposits 2019 53,456 53,456 2018 3,505 — — — 3,505 Total financial assets 2019 3,003,963 3,003,963 2018 5,791,923 — — — 5,791,923 Financial liabilities Trade and other payables 2019 1,005,308 1,005,308 2018 945,130 — — — 945,130 Total financial liabilities 2019 1,005,308 1,005,308 2018 945,130 — — — 945,130 Net maturity 2019 (1,998,655 ) (1,998,655 ) 2018 4,846,793 — — — 4,846,793 The Company had access to the following undrawn borrowing facility as at June 30, 2019: Facility limit Amount used Amount available A$ A$ A$ Nature of facility Credit card facility 95,714 -6,516 89,198

Basis of Preparation of Half-_3

Basis of Preparation of Half-Year Report (Details Narrative) (6-K) - AUD ($)	6 Months Ended			12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jul. 02, 2019	Aug. 08, 2018	Jun. 30, 2016
Statement Line Items [Line Items]
Profit loss	$ (2,647,698)	$ (3,028,861)	$ (3,123,372)	$ (6,425,604)	$ (5,463,872)	$ (8,403,826)
Net assets	2,862,305	2,862,305		1,771,206	4,711,878
Cash and cash equivalents	$ 3,277,074	$ 3,277,074	$ 3,234,640	$ 2,131,741	$ 5,487,035	$ 10,988,255			$ 11,179,687
Weighted average lessee's incremental borrowing rate							5.37%
Loss per share	$ 0.03
Description on short-term leases	Short-term leases are leases with a lease term of 12 months or less.
Equity Placement Facility With Kentgrove Capital Private Limited [Member]
Statement Line Items [Line Items]
Equity capital								$ 20,000,000
Individual placements								$ 1,000,000

Basis of Preparation of Half-_4

Basis of Preparation of Half-Year Report - Schedule of Operating Lease Liability (Details) (6-K) - AUD ($)	6 Months Ended
	Dec. 31, 2019	Jul. 02, 2019	Jun. 30, 2019
Basis Of Preparation Of Half-year Report
Operating lease commitments disclosed as at 30 June 2019	$ 487,837		$ 487,849
Discounted using the lessee's incremental borrowing rate of at the date of initial application	461,358
Lease liability recognised as at 1 July 2019	461,358
Current lease liabilities	224,780	$ 209,887
Non-current lease liabilities	137,307	$ 251,471
Right of use of assets increased by	446,645
Lease liabilities increased by	461,358
The net impact on retained earnings on 1 July 2019 was a decrease of	$ 14,712

Segment Information (Details Na

Segment Information (Details Narrative) (6-K)	6 Months Ended		12 Months Ended
	Dec. 31, 2019AUD ($)CustomersSegment	Dec. 31, 2018AUD ($)Customers	Jun. 30, 2019AUD ($)	Dec. 31, 2018AUD ($)Customers	Jun. 30, 2018AUD ($)	Jun. 30, 2017AUD ($)
Statement Line Items [Line Items]
Number of operating segments | Segment	1
Property, plant and equipment, depreciation	$ 12,156		$ 55,480	$ 12,199	$ 65,853	$ 71,139
Leased assets	103,635
Employee expenses			2,414,408		2,657,232	3,594,936
Cost of goods sold	$ 194,501	$ 79,674	$ 276,267		$ 300,088	$ 492,417
Number of customer generated revenues representing more than 10% of total consolidated revenue from operations | Customers	0	0		0
Laboratory Specific Employees [Member]
Statement Line Items [Line Items]
Cost of goods sold	$ 109,581	$ 32,670
Laboratory Specific Equipment [Member]
Statement Line Items [Line Items]
Property, plant and equipment, depreciation	27,405	28,408
Laboratory and Research and Development [Member]
Statement Line Items [Line Items]
Employee expenses	$ 675,822	$ 1,100,509

Segment Information - Summary o

Segment Information - Summary of Reportable Segments Financial Information (Details) (6-K) - AUD ($)	6 Months Ended			12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Other	$ 447,756		$ 338,588
Profit/(loss)	(2,647,698)	$ (3,028,861)	(3,123,372)	$ (6,425,604)	$ (5,463,872)	$ (8,403,826)
Assets	4,343,606	4,343,606		3,265,005	6,165,981
Liabilities	(1,481,301)	(1,481,301)		(1,493,799)	(1,454,103)
Business Segments [Member]
Statement Line Items [Line Items]
Sales	586		18,402	25,444	189,254	518,506
Other	447,756		338,588	1,019,769	441,476	344,112
Totals	448,342		356,990	1,045,213	630,730	862,618
Profit/(loss)	(2,647,698)		$ (3,123,372)	(6,425,604)	(5,463,872)	(8,403,826)
Assets	4,343,606	4,343,606		3,265,005	6,165,981	12,108,297
Liabilities	(1,481,301)	$ (1,481,301)		(1,493,799)	(1,454,103)	(1,529,253)
Amortisation/depreciation	(39,561)			(156,248)	(303,749)	(371,611)
Purchases of equipment	$ 2,521			$ 5,353	$ 2,385	$ 234,799

Segment Information - Summary_2

Segment Information - Summary of Geographical Information (Details) (6-K) - AUD ($)	6 Months Ended			12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Other	$ 447,756		$ 338,588
Profit/(loss)	(2,647,698)	$ (3,028,861)	(3,123,372)	$ (6,425,604)	$ (5,463,872)	$ (8,403,826)
Business Segments [Member]
Statement Line Items [Line Items]
Sales	586		18,402	25,444	189,254	518,506
Other	447,756		338,588	1,019,769	441,476	344,112
Totals	448,342		356,990	1,045,213	630,730	862,618
Profit/(loss)	(2,647,698)		(3,123,372)	(6,425,604)	(5,463,872)	(8,403,826)
Business Segments [Member] | Australia [Member]
Statement Line Items [Line Items]
Sales				5,247		18,215
Other	447,756		338,588	1,019,769	441,476	344,112
Totals	447,756		338,588	1,025,016	441,476	362,327
Profit/(loss)	(2,418,577)		(1,580,663)	$ (5,791,950)	$ (3,504,098)	$ (7,000,994)
Business Segments [Member] | U.S. [Member]
Statement Line Items [Line Items]
Sales	586		18,402
Other
Totals	586		18,402
Profit/(loss)	$ (229,121)		$ (1,542,709)

Other Income and Expense Item_2

Other Income and Expense Items - Schedule of Other income (Details) (6-K) - AUD ($)		6 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Other Income And Expense Items
R&D Grant Income	[1]	$ 400,000	$ 186,000
Other		47,756	152,588
Total Other income		$ 447,756	$ 338,588
[1]	The group's research and development activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the half year ended 31 December 2019, the group has included an item in other income of $400,000 (2018: $186,000) to recognise income over the period necessary to match the grant on a systematic basis with the costs that they are intended to compensate.

Other Income and Expense Item_3

Other Income and Expense Items - Schedule of Other income (Details) (6-K) (Parenthetical) - AUD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Other Income And Expense Items
Other income recognized over the period	$ 400,000	$ 186,000

Equity - Schedule of Issued and

Equity - Schedule of Issued and Paid-up Capital (Details) (6-K) - Ordinary Shares [Member] - AUD ($)	Dec. 31, 2019	Jun. 30, 2019
Statement Line Items [Line Items]
Fully paid, shares	4,063,134,143	2,938,134,143
Fully paid, value	$ 127,807,987	$ 125,498,824

Equity - Schedule of Movements

Equity - Schedule of Movements in Shares On Issue (Details) (6-K) - AUD ($)		Oct. 11, 2019	Dec. 31, 2019		Jun. 30, 2019	Jun. 30, 2018
Statement Line Items [Line Items]
Less: transaction costs arising on share issue, value					$ (431,347)	$ (9,963)
Ordinary Shares [Member]
Statement Line Items [Line Items]
Balance at 1 July 2019, shares			2,938,134,143
Balance at 1 July 2019, value			$ 125,498,824
Rights issue, shares		1,125,000,000	1,125,000,000	[1]
Rights issue, value	[1]		$ 4,499,965
Less: transaction costs arising on share issue, value			$ (2,190,802)
Balance at 31 December 2019, shares			4,063,134,143		2,938,134,143
Balance at 31 December 2019, value			$ 127,807,987		$ 125,498,824
[1]	On 11 October 2019, the company invited its shareholders to subscribe to a fully underwritten rights issue of 1,125,000,000 ordinary shares at an issue price of $0.4 cents per share on the basis of 1 new share for every 2 fully paid ordinary shares held.

Equity - Schedule of Movement_2

Equity - Schedule of Movements in Shares On Issue (Details) (6-K) (Parenthetical) - $ / shares	Oct. 11, 2019	Dec. 31, 2019	[1]	Oct. 04, 2019
Statement Line Items [Line Items]
Shares issued price per share				$ 0.40
Ordinary Shares [Member]
Statement Line Items [Line Items]
Rights issue, shares	1,125,000,000	1,125,000,000
Shares issued price per share	$ 0.4
Description on movements in ordinary shares	On the basis of 1 new share for every 2 fully paid ordinary shares held.
[1]	On 11 October 2019, the company invited its shareholders to subscribe to a fully underwritten rights issue of 1,125,000,000 ordinary shares at an issue price of $0.4 cents per share on the basis of 1 new share for every 2 fully paid ordinary shares held.

Equity - Schedule of Other Rese

Equity - Schedule of Other Reserves (Details) (6-K) - AUD ($)	6 Months Ended			12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Balance at the beginning	$ 6,009,932		$ 5,651,162	$ 5,651,162
Currency translation differences	(381,163)		(54,789)	23,668	$ (522,966)	$ (130,655)
Other comprehensive income for the period	(381,163)			23,668	(522,966)	(130,655)
Share-based payment expenses	33,771	$ 33,771	138,381	341,201	129,635	$ 120,287
Reversal of forfeited performance rights	(81,982)
Issue of options to underwriters	1,873,720	1,873,720
Reversal of forfeited options		(81,982)		(6,099)
Balance at the end	$ 7,454,278	$ 7,454,278		$ 6,009,932	5,651,162
Balance at the beginning, performance rights	76,250,000
Reversal of forfeited performance rights	(61,250,000)
Balance at the end, performance rights	15,000,000	15,000,000		76,250,000
Balance at the beginning, options	38,000,000
Issue of Options to underwriters	500,000,000
Balance at the end, options	538,000,000	538,000,000		38,000,000
Share-based Payment Arrangements [Member]
Statement Line Items [Line Items]
Balance at the beginning	$ 5,220,334		4,885,232	$ 4,885,232
Currency translation differences
Other comprehensive income for the period
Share-based payment expenses	33,771			341,201
Reversal of forfeited performance rights	(81,982)
Issue of options to underwriters	1,873,720
Reversal of forfeited options				(6,099)
Balance at the end	7,045,843	$ 7,045,843		5,220,334	4,885,232
Foreign Currency Translation [Member]
Statement Line Items [Line Items]
Balance at the beginning	789,598		$ 765,930	765,930
Currency translation differences	(381,163)			23,668
Other comprehensive income for the period	(381,163)			23,668
Share-based payment expenses
Reversal of forfeited performance rights
Issue of options to underwriters
Reversal of forfeited options
Balance at the end	$ 470,648	$ 470,648		$ 789,598	$ 765,930

Equity - Schedule of Option Iss

Equity - Schedule of Option Issued (Details) (6-K)	Dec. 20, 2019shares$ / shares	Oct. 30, 2019shares$ / shares	Jun. 30, 2019shares
Disclosure of classes of share capital [abstract]
Options issued | shares	250,000,000	250,000,000	16,000,000
Dividend yield
Historic volatility and expected volatility	136.00%	136.00%
Option exercise price	$ 0.008	$ 0.008
Fair value of options at grant date	0.004	0.003
Weighted average exercise price	$ 0.008	$ 0.008
Risk-free interest rate	0.85%	0.78%
Expected life of an option	3 years	3 years
Model used	Black-Scholes	Black-Scholes

Loss Per Share - Schedule of Lo

Loss Per Share - Schedule of Loss Per Share (Details) (6-K) - $ / shares	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Loss per share for profit attributable to the ordinary equity holders of the company:
From continuing operations	$ (0.08)	$ (0.12)

Loss Per Share - Schedule of Re

Loss Per Share - Schedule of Reconciliation of Earnings Used in Calculating Earnings Per Share (Details) (6-K) - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Loss per share for profit attributable to the ordinary equity holders of the company:
Loss attributable to the ordinary equity holders of the company used in calculating basic/diluted earnings per share: From continuing operations	$ 2,647,698	$ 3,123,372	$ (6,425,604)	$ (5,463,872)	$ (8,403,826)

Loss Per Share - Schedule of We

Loss Per Share - Schedule of Weighted Average Number of Shares Used as Denominator (Details) (6-K) - shares	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Loss per share for profit attributable to the ordinary equity holders of the company:
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share	3,331,576,766	2,558,004,460	2,635,454,870	2,435,282,724	2,121,638,888

Related Party Transactions (Det

Related Party Transactions (Details Narrative) (6-K)

Dec. 20, 2019$ / shares

Oct. 30, 2019$ / shares

Oct. 11, 2019AUD ($)$ / sharesshares

Jul. 11, 2019AUD ($)

Nov. 29, 2018shares

Aug. 02, 2018Tranchesshares

Dec. 31, 2018AUD ($)

Dec. 31, 2019AUD ($)Shareholdershares

Jun. 30, 2019AUD ($)shares$ / shares

Jun. 30, 2018AUD ($)

Jun. 30, 2017AUD ($)

Oct. 04, 2019$ / shares

Aug. 31, 2018AUD ($)

Statement Line Items [Line Items]

Number of shareholders that control more than 50% of the issued capital | Shareholder

Number of shares issued price per share | $ / shares

$ 0.40

Exercise price of options | $ / shares

$ 0.008

$ 0.008

Share-based payments expense

$ 335,102

$ 129,635

$ 120,287

Investment

11,018

11,018

Blockshine Health Pty Ltd [Member]

Statement Line Items [Line Items]

Investments in joint ventures accounted for using equity method

$ 250,000

$ 250,000

$ 250,000

Ownership interest, percentage

49.00%

49.00%

49.00%

Genetic Technologies Hk Limited And Aocheng Genetic Technologies Co. Ltd [Member]

Statement Line Items [Line Items]

Minimum amount for gaining access

$ 800,000,000,000

Performance Rights [Member]

Statement Line Items [Line Items]

Exercise price of options | $ / shares

$ 0

Number of rights issued | shares

76,250,000

Share-based payments expense

$ 33,771

$ 104,441

$ 120,287

Framework Agreement With Blockchain Global Limited [Member]

Statement Line Items [Line Items]

Number of shares proposed to be issued upon achievement of milestone | shares

486,000,000

Number of tranches | Tranches

3

Framework Agreement With Blockchain Global Limited [Member] | Mr. Sam Lee [Member]

Statement Line Items [Line Items]

Percentage of direct and indirect share interest on entity

21.00%

Framework Agreement With Blockchain Global Limited [Member] | Mr Peter Rubinstein [Member]

Statement Line Items [Line Items]

Percentage of direct and indirect share interest on entity

8.00%

Framework Agreement With Blockchain Global Limited [Member] | Mr. George Muchnicki [Member]

Statement Line Items [Line Items]

Percentage of direct and indirect share interest on entity

3.40%

Lodge Corporate [Member]

Statement Line Items [Line Items]

Services received, related party transactions

$ 121,225

$ 67,000

Underwriting of capital raise

$ 88,000

Percentage of underwriting capital raise

2.00%

Mr. Philips Hains [Member]

Statement Line Items [Line Items]

Services received, related party transactions

$ 251,170

Number of years of extensive experience

30 years

Peter Rubinstein and Dr. George Muchnicki [Member]

Statement Line Items [Line Items]

Description on transaction with related parties

On 11 October 2019, the Company updated the market to advise that the offer was from that time agreed to be underwritten by Lodge Corporate Pty Ltd and that two of the Company's directors (Peter Rubinstein and Dr. George Muchnicki), had agreed to sub-underwrite the offer. Both directors, in conjunction with the underwriter Lodge Corporate Pty Ltd, subsequently agreed amongst themselves to alter the respective sub-underwritten amounts, but the total to be sub-written between them ($2 million) remained same, as did the total underwritten amount (of $4 million). Accordingly, the underwritten offer subsequently was sub-underwritten by Peter Rubinstein and Dr. George Muchnicki (each as up to $1 million) in conjunction with a consortium of non-associated wholesale investors (also as sub-underwriters) who in aggregate equate to the underwritten amount of $4 million, each in accordance with the terms of their separate sub-underwriting agreements with Lodge Corporate Pty Ltd (each a Sub-Underwriting Agreement).

Sub-underwritten amount

$ 2,000,000

Total underwritten amount

$ 4,000,000

Number of options issued calculated for every two shares | shares

1

Peter Rubinstein [Member]

Statement Line Items [Line Items]

Number of unlisted options issued | shares

125,000,000

Dr. George Muchnicki [Member]

Statement Line Items [Line Items]

Number of unlisted options issued | shares

125,000,000

Underwriter Option [Member]

Statement Line Items [Line Items]

Options expiration term

3 years

Exercise price of options | $ / shares

$ 0.08

Floor exercise price of options | $ / shares

$ 0.004

Dr. Paul Kaisian [Member] | Performance Rights [Member]

Statement Line Items [Line Items]

Number of rights cancelled during period | shares

57,500,000

Value of forfeiture of performance rights

$ 81,983

Dr. Paul Kaisian [Member] | Class A Performance Rights [Member]

Statement Line Items [Line Items]

Number of rights issued | shares

7,500,000

7,500,000

Share-based payments expense

$ 11,229

Dr. Paul Kaisian [Member] | Class B Performance Rights [Member]

Statement Line Items [Line Items]

Number of rights issued | shares

25,000,000

25,000,000

Share-based payments expense

$ 37,431

Dr. Paul Kaisian [Member] | Class C Performance Rights [Member]

Statement Line Items [Line Items]

Number of rights issued | shares

25,000,000

25,000,000

Share-based payments expense

$ 27,708

Dr. Lindsay Wakefield [Member] | Class A Performance Rights [Member]

Statement Line Items [Line Items]

Number of rights issued | shares

3,750,000

3,750,000

Share-based payments expense

$ 5,614

Mr. George Muchnicki [Member] | Class A Performance Rights [Member]

Statement Line Items [Line Items]

Number of rights issued | shares

6,250,000

Mr Peter Rubinstein [Member] | Class A Performance Rights [Member]

Statement Line Items [Line Items]

Number of rights issued | shares

5,000,000

5,000,000

Share-based payments expense

$ 7,486

Mr. Xue Lee [Member] | Class A Performance Rights [Member]

Statement Line Items [Line Items]

Number of rights issued | shares

3,750,000

Number of rights cancelled during period | shares

3,750,000

Blockshine Technology Corporation [Member]

Statement Line Items [Line Items]

Investment

$ 43,380

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) (20-F)

Dec. 20, 2019$ / shares

Oct. 30, 2019$ / shares

Dec. 12, 2018$ / shares

Oct. 05, 2018$ / shares

Dec. 31, 2019AUD ($)

Dec. 31, 2019AUD ($)

Dec. 31, 2018AUD ($)

Jun. 30, 2019AUD ($)$ / sharesSubsidiary

Jun. 30, 2018AUD ($)

Jun. 30, 2017AUD ($)

Aug. 08, 2018AUD ($)

Jun. 30, 2016AUD ($)

Statement Line Items [Line Items]

Total comprehensive loss

$ (3,028,861)

$ (3,028,861)

$ (3,178,161)

$ (6,401,936)

$ (5,986,838)

$ (8,534,481)

Net cash outflow from operations

(2,859,251)

(3,703,002)

(6,073,182)

(5,636,533)

(6,852,404)

Total cash and cash equivalents

3,277,074

3,277,074

3,234,640

2,131,741

$ 5,487,035

$ 10,988,255

$ 11,179,687

Operating lease commitments

$ 487,837

487,837

487,849

Decrease in net current assets

$ 14,712

Repayment of lease liabilities

$ 99,723

Number of overseas subsidiaries | Subsidiary

2

Maximum annual aggregate turnover to avail refundable tax offset

$ 20,000,000

Exercise price (cents) | $ / shares

$ 0.008

$ 0.008

Risk-free interest rate

0.85%

0.78%

Expected life of an option

3 years

3 years

Volatility measure

80.00%

Patents [Member]

Statement Line Items [Line Items]

Intangible assets, estimated useful life

10 years

Employee Stock Option [Member]

Statement Line Items [Line Items]

Exercise price (cents) | $ / shares

$ 0.010

Risk-free interest rate

2.02%

Expected life of an option

2 years 9 months 18 days

Performance Rights [Member]

Statement Line Items [Line Items]

Exercise price (cents) | $ / shares

$ 0

Share price | $ / shares

$ 1.1

Consecutive share price hurdle (in days)

10 days

Risk-free interest rate

2.02%

Expected life of an option

2 years 9 months 18 days

Performance Rights [Member] | Bottom of Range [Member]

Statement Line Items [Line Items]

Exercise price (cents) | $ / shares

$ 0.5

Percentage of discount or premium on share options

50.00%

Performance Rights [Member] | Top of range [Member]

Statement Line Items [Line Items]

Exercise price (cents) | $ / shares

$ 1.5

Percentage of discount or premium on share options

50.00%

Class A Performance Rights [Member]

Statement Line Items [Line Items]

Share price, VWAP hurdle | $ / shares

2

Class B Performance Rights [Member]

Statement Line Items [Line Items]

Share price, VWAP hurdle | $ / shares

2

Class C Performance Rights [Member]

Statement Line Items [Line Items]

Share price, VWAP hurdle | $ / shares

3.3

Lease Liabilities [Member]

Statement Line Items [Line Items]

Repayment of lease liabilities

$ 221,281

Equity Placement Facility With Kentgrove Capital Private Limited [Member]

Statement Line Items [Line Items]

Equity capital

$ 20,000,000

Individual placements

$ 1,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details) (20-F)	12 Months Ended
	Jun. 30, 2019
Laboratory Equipment [Member] | Bottom of Range [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful life	3 years
Laboratory Equipment [Member] | Top of range [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful life	5 years
Computer Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful life	3 years
Office Equipment [Member] | Bottom of Range [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful life	3 years
Office Equipment [Member] | Top of range [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful life	5 years
Leasehold Improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful life, period description	lease term, being between 1 and 3 years
Leasehold Improvements [Member] | Bottom of Range [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful life	1 year
Leasehold Improvements [Member] | Top of range [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful life	3 years

Cost of Sales - Schedule of Cos

Cost of Sales - Schedule of Cost of Sales (Details) (20-F) - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Jun. 30, 2017
COST OF SALES
Inventories used			$ 55,995		$ 93,869	$ 172,070
Direct labour costs			103,601		88,690	152,767
Depreciation expense	$ 12,156		55,480	$ 12,199	65,853	71,139
Inventories written off			61,191		51,676	96,441
Total cost of sales	$ 194,501	$ 79,674	$ 276,267		$ 300,088	$ 492,417

Cost of Sales - Schedule of C_2

Cost of Sales - Schedule of Cost of Sales (Details) (20-F) (Parenthetical) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
COST OF SALES
Inventories expired during the year		$ 24,506	$ 53,856

Non Operating Income and Expe_3

Non Operating Income and Expenditure - Schedule of Non Operating Income and Expenditure (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
NON OPERATING INCOME AND EXPENDITURE
Net profit on disposal of plant and equipment			$ 52,188
Research and development tax incentive	856,707	299,351	253,159
Export Marketing & Development Grant		126,907
Interest income	25,794	15,218	38,765
Rental income
Other income	137,268
Total non operating income and expenditure	$ 1,019,769	$ 441,476	$ 344,112

Foreign Exchange Gain Reclass_3

Foreign Exchange Gain Reclassified on Liquidation of Subsidiary - Schedule of Foreign Exchange Gain Reclassified On Liquidation of Subsidiary (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
FOREIGN EXCHANGE GAIN RECLASSIFIED ON LIQUIDATION OF SUBSIDIARY
Reclassification of net foreign exchange gains previously recognised in other comprehensive income, reclassified to profit or loss
Total gain on liquidation of subsidiary		$ 527,049

Other Gains _ (Losses) - Schedu

Other Gains / (Losses) - Schedule of Other Gains / (losses) (Details) (20-F) - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019		Jun. 30, 2018	Jun. 30, 2017
OTHER GAINS / (LOSSES)
Net foreign exchange gains / (losses)			$ 92,518
Net impairment losses			(500,000)	[1]
Total other gains / (losses)	$ 258,078	$ 161,857	$ (407,482)
[1]	In August 2018, the Company invested $250,000 into Swisstec towards the proposed joint venture to enable the Company and Swisstec to collaborate to develop a medical and health service platform using blockchain technology. The Company has recorded an impairment against the investment during the financial year ended June 30, 2019, due to cessation of activities in relation to the joint venture. In December 2018, Genetic Technologies Limited entered and invested $250,000 into a Joint Venture agreement with Blockshine Health Pty Ltd. with an ownership of 49%. The Company has recorded an impairment against the investment during the financial year ended June 30, 2019, due to the cancellation of the project.

Other Gains _ (Losses) - Sche_2

Other Gains / (Losses) - Schedule of Other Gains / (losses) (Details) (20-F) (Parenthetical) - AUD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2019	Jun. 30, 2019	Aug. 31, 2018
Swisstec [Member]
Statement Line Items [Line Items]
Investment in joint venture				$ 250,000
Blockshine Health Pty Ltd [Member]
Statement Line Items [Line Items]
Investment in joint venture	$ 250,000	$ 250,000	$ 250,000
Ownership interest (as a percent)	49.00%	49.00%	49.00%

Expenses - Schedule of Expenses

Expenses - Schedule of Expenses (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Expenses by nature [abstract]
Amortization of intangible assets			$ 63,783
Depreciation of fixed assets	156,248	303,749	307,828
Employee benefits expenses	2,414,408	2,657,232	3,594,936
Operating lease expenses	312,956	326,192	310,413
Research and development expenses	$ 310,703	$ 459,026	$ 418,598

Income Tax (Details Narrative)

Income Tax (Details Narrative) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Jun. 30, 2016
Income tax disclosure [line items]
Potential tax benefit	$ 23,104,882		$ 22,596,182		$ 22,194,323
Applicable tax rate	27.50%		27.50%		28.50%	28.50%
Unrecognized temporary differences associated with the Group's investments in subsidiaries
U.S
Income tax disclosure [line items]
Applicable tax rate		21.00%		35.00%
Expiration period limitation on carry forward net operating losses	20 years
Subsidiaries United States [Member]
Income tax disclosure [line items]
Potential tax benefit	$ 5,541,152		$ 5,155,038
Subsidiaries Australia [Member]
Income tax disclosure [line items]
Potential tax benefit	$ 17,563,730		$ 17,441,144

Income Tax - Schedule of Income

Income Tax - Schedule of Income Tax Expense (Details) (20-F) - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Major components of tax expense (income) [abstract]
Loss before income tax expense			$ (6,425,604)	$ (5,463,872)	$ (8,403,826)
Tax at the Australian tax rate of 27.50% (2018: 27.50% and 2017: 28.50%)			$ (1,767,041)	$ (1,502,565)	$ (2,311,052)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income			27.50%	27.50%	28.50%	28.50%
Share-based payments expense			$ 92,153	$ 35,650	$ 33,079
Research and development tax incentive			541,596	148,346	108,163
Other non-deductible items			590	1,509	1,257
Other assessable items					81,155
Income tax expenses before unrecognized tax losses			(1,132,702)	(1,317,060)	(2,087,398)
Difference in overseas tax rates			41,009	67,557	(96,775)
Under /(over) provision			1,126,722	(268,092)	(75,054)
Temporary differences not recognized			(121,965)
Research and development tax credit			(238,084)	(82,322)	(69,619)
Tax losses not recognized			325,020	1,599,917	2,328,846
Income tax expense

Income Tax - Schedule of Net De

Income Tax - Schedule of Net Deferred Tax Assets (Details) (20-F) - AUD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total deferred tax assets	$ 2,314,369	$ 2,499,844	$ 2,659,827
Net deferred tax assets on temporary differences not brought to account	(2,314,369)	(2,499,844)	(2,659,827)
Total net deferred tax assets
Property Plant and Equipment [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total deferred tax assets	863	1,381	2,802
Capital Raising Costs [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total deferred tax assets	232,328	347,370	320,417
Applera Settlement [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total deferred tax assets
Intangible Assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total deferred tax assets	1,893,220
Provisions [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total deferred tax assets	187,958	201,492	333,103
Other [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total deferred tax assets
Prepayments [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax assets on temporary differences not brought to account
Intangible Assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total deferred tax assets		$ 1,949,601	$ 2,003,505

Income Tax - Schedule of Tax Lo

Income Tax - Schedule of Tax Losses (Details) (20-F) - AUD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Major components of tax expense (income) [abstract]
Unused tax losses for which no deferred tax asset has been recognized	$ 90,254,547	$ 87,970,140	$ 80,706,629
Potential tax benefit @ 27.50% (2016: 28.50%)	$ 23,104,882	$ 22,596,182	$ 22,194,323

Income Tax - Schedule of Tax _2

Income Tax - Schedule of Tax Losses (Details) (20-F) (Parenthetical)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Major components of tax expense (income) [abstract]
Applicable tax rate	27.50%	27.50%	28.50%	28.50%

Loss Per Share - Schedule of _2

Loss Per Share - Schedule of Weighted Average Number of Shares Used as Denominator (Details) (20-F) - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Loss per share for profit attributable to the ordinary equity holders of the company:
Loss for the year attributable to the owners of Genetic Technologies Limited	$ 2,647,698	$ 3,123,372	$ (6,425,604)	$ (5,463,872)	$ (8,403,826)
Weighted average number of Ordinary Shares used in calculating loss per share	3,331,576,766	2,558,004,460	2,635,454,870	2,435,282,724	2,121,638,888

Loss Per Share - Schedule of _3

Loss Per Share - Schedule of Weighted Average Number of Shares Used as Denominator (Details) (20-F) (Parenthetical) - shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Loss per share for profit attributable to the ordinary equity holders of the company:
Number of options outstanding excluded from calculation diluted earnings per share	114,250,000	55,102,778	75,102,778

Cash and Cash Equivalents - Sch

Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) (20-F) - AUD ($)	6 Months Ended			12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Cash and cash equivalents [abstract]
Cash at bank and on hand				$ 2,131,741	$ 5,487,035	$ 10,988,255
Total cash and cash equivalents	$ 3,277,074	$ 3,277,074	$ 3,234,640	2,131,741	5,487,035	10,988,255	$ 11,179,687
Loss for the year	$ (2,647,698)	$ (3,028,861)	$ (3,123,372)	(6,425,604)	(5,463,872)	(8,403,826)
Amortization and depreciation expenses				156,260	303,749	371,611
Impairment of intangible assets						544,694
Impairment of investments				500,000
Share-based payments expense				335,102	129,635	120,287
interest classified as investing cash flows				(25,850)	15,219
Net (profit) / loss on disposal of plant and equipment						(52,188)
Net (gains) / losses on liquidation of subsidiary					(527,049)
Net foreign exchange (gains) / losses				(92,518)	(128,360)	175,038
(Increase) / decrease in trade and other receivables				(517,383)	124,889	204,501
(Increase) / decrease in prepayments and other assets				(42,885)	14,843	103,488
Increase / (decrease) in trade and other payables				60,178	47,027	60,120
Increase / (decrease) in provisions				(20,482)	(122,176)	62,636
Net cash flows from / (used in) operating activities				(6,073,182)	(5,636,533)	(6,813,639)
Total facilities - Credit cards				95,714	183,770	306,128
Facilities used as at reporting date - Credit cards				(6,516)	(12,031)	(12,428)
Facilities unused as at reporting date - Credit cards				$ 89,198	$ 171,739	$ 293,700

Trade and Other Receivables (_3

Trade and Other Receivables (Current) - Schedule of Trade and Other Receivables (Current) (Details) (20-F) - AUD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Trade and other current receivables [abstract]
Trade receivables		$ 16,529	$ 10,503
Less: 2019: Impairment allowance / 2018: provision for doubtful debts
Net trade receivables		16,529	10,503
Other receivables		802,237	290,880
Total net current trade and other receivables	$ 440,278	$ 818,766	$ 301,383

Trade and Other Receivables (_4

Trade and Other Receivables (Current) - Schedule of Trade and Other Receivables (Current) (Details) (20-F) (Parenthetical) - AUD ($)	Jun. 30, 2019	Jun. 30, 2018
Trade and other current receivables [abstract]
Trade and other receivables, amounts due		$ 7,114

Prepayments and Other Assets _3

Prepayments and Other Assets (Current) - Schedule of Prepayments and Other Assets (Current) (Details) (20-F) - AUD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
PREPAYMENTS AND OTHER ASSETS (CURRENT)
Prepayments		$ 159,844	$ 139,767
Inventories at the lower of cost and net realizable value	$ 76,522	31,865	59,007
Performance bond and deposits		53,456	3,505
Total current prepayments and other assets		$ 245,165	$ 202,279

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	$ 175,284
Add: additions purchased during the year	50,927
Less: disposals made during the year
Less: depreciation expense charged	(156,248)	$ (303,749)	$ (307,828)
Closing net carrying amount	69,333	175,284
Gross Carrying Amount [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	3,285,926	3,283,541
Add: additions purchased during the year	50,297	2,385
Less: disposals made during the year
Closing net carrying amount	3,336,223	3,285,926	3,283,541
Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	(3,110,642)	(2,806,893)
Less: disposals made during the year
Less: depreciation expense charged	(156,248)	(303,749)
Closing net carrying amount	(3,266,890)	(3,110,642)	$ (2,806,893)
Laboratory Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	95,992
Add: additions purchased during the year
Less: disposals made during the year
Less: depreciation expense charged	(55,480)
Closing net carrying amount	40,512	95,992
Laboratory Equipment [Member] | Gross Carrying Amount [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	1,451,389
Add: additions purchased during the year
Closing net carrying amount	1,451,389	1,451,389
Laboratory Equipment [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	(1,355,397)
Add: additions purchased during the year
Closing net carrying amount	(1,410,877)	(1,355,397)
Computer Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	46,342
Add: additions purchased during the year	47,715
Less: disposals made during the year
Less: depreciation expense charged	(66,416)
Closing net carrying amount	28,397	46,342
Computer Equipment [Member] | Gross Carrying Amount [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	609,550
Add: additions purchased during the year
Closing net carrying amount	609,550	609,550
Computer Equipment [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	(563,208)
Add: additions purchased during the year
Closing net carrying amount	(628,868)	(563,208)
Office Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	757
Add: additions purchased during the year
Closing net carrying amount		757
Office Equipment [Member] | Gross Carrying Amount [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	167,564
Add: additions purchased during the year
Closing net carrying amount	167,564	167,564
Office Equipment [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	(166,807)
Add: additions purchased during the year
Closing net carrying amount	(167,564)	(166,807)
Equipment Under Hire Purchase [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount
Add: additions purchased during the year
Closing net carrying amount
Equipment Under Hire Purchase [Member] | Gross Carrying Amount [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	594,626
Add: additions purchased during the year
Closing net carrying amount	594,626	594,626
Equipment Under Hire Purchase [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	(594,626)
Add: additions purchased during the year
Closing net carrying amount	(594,626)	(594,626)
Leasehold Improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	32,193
Add: additions purchased during the year	2,583
Less: disposals made during the year
Less: depreciation expense charged	(34,352)
Closing net carrying amount	424	32,193
Leasehold Improvements [Member] | Gross Carrying Amount [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	462,797
Add: additions purchased during the year
Closing net carrying amount	462,797	462,797
Leasehold Improvements [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	(430,604)
Add: additions purchased during the year
Closing net carrying amount	$ (464,956)	$ (430,604)

Property, Plant and Equipment_2

Property, Plant and Equipment - Schedule of Reconciliation of Movements in Property, Plant and Equipment by Asset Category (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	$ 175,284
Additions during year	50,297
Disposals during year
Depreciation expense	(156,248)	$ (303,749)	$ (307,828)
Closing net carrying amount	69,333	175,284
Laboratory Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	95,992
Additions during year
Disposals during year
Depreciation expense	(55,480)
Closing net carrying amount	40,512	95,992
Computer Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	46,342
Additions during year	47,714
Disposals during year
Depreciation expense	(66,416)
Closing net carrying amount	28,397	46,342
Leasehold Improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net carrying amount	32,193
Additions during year	2,583
Disposals during year
Depreciation expense	(34,352)
Closing net carrying amount	$ 424	$ 32,193

Trade and Other Payables (Cur_3

Trade and Other Payables (Current) - Schedule of Trade and Other Payables (Details) (20-F) - AUD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Trade and other payables [abstract]
Trade payables		$ 590,231	$ 535,924
Other payables		68,423	222,502
Accrued expenses		346,654	186,704
Total current trade and other payables	$ 727,430	$ 1,005,308	$ 945,130

Trade and Other Payables (Cur_4

Trade and Other Payables (Current) - Schedule of Trade and Other Payables (Details) (20-F) (Parenthetical) - AUD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Trade and other payables [abstract]
Trade payables, amounts due	$ 126,829	$ 116,063	$ 380

Provisions (Current and Non-C_3

Provisions (Current and Non-Current) - Schedule of Current and Non-current Provisions (Details) (20-F) - AUD ($)	Jun. 30, 2019	Jun. 30, 2018
Disclosure of other provisions [line items]
Current provisions	$ 487,682	$ 505,583
Non-current provisions	809	3,390
Total provisions	488,491	508,973
Annual Leave Provision [Member]
Disclosure of other provisions [line items]
Current provisions	152,352	145,449
Long Service Leave Provision [Member]
Disclosure of other provisions [line items]
Current provisions	243,740	268,544
Non-current provisions	809	3,390
Make Good Provision [Member]
Disclosure of other provisions [line items]
Current provisions	91,590	91,590
Non-current provisions

Provisions (Current and Non-C_4

Provisions (Current and Non-Current) - Schedule of Reconciliation of Provision (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Annual Leave Provision [Member]
Disclosure of other provisions [line items]
Balance at the beginning of the financial year	$ 145,499	$ 239,821
(Less)/ Add: obligation accrued during the year	91,106	155,967
Less: utilized during the year	(84,253)	(250,289)
Balance at the end of the financial year	152,352	145,499
Long Service Leave Provision [Member]
Disclosure of other provisions [line items]
Balance at the beginning of the financial year	271,933	299,739
(Less)/ Add: obligation accrued during the year	10,226	(27,806)
Less: utilized during the year	(37,610)
Balance at the end of the financial year	$ 244,549	$ 271,933

Provisions (Current and Non-C_5

Provisions (Current and Non-Current) - Schedule of Reconciliation of Provision (Details) (20-F) (Parenthetical) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Statement Line Items [Line Items]
Current provisions	$ 487,682	$ 505,583
Estimated term for provision settlement	12 months
Annual Leave And Long Service Leave [Member]
Statement Line Items [Line Items]
Current provisions	$ 335,655	$ 325,421

Contributed Equity - Schedule o

Contributed Equity - Schedule of Issued and Paid-Up Capital (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Disclosure of classes of share capital [abstract]
Fully paid Ordinary Shares	$ 125,498,824	$ 122,372,662
Share capital	$ 125,498,824	$ 122,372,662

Contributed Equity - Schedule_2

Contributed Equity - Schedule of Movements in Shares on Issue (Details) (20-F) - AUD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Disclosure of classes of share capital [abstract]
Balance at the beginning of the financial year	2,938,134,143	2,435,282,724	2,435,282,724
Shares issued during the year (in shares)		502,851,419
Balance at the end of the financial year		2,938,134,143	2,435,282,724
Share capital	$ 125,498,824	$ 122,372,662	$ 122,382,625
Shares issued during the year		3,557,509
Less: transaction costs arising on share issue		(431,347)	(9,963)
Share capital	$ 127,807,987	$ 125,498,824	$ 122,372,662

Reserves - Schedule of Reserves

Reserves - Schedule of Reserves (Details) (20-F) - AUD ($)	6 Months Ended			12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Disclosure of reserves within equity [abstract]
Foreign currency translation	$ 789,598		$ 765,930	$ 765,930	$ 1,288,896	$ 1,288,896	$ 789,598	$ 765,930
Share-based payments	5,220,334		4,885,232	4,885,232	4,755,597	4,755,597	5,220,334	4,885,232
Total reserves	7,454,278	$ 7,454,278					$ 6,009,932	$ 5,651,162
Reconciliation of foreign currency translation reserve, Balance at the beginning of the financial year	789,598		765,930	765,930	1,288,896
Reconciliation of foreign currency translation reserve, Add: net currency translation gain / (loss)	(381,163)		(54,789)	23,668	(522,966)	(130,655)
Reconciliation of foreign currency translation reserve, Balance at the end of the financial year				789,598	765,930	1,288,896
Reconciliation of share-based payments reserve, Balance at the beginning of the financial year	5,220,334		4,885,232	4,885,232	4,755,597
Reconciliation of share-based payments reserve, Add: share-based payments expense	$ 33,771	33,771	$ 138,381	341,201	129,635	120,287
Reconciliation of share-based payments reserve, Less: Reversal of forfeited/lapsed options		$ (81,982)		(6,099)
Reconciliation of share-based payments reserve, Balance at the end of the financial year				$ 5,220,334	$ 4,885,232	$ 4,755,597

Accumulated Losses - Schedule o

Accumulated Losses - Schedule of Accumulated Losses (Details) (20-F) - AUD ($)	6 Months Ended			12 Months Ended
	Dec. 31, 2019		Dec. 31, 2018	Jun. 30, 2019		Jun. 30, 2018	Jun. 30, 2017
ACCUMULATED LOSSES
Balance at the beginning of the financial year	$ (129,737,550)	[1]	$ (123,311,946)	$ (123,311,946)		$ (117,848,074)
Add: net loss attributable to owners of Genetic Technologies Limited	(3,028,861)		$ (3,178,161)	(6,425,604)		(5,463,872)	$ (8,403,826)
Balance at the end of the financial year	$ (132,399,960)	[1]		$ (129,737,550)	[1]	$ (123,311,946)	$ (117,848,074)
[1]	The group has adopted AASB 16 on 1 July 2019 but has not restated comparatives for the 2019 reporting period, as permitted under the specific transitional provisions in the standard. The reclassifications and the adjustments arising from the new leasing rules are therefore recognised in the opening balance sheet on 1 July 2019.

Options (Details Narrative) (20

Options (Details Narrative) (20-F)	Dec. 20, 2019shares	Oct. 30, 2019shares	Dec. 12, 2018shares	Aug. 08, 2018shares$ / shares	Aug. 08, 2018shares$ / shares	Jun. 30, 2019sharesExecutiveEmployees	Jun. 30, 2018shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted during the year	250,000,000	250,000,000				16,000,000
Weighted average remaining contractual life of outstanding share options						2 years 1 month 27 days	1 year 11 months 8 days
Number of executives | Executive						1
Number of employees | Employees						12
Kentgrove Capital Pty Ltd [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted during the year				12,500,000
Options exercisable rate | $ / shares				$ 0.0153
Employee Stock Option [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted during the year			16,000,000			16,000,000
Options exercised during period
Establishment Shares [Member] | Kentgrove Capital Pty Ltd [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares issued				8,833,100	8,833,100
Establishment Options [Member] | Kentgrove Capital Pty Ltd [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted during the year					12,500,000
Options exercisable rate | $ / shares					$ 0.0153
Weighted average remaining contractual life of outstanding share options					3 years
Collateral Shares [Member] | Kentgrove Capital Pty Ltd [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares issued				100,000,000	100,000,000

Options - Schedule of Number an

Options - Schedule of Number and Weighted Average Exercise Prices of Share Options (Details) (20-F)	Dec. 20, 2019shares	Oct. 30, 2019shares	Aug. 08, 2018shares	Jun. 30, 2019shares$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price of options, balance at the beginning of the financial year | $ / shares				$ 0.016
Weighted average exercise price of options, balance at the end of the financial year | $ / shares				$ 0.015
Balance at the beginning of the financial year				55,102,778
Options granted during the year	250,000,000	250,000,000		16,000,000
Balance at the end of the financial year				38,000,000
Kentgrove Capital Pty Ltd [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted during the year			12,500,000
Listed and Unlisted Options Including ESOP [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price of options, balance at the beginning of the financial year | $ / shares				$ 0.017
Weighted average exercise price of options, granted during the year | $ / shares				0.010
Weighted average exercise price of options, lapsed during the year | $ / shares				0.020
Weighted average exercise price of options, forfeited during the year | $ / shares				0.001
Weighted average exercise price of options, balance at the end of the financial year | $ / shares				$ 0.015
Balance at the beginning of the financial year				55,102,778
Options granted during the year				16,000,000
Options lapsed during the year				(19,236,111)
Options forfeited during the year				(6,000,000)
Balance at the end of the financial year				38,000,000
Listed and Unlisted Options Including ESOP [Member] | Kentgrove Capital Pty Ltd [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price of options, granted during the year | $ / shares				$ 0.015
Options granted during the year				12,500,000
Unlisted Options Attached to Convertible Notes [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price of options, balance at the beginning of the financial year | $ / shares				$ 0.015
Weighted average exercise price of options, lapsed during the year | $ / shares				0.015
Weighted average exercise price of options, balance at the end of the financial year | $ / shares
Balance at the beginning of the financial year				20,366,667
Balance at the end of the financial year

Options - Schedule of Fair Valu

Options - Schedule of Fair Value of Each Option Granted by an External Valuer (Details) (20-F)	Dec. 20, 2019shares$ / shares	Oct. 30, 2019shares$ / shares	Aug. 08, 2018shares$ / shares	Jun. 30, 2019shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted during the year | shares	250,000,000	250,000,000		16,000,000
Dividend yield
Historic volatility and expected volatility	136.00%	136.00%
Weighted average exercise price	$ 0.008	$ 0.008
Risk-free interest rate	0.85%	0.78%
Expected life of an option	3 years	3 years
Fair value of options at grant date	$ 0.004	$ 0.003
Kentgrove Capital Pty Ltd [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted during the year | shares			12,500,000
Dividend yield			0.00%
Historic volatility and expected volatility			80.00%
Option exercise price			$ 0.0153
Weighted average exercise price			$ 0.0153
Risk-free interest rate			2.02%
Expected life of an option			3 years
Model used			Black-Scholes
Fair value of options at grant date			$ 0.0040

Options - Summary of Options Ov

Options - Summary of Options Over Ordinary Shares Outstanding (Details) (20-F)	Jun. 30, 2019shares$ / shares	Jun. 30, 2018shares$ / shares	Jun. 30, 2017shares$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options outstanding | shares	38,000,000	55,102,778
Weighted average exercise price | $ / shares	$ 0.015	$ 0.016
Unlisted Employee Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options outstanding | shares	25,500,000	34,736,111	54,736,111
Weighted average exercise price | $ / shares	$ 0.015	$ 0.017	$ 0.016
Unlisted Options Attached to Convertible Notes [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options outstanding | shares		20,366,667
Weighted average exercise price | $ / shares		$ 0.015
Unlisted Options Granted to Kentgrove Capital [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options outstanding | shares	12,500,000
Weighted average exercise price | $ / shares	$ 0.015

Options - Schedule of Number of

Options - Schedule of Number of Options Granted Under the Plans (Details) (20-F)	Dec. 20, 2019shares	Oct. 30, 2019shares	Jun. 30, 2019shares$ / shares	Jun. 30, 2018shares$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the beginning of the financial year			55,102,778
Add: options granted during the year	250,000,000	250,000,000	16,000,000
Balance at the end of the financial year			38,000,000	55,102,778
Weighted average exercise price of options, balance at the beginning of the financial year | $ / shares			$ 0.016
Weighted average exercise price of options, balance at the end of the financial year | $ / shares			$ 0.015	$ 0.016
Unlisted Employee Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the beginning of the financial year			34,736,111	54,736,111
Add: options granted during the year			16,000,000
Less: options lapsed during the year			(19,236,111)
Less: options forfeited during the year			(6,000,000)	(20,000,000)
Balance at the end of the financial year			25,500,000	34,736,111
Weighted average exercise price of options, balance at the beginning of the financial year | $ / shares			$ 0.017	$ 0.016
Weighted average exercise price of options, granted during the year | $ / shares			0.010
Weighted average exercise price of options, lapsed during the year | $ / shares			0.020
Weighted average exercise price of options, forfeited during the year | $ / shares			0.010	0.014
Weighted average exercise price of options, balance at the end of the financial year | $ / shares			$ 0.015	$ 0.017

Options - Schedule of Members o

Options - Schedule of Members of Options outstanding by ASX code (Details) (20-F)	Jun. 30, 2019shares$ / shares	Jun. 30, 2018shares$ / shares	Jun. 30, 2017shares$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the end of the financial year | shares	38,000,000	55,102,778
Exercisable at the end of the financial year | shares	38,000,000	48,102,778
Weighted average exercise price of options, balance at the end of the financial year | $ / shares	$ 0.015	$ 0.016
Weighted average exercise price of options, exercisable at the end of the financial year | $ / shares	$ 0.015	$ 0.017
Unlisted Employee Options, to Kentgrove (Expiring August 8, 2021)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the end of the financial year | shares	12,500,000
Weighted average exercise price of options, balance at the end of the financial year | $ / shares	$ 0.015
Unlisted Employee Options, GTGAD (Expiring September 14, 2020)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the end of the financial year | shares
Weighted average exercise price of options, balance at the end of the financial year | $ / shares
Unlisted Employee Options, GTGAD (Expiring November 24, 2020)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the end of the financial year | shares		19,236,111
Weighted average exercise price of options, balance at the end of the financial year | $ / shares		$ 0.020
Unlisted Employee Options, GTGAD (Expiring March 31, 2021)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the end of the financial year | shares	5,000,000	5,000,000
Weighted average exercise price of options, balance at the end of the financial year | $ / shares	$ 0.020	$ 0.020
Unlisted Employee Options, GTGAD (Expiring February 16, 2022)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the end of the financial year | shares	5,500,000	10,500,000
Weighted average exercise price of options, balance at the end of the financial year | $ / shares	$ 0.010	$ 0.010
Unlisted Employee Options, ESOP Options (Expiring December 11, 2021)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the end of the financial year | shares	15,000,000
Weighted average exercise price of options, balance at the end of the financial year | $ / shares	$ 0.010
Unlisted Employee Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the end of the financial year | shares	25,500,000	34,736,111	54,736,111
Weighted average exercise price of options, balance at the end of the financial year | $ / shares	$ 0.015	$ 0.017	$ 0.016
Unlisted Options Attached to Convertible Notes, GTGAC (expiring December 2, 2018) [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the end of the financial year | shares		20,366,667
Weighted average exercise price of options, balance at the end of the financial year | $ / shares		$ 0.015

Segment Information (Details _2

Segment Information (Details Narrative) (20-F) - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Disclosure of operating segments [abstract]
Interest received	$ 10,754	$ 15,320	$ 25,790	$ 15,218	$ 38,765
Employee benefits expenses			$ 2,414,408	$ 2,657,232	$ 3,594,936

Segment Information - Summary_3

Segment Information - Summary of Reportable Segments Financial Information (Details) (20-F) - AUD ($)	6 Months Ended			12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Other	$ 447,756		$ 338,588
Profit/(loss)	(2,647,698)	$ (3,028,861)	(3,123,372)	$ (6,425,604)	$ (5,463,872)	$ (8,403,826)
Assets	4,343,606	4,343,606		3,265,005	6,165,981
Liabilities	(1,481,301)	(1,481,301)		(1,493,799)	(1,454,103)
Business Segments [Member]
Statement Line Items [Line Items]
Sales	586		18,402	25,444	189,254	518,506
Other	447,756		338,588	1,019,769	441,476	344,112
Totals	448,342		356,990	1,045,213	630,730	862,618
Profit/(loss)	(2,647,698)		$ (3,123,372)	(6,425,604)	(5,463,872)	(8,403,826)
Assets	4,343,606	4,343,606		3,265,005	6,165,981	12,108,297
Liabilities	(1,481,301)	$ (1,481,301)		(1,493,799)	(1,454,103)	(1,529,253)
Amortization\depreciation	(39,561)			(156,248)	(303,749)	(371,611)
Purchases of equipment	$ 2,521			$ 5,353	$ 2,385	$ 234,799

Segment Information - Summary_4

Segment Information - Summary of Geographical Information (Details) (20-F) - AUD ($)	6 Months Ended			12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Other	$ 447,756		$ 338,588
Profit/(loss)	(2,647,698)	$ (3,028,861)	(3,123,372)	$ (6,425,604)	$ (5,463,872)	$ (8,403,826)
Business Segments [Member]
Statement Line Items [Line Items]
Sales	586		18,402	25,444	189,254	518,506
Other	447,756		338,588	1,019,769	441,476	344,112
Totals	448,342		356,990	1,045,213	630,730	862,618
Profit/(loss)	(2,647,698)		(3,123,372)	(6,425,604)	(5,463,872)	(8,403,826)
Business Segments [Member] | Australia [Member]
Statement Line Items [Line Items]
Sales				5,247		18,215
Other	447,756		338,588	1,019,769	441,476	344,112
Totals	447,756		338,588	1,025,016	441,476	362,327
Profit/(loss)	$ (2,418,577)		$ (1,580,663)	(5,791,950)	(3,504,098)	(7,000,994)
Business Segments [Member] | U.S. [Member]
Statement Line Items [Line Items]
Sales				20,197	189,254	500,291
Other
Totals				20,197	189,254	500,291
Profit/(loss)				(633,654)	(1,959,774)	(1,371,001)
Business Segments [Member] | Other [Member]
Statement Line Items [Line Items]
Sales
Other
Totals
Profit/(loss)						$ (31,831)

Segment Information - Summary_5

Segment Information - Summary of Intersegment Balances and Transactions (Details) (20-F) - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Foreign exchange gain (U.S.) and foreign exchange loss (Australia)			$ 92,518
Cost of sales (U.S.) and sales (Australia)	$ 194,501	$ 79,674	276,267	300,088	492,417
Elimination Of Intersegment Amounts [Member]
Statement Line Items [Line Items]
Foreign exchange gain (U.S.) and foreign exchange loss (Australia)			291,542	981,141	776,295
Cost of sales (U.S.) and sales (Australia)			$ 9,708	$ 38,352	$ 74,762

Share Based Payments (Details N

Share Based Payments (Details Narrative) (20-F)	Dec. 20, 2019shares	Oct. 30, 2019shares	Dec. 12, 2018shares$ / shares	Nov. 29, 2018shares	Feb. 17, 2017shares$ / shares	Apr. 01, 2016shares$ / shares	Nov. 25, 2015shares$ / shares	Dec. 31, 2019AUD ($)	Jun. 30, 2019AUD ($)shares$ / sharesEmployees	Jun. 30, 2018AUD ($)sharesEmployees	Jun. 30, 2017AUD ($)sharesTranches	Jun. 30, 2016sharesTranches
Statement Line Items [Line Items]
Options granted during the year	250,000,000	250,000,000							16,000,000
Expenses arising from share-based payments | $									$ 335,102	$ 129,635	$ 120,287
Risk-free interest rate	0.85%	0.78%
Expected life of an option	3 years	3 years
Expected volatility	136.00%	136.00%
Employee Stock Option [Member]
Statement Line Items [Line Items]
Options granted during the year			16,000,000						16,000,000
Option expire date									Dec. 11, 2021
Option exercise price | $ / shares			$ 0.010						$ 0.01
Number of employees | Employees									14
Risk-free interest rate			2.02%
Expected life of an option			2 years 9 months 18 days
Expected volatility			80.00%
Employee Stock Option [Member] | Subsidiaries [Member]
Statement Line Items [Line Items]
Options granted during the year					1,250,000	500,000	1,500,000				1,250,000	2,000,000
Option exercise price | $ / shares					$ 0.010	$ 0.039	$ 0.058
Number of employees | Employees									1	1
Number of tranches | Tranches											3	3
Risk-free interest rate					2.19%	1.93%	2.22%
Expected life of an option					4 years 6 months	4 years 3 months 19 days	4 years 6 months
Expected volatility					60.00%	80.00%	80.00%
Employee Stock Option [Member] | Key Management Personnel [Member]
Statement Line Items [Line Items]
Options granted during the year					21,500,000						21,500,000
Option exercise price | $ / shares					$ 0.010
Number of tranches | Tranches											3
Risk-free interest rate					2.19%
Expected life of an option					4 years 6 months
Expected volatility					60.00%
Unlisted Employee Options [Member]
Statement Line Items [Line Items]
Options granted during the year									16,000,000
Performance Rights [Member]
Statement Line Items [Line Items]
Option exercise price | $ / shares									$ 0
Number of rights issued				76,250,000
Expenses arising from share-based payments | $								$ 33,771	$ 104,441		$ 120,287
Consecutive share price hurdle									10 days
Risk-free interest rate									2.02%
Expected life of an option									2 years 9 months 18 days
Expected volatility									80.00%
Class A Performance Rights [Member]
Statement Line Items [Line Items]
Share price, VWAP hurdle | $ / shares									2
Class A Performance Rights [Member] | Dr. Paul Kaisian [Member]
Statement Line Items [Line Items]
Number of rights issued				7,500,000					7,500,000
Expenses arising from share-based payments | $									$ 11,229
Class A Performance Rights [Member] | Dr. Lindsay Wakefield [Member]
Statement Line Items [Line Items]
Number of rights issued				3,750,000					3,750,000
Expenses arising from share-based payments | $									$ 5,614
Class A Performance Rights [Member] | Dr Jerzy Muchnicki [Member]
Statement Line Items [Line Items]
Number of rights issued				6,250,000					6,250,000
Expenses arising from share-based payments | $									$ 9,358
Class A Performance Rights [Member] | Mr Peter Rubinstein [Member]
Statement Line Items [Line Items]
Number of rights issued				5,000,000					5,000,000
Expenses arising from share-based payments | $									$ 7,486
Class A Performance Rights [Member] | Mr. Xue Lee [Member]
Statement Line Items [Line Items]
Number of rights issued				3,750,000
Class B Performance Rights [Member]
Statement Line Items [Line Items]
Share price, VWAP hurdle | $ / shares									2
Class B Performance Rights [Member] | Dr. Paul Kaisian [Member]
Statement Line Items [Line Items]
Number of rights issued				25,000,000					25,000,000
Expenses arising from share-based payments | $									$ 37,431
Class C Performance Rights [Member]
Statement Line Items [Line Items]
Share price, VWAP hurdle | $ / shares									3.3
Class C Performance Rights [Member] | Dr. Paul Kaisian [Member]
Statement Line Items [Line Items]
Number of rights issued				25,000,000					25,000,000
Expenses arising from share-based payments | $									$ 27,708

Share Based Payments - Schedule

Share Based Payments - Schedule of Fair Value of Each Option Granted by an External Valuer (Details) (20-F)	Dec. 20, 2019shares$ / shares	Oct. 30, 2019shares$ / shares	Dec. 12, 2018shares$ / shares	Feb. 17, 2017shares$ / shares	Apr. 01, 2016shares$ / shares	Nov. 25, 2015shares$ / shares	Jun. 30, 2019shares$ / shares	Jun. 30, 2017shares	Jun. 30, 2016shares
Statement Line Items [Line Items]
Options issued | shares	250,000,000	250,000,000					16,000,000
Historic volatility and expected volatility	136.00%	136.00%
Weighted average exercise price	$ 0.008	$ 0.008
Risk-free interest rate	0.85%	0.78%
Expected life of an option	3 years	3 years
Fair value of options at grant date	$ 0.004	$ 0.003
Employee Stock Option [Member]
Statement Line Items [Line Items]
Options issued | shares			16,000,000				16,000,000
Dividend yield
Historic volatility and expected volatility			80.00%
Option exercise price			$ 0.010				$ 0.01
Weighted average exercise price			$ 0.030
Risk-free interest rate			2.02%
Expected life of an option			2 years 9 months 18 days
Model used			Black-Scholes
Fair value of options at grant date			$ 0.0051
Employee Stock Option [Member] | Phenogen Sciences Inc. [Member]
Statement Line Items [Line Items]
Options issued | shares				1,250,000
Dividend yield
Historic volatility and expected volatility				60.00%
Option exercise price				$ 0.010
Weighted average exercise price				$ 0.010
Risk-free interest rate				2.19%
Expected life of an option				4 years 6 months
Model used				Black-Scholes
Fair value of options at grant date				$ 0.0050
Employee Stock Option [Member] | Key Management Personnel [Member]
Statement Line Items [Line Items]
Options issued | shares				21,500,000				21,500,000
Dividend yield
Historic volatility and expected volatility				60.00%
Option exercise price				$ 0.010
Weighted average exercise price				$ 0.010
Risk-free interest rate				2.19%
Expected life of an option				4 years 6 months
Model used				Black-Scholes
Fair value of options at grant date				$ 0.0050
Employee Stock Option [Member] | Subsidiaries [Member]
Statement Line Items [Line Items]
Options issued | shares				1,250,000	500,000	1,500,000		1,250,000	2,000,000
Dividend yield
Historic volatility and expected volatility				60.00%	80.00%	80.00%
Option exercise price				$ 0.010	$ 0.039	$ 0.058
Weighted average exercise price				$ 0.010	$ 0.039	$ 0.058
Risk-free interest rate				2.19%	1.93%	2.22%
Expected life of an option				4 years 6 months	4 years 3 months 19 days	4 years 6 months
Model used				Black-Scholes	Black-Scholes	Black-Scholes
Fair value of options at grant date				$ 0.0050	$ 0.0065	$ 0.0139

Share Based Payments - Schedu_2

Share Based Payments - Schedule of Independent Valuation of Performance Rights Granted (Details) (20-F)	Nov. 29, 2018shares	Jun. 30, 2019AUD ($)shares$ / shares	Jun. 30, 2018AUD ($)	Jun. 30, 2017AUD ($)
Statement Line Items [Line Items]
Expenses arising from share-based payments		$ 335,102	$ 129,635	$ 120,287
Dr. Paul Kaisian [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of Performance Rights issued | shares	7,500,000	7,500,000
Valuation per options (cents) | $ / shares		$ 0.77
Total fair value of performance rights		$ 57,750
Expenses arising from share-based payments		$ 11,229
Dr. Paul Kaisian [Member] | Class B Performance Rights [Member]
Statement Line Items [Line Items]
Number of Performance Rights issued | shares	25,000,000	25,000,000
Valuation per options (cents) | $ / shares		$ 0.77
Total fair value of performance rights		$ 192,500
Expenses arising from share-based payments		$ 37,431
Dr. Paul Kaisian [Member] | Class C Performance Rights [Member]
Statement Line Items [Line Items]
Number of Performance Rights issued | shares	25,000,000	25,000,000
Valuation per options (cents) | $ / shares		$ 0.57
Total fair value of performance rights		$ 142,500
Expenses arising from share-based payments		$ 27,708
Dr. Lindsay Wakefield [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of Performance Rights issued | shares	3,750,000	3,750,000
Valuation per options (cents) | $ / shares		$ 0.77
Total fair value of performance rights		$ 28,875
Expenses arising from share-based payments		$ 5,614
Dr Jerzy Muchnicki [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of Performance Rights issued | shares	6,250,000	6,250,000
Valuation per options (cents) | $ / shares		$ 0.77
Total fair value of performance rights		$ 48,125
Expenses arising from share-based payments		$ 9,358
Mr Peter Rubinstein [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of Performance Rights issued | shares	5,000,000	5,000,000
Valuation per options (cents) | $ / shares		$ 0.77
Total fair value of performance rights		$ 38,500
Expenses arising from share-based payments		$ 7,486
Mr Sam Lee [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of Performance Rights issued | shares		3,750,000
Valuation per options (cents) | $ / shares		$ 0.77
Total fair value of performance rights		$ 28,875
Expenses arising from share-based payments		$ 5,614

Share Based Payments - Schedu_3

Share Based Payments - Schedule of Expenses Arising from Share-based Payment Transactions Recognized as Part of Employee Benefit Expense (Details) (20-F) - AUD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Total expenses arising from share-based payments		$ 335,102	$ 129,635	$ 120,287
Performance Rights [Member]
Statement Line Items [Line Items]
Total expenses arising from share-based payments	$ 33,771	104,441		120,287
Employee Option Plan [Member]
Statement Line Items [Line Items]
Total expenses arising from share-based payments		215,383
Employee Stock Option [Member]
Statement Line Items [Line Items]
Total expenses arising from share-based payments			129,635	120,287
Kentgrove Capital Pty Ltd [Member]
Statement Line Items [Line Items]
Total expenses arising from share-based payments		$ 15,278

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) (20-F) - AUD ($)	Jul. 03, 2018	Jun. 30, 2019
Disclosure of contingent liabilities [abstract]
Other commitments or contingencies		$ 0
Number of years extended in lease agreement	3 years

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Operating Lease Expenditure Commitments (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Total minimum operating lease payments	$ 516,628	$ 41,625	$ 263,668
Not later than one year [member]
Statement Line Items [Line Items]
Total minimum operating lease payments	250,068	41,625	227,992
Later than one year but not later than five years [member]
Statement Line Items [Line Items]
Total minimum operating lease payments	266,560		35,676
Later than five years [member]
Statement Line Items [Line Items]
Total minimum operating lease payments

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Operating Lease Payments (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Minimum payments	$ 516,628	$ 41,625	$ 263,668
Crude Pty. Ltd. [Member]
Statement Line Items [Line Items]
Location	60-66 Hanover Street Fitzroy, Victoria 3065 Australia
Use	Office / laboratory
Date of expiry of lease	August 31, 2021
Minimum payments	$ 487,837
Mid-Town Partners LLC [Member]
Statement Line Items [Line Items]
Location	1300 Baxter Street, Suite 157, Charlotte, North Carolina
Use	Office
Date of expiry of lease	Month to month
Minimum payments	$ 28,791

Auditors' Remuneration - Schedu

Auditors' Remuneration - Schedule of Auditors' Remuneration (Details) (20-F) - AUD ($)		12 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Line Items [Line Items]
Total remuneration in respect of audit services		$ 288,000	$ 288,200	$ 437,493
Price Water House Coopers [Member]
Statement Line Items [Line Items]
Audit	[1]	288,000	288,200	325,972
Audit related				107,451
Other Audit Firms [Member]
Statement Line Items [Line Items]
Audit				$ 4,070
[1]	Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.

Related Party Transactions (D_2

Related Party Transactions (Details Narrative) (20-F)	Nov. 29, 2018shares	Dec. 31, 2018AUD ($)	Dec. 31, 2019AUD ($)	Jun. 30, 2019AUD ($)shares	Jun. 30, 2018AUD ($)	Jun. 30, 2017AUD ($)	Jun. 30, 2015AUD ($)	Aug. 31, 2018AUD ($)	Aug. 02, 2018shares
Statement Line Items [Line Items]
Shareholder controls, description				As at the date of this Report, no shareholder controls more than 50% of the issued capital of the Company.
Share-based payments expense				$ 335,102	$ 129,635	$ 120,287
Blockshine Health Pty Ltd [Member]
Statement Line Items [Line Items]
Investments in joint ventures accounted for using equity method		$ 250,000	$ 250,000	$ 250,000
Ownership interest		49.00%	49.00%	49.00%
Genetic Technologies HK Limited and Aocheng Genetic Technologies Co. Ltd [Member]
Statement Line Items [Line Items]
Minimum amount for gaining access								$ 800,000,000,000
Performance Rights [Member]
Statement Line Items [Line Items]
Number of rights issued | shares	76,250,000
Share-based payments expense			$ 33,771	$ 104,441		$ 120,287
Framework Agreement With Blockchain Global Limited [Member]
Statement Line Items [Line Items]
Number of Shares Proposed to be Issued Upon Achievement of Milestone | shares									486,000,000
Dr. Lindsay Wakefield [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of rights issued | shares	3,750,000			3,750,000
Share-based payments expense				$ 5,614
Dr. Paul Kaisian [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of rights issued | shares	7,500,000			7,500,000
Share-based payments expense				$ 11,229
Dr. Paul Kaisian [Member] | Class B Performance Rights [Member]
Statement Line Items [Line Items]
Number of rights issued | shares	25,000,000			25,000,000
Share-based payments expense				$ 37,431
Dr. Paul Kaisian [Member] | Class C Performance Rights [Member]
Statement Line Items [Line Items]
Number of rights issued | shares	25,000,000			25,000,000
Share-based payments expense				$ 27,708
Dr Jerzy Muchnicki [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of rights issued | shares	6,250,000			6,250,000
Share-based payments expense				$ 9,358
Mr Peter Rubinstein [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of rights issued | shares	5,000,000			5,000,000
Share-based payments expense				$ 7,486
Mr. Xue Lee [Member] | Class A Performance Rights [Member]
Statement Line Items [Line Items]
Number of rights issued | shares	3,750,000
Lodge Corporate [Member]
Statement Line Items [Line Items]
Services received, related party transactions			$ 121,225	67,000
The CFO Solution [Member]
Statement Line Items [Line Items]
Services received, related party transactions				$ 45,459
Number of years of extensive experience				30 years
Debt Convertible Notes [Member]
Statement Line Items [Line Items]
Proceeds from borrowings							$ 2,150,000
Coupon rate							10.00%
Discount rate on convertible notes							10.00%
Number of days for VWAP							5 days
Debt Convertible Notes [Member] | Dr. Lindsay Wakefield [Member]
Statement Line Items [Line Items]
Proceeds from borrowings							$ 125,000
Share options unexercised at the end of the year | shares				8,333,333
Debt Convertible Notes [Member] | George Muchnicki [Member]
Statement Line Items [Line Items]
Shares options indirectly held | shares				6,666,667
Debt Convertible Notes [Member] | Peter Rubinstein [Member]
Statement Line Items [Line Items]
Shares options indirectly held | shares				5,000,000

Related Party Transactions - Sc

Related Party Transactions - Schedule of Remuneration of Key Management Personnel (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Disclosure of transactions between related parties [abstract]
Short-term employee benefits	$ 964,162	$ 1,215,632	$ 1,533,457
Post-employment benefits	86,130	96,315	101,320
Share-based payments	157,886	130,385	121,269
Other long-term benefits	734	2,371	61,594
Termination benefits		164,760
Total remuneration of Key Management Personnel	$ 1,208,912	$ 1,609,463	$ 1,817,640

Subsidiaries - Schedule of Subs

Subsidiaries - Schedule of Subsidiary Undertakings (Details) (20-F) - AUD ($)		12 Months Ended
		Jun. 30, 2019	Jun. 30, 2018
Statement Line Items [Line Items]
Net carrying value		$ 11,018	$ 11,018
GeneType Pty. Ltd. [Member]
Statement Line Items [Line Items]
Incorporation details		September 5, 1990 Victoria, Australia	September 5, 1990 Victoria, Australia
Interest		100.00%	100.00%
Net carrying value
Genetic Technologies Corporation Pty. Ltd. [Member]
Statement Line Items [Line Items]
Incorporation details		October 11, 1996 N.S.W., Australia	October 11, 1996 N.S.W., Australia
Interest		100.00%	100.00%
Net carrying value		$ 2	$ 2
Gene Ventures Pty. Ltd. [Member]
Statement Line Items [Line Items]
Incorporation details	[1]	March 7, 2001 N.S.W., Australia	March 7, 2001 N.S.W., Australia
Interest	[1]	100.00%	100.00%
Net carrying value	[1]	$ 10	$ 10
GeneType AG [Member]
Statement Line Items [Line Items]
Incorporation details	[2]	February 13, 1989 Zug, Switzerland	February 13, 1989 Zug, Switzerland
Interest	[2]	0.00%	0.00%
Net carrying value	[2]
GeneType Corporation [Member]
Statement Line Items [Line Items]
Incorporation details		December 18, 1989 California, U.S.A.	December 18, 1989 California, U.S.A.
Interest		100.00%	100.00%
Net carrying value
Phenogen Sciences Inc. [Member]
Statement Line Items [Line Items]
Incorporation details		June 28, 2010 Delaware, U.S.A	June 28, 2010 Delaware, U.S.A
Interest		100.00%	100.00%
Net carrying value		$ 11,006	$ 11,006
Genetic Technologies HK Ltd [Member]
Statement Line Items [Line Items]
Incorporation details		March 18, 2019 Hong Kong, China	March 18, 2019 Hong Kong, China
Interest		100.00%	0.00%
Net carrying value
[1]	On 26 April 2018, the name of RareCellect Pty Ltd (ACN 096 135 9847) was changed to Gene Ventures Pty Ltd (ACN 096 135 947)
[2]	Liquidation of GeneType AG was completed on 13 December 2017

Financial Risk Management (Deta

Financial Risk Management (Details Narrative) (20-F)	12 Months Ended
	Jun. 30, 2019AUD ($)	Jun. 30, 2018AUD ($)
Statement Line Items [Line Items]
Accrued net trade receivables	$ 16,529	$ 10,503
Currency Risk [Member]
Statement Line Items [Line Items]
Percentage of foreign exchange rate decrease	5.13%
Exchange rate	0.7023	0.7403
Percentage of reasonably possible increase in risk assumption	10.00%
Percentage of reasonably possible decrease in risk assumption	10.00%
Increase (decrease) in profit and loss due to reasonably possible increase in designated risk component	$ 11,851	$ 306,000
Increase (decrease) in profit and loss due to reasonably possible decrease in designated risk component	9,696	250,000
Interest Rate Risk [Member]
Statement Line Items [Line Items]
Increase (decrease) in profit and loss due to reasonably possible increase in designated risk component	8,969	12,000
Increase (decrease) in profit and loss due to reasonably possible decrease in designated risk component	$ (8,969)	$ (12,000)

Financial Risk Management - Sch

Financial Risk Management - Schedule of Financial Instruments (Details) (20-F) - AUD ($)	Jun. 30, 2019	Jun. 30, 2018
Statement Line Items [Line Items]
Financial assets	$ 3,003,963	$ 5,791,923
Financial liabilities	1,005,308	945,130
Cash at Bank / on Hand [Member]
Statement Line Items [Line Items]
Financial assets	2,131,741	5,487,035
Trade and Other Receivables [Member]
Statement Line Items [Line Items]
Financial assets	818,766	301,383
Performance Bond and Deposits [Member]
Statement Line Items [Line Items]
Financial assets	53,456	3,505
Trade and Other Payables [Member]
Statement Line Items [Line Items]
Financial liabilities	$ 1,005,308	$ 945,130

Financial Risk Management - S_2

Financial Risk Management - Schedule of Analysis of Aging of Trade and Other Receivables (Details) (20-F) - AUD ($)	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Statement Line Items [Line Items]
Total net trade and other receivables	$ 440,278	$ 818,766	$ 301,383
Current [Member]
Statement Line Items [Line Items]
Total net trade and other receivables		802,237	294,454
31 days to 60 days [Member]
Statement Line Items [Line Items]
Total net trade and other receivables		11,159	3,142
61 days to 90 days [Member]
Statement Line Items [Line Items]
Total net trade and other receivables			783
Greater than 90 days [Member]
Statement Line Items [Line Items]
Total net trade and other receivables		$ 5,370	$ 3,004

Financial Risk Management - S_3

Financial Risk Management - Schedule of Financial Assets and Liabilities That Were Denominated in Foreign Currencies (Details) (20-F)	Jun. 30, 2019AUD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2019CHF (SFr)	Jun. 30, 2019EUR (€)	Jun. 30, 2018AUD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2018CHF (SFr)	Jun. 30, 2018EUR (€)
Statement Line Items [Line Items]
Financial assets	$ 3,003,963				$ 5,791,923
Financial liabilities	1,005,308				945,130
USD [Member]
Statement Line Items [Line Items]
Financial assets		$ 203,723				$ 2,157,796
Financial liabilities		117,992				116,063
EUR [Member]
Statement Line Items [Line Items]
Financial assets | €				€ 27,052				€ 28,952
Financial liabilities | €				1,900
CHF [Member]
Statement Line Items [Line Items]
Financial assets | SFr
Financial liabilities | SFr
Cash at Bank / on Hand [Member]
Statement Line Items [Line Items]
Financial assets	2,131,741				5,487,035
Cash at Bank / on Hand [Member] | USD [Member]
Statement Line Items [Line Items]
Financial assets		201,737				2,154,291
Cash at Bank / on Hand [Member] | EUR [Member]
Statement Line Items [Line Items]
Financial assets | €				27,052				28,952
Cash at Bank / on Hand [Member] | CHF [Member]
Statement Line Items [Line Items]
Financial assets | SFr
Bonds and Deposits [Member] | USD [Member]
Statement Line Items [Line Items]
Financial assets		1,986				3,505
Bonds and Deposits [Member] | EUR [Member]
Statement Line Items [Line Items]
Financial assets | €
Bonds and Deposits [Member] | CHF [Member]
Statement Line Items [Line Items]
Financial assets | SFr
Trade and Other Payables [Member]
Statement Line Items [Line Items]
Financial liabilities	$ 1,005,308				$ 945,130
Trade and Other Payables [Member] | USD [Member]
Statement Line Items [Line Items]
Financial liabilities		$ 117,992				$ 116,063
Trade and Other Payables [Member] | EUR [Member]
Statement Line Items [Line Items]
Financial liabilities | €				€ 1,900
Trade and Other Payables [Member] | CHF [Member]
Statement Line Items [Line Items]
Financial liabilities | SFr

Financial Risk Management - S_4

Financial Risk Management - Schedule of Exposure to Interest Rate Risks and Effective Interest Rates of Financial Assets and Liabilities (Details) (20-F) - AUD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Statement Line Items [Line Items]
Financial assets	$ 3,003,963	$ 5,791,923
Financial liabilities	1,005,308	945,130
Floating Interest Rate [Member]
Statement Line Items [Line Items]
Financial assets	2,131,741	2,394,754
Financial liabilities
Fixed Interest Rate [Member]
Statement Line Items [Line Items]
Financial assets	53,456	3,505
Financial liabilities
Interest Rate [Member]
Statement Line Items [Line Items]
Financial assets	2,131,741	2,398,259
Financial liabilities
Cash at Bank / on Hand [Member]
Statement Line Items [Line Items]
Financial assets	$ 2,131,741	$ 5,487,035
Weighted ave. effective rate %	1.74%	1.74%
Cash at Bank / on Hand [Member] | Floating Interest Rate [Member]
Statement Line Items [Line Items]
Financial assets	$ 2,131,741	$ 2,394,754
Cash at Bank / on Hand [Member] | Fixed Interest Rate [Member]
Statement Line Items [Line Items]
Financial assets
Performance Bond and Deposits [Member]
Statement Line Items [Line Items]
Financial assets	$ 53,456	$ 3,505
Weighted ave. effective rate %	0.00%	0.00%
Performance Bond and Deposits [Member] | Floating Interest Rate [Member]
Statement Line Items [Line Items]
Financial assets
Performance Bond and Deposits [Member] | Fixed Interest Rate [Member]
Statement Line Items [Line Items]
Financial assets	53,456	3,505
Financial Liabilities at Fair Value Through Profit or Loss [Member]
Statement Line Items [Line Items]
Financial liabilities
Weighted ave. effective rate %	0.00%	0.00%
Financial Liabilities at Fair Value Through Profit or Loss [Member] | Floating Interest Rate [Member]
Statement Line Items [Line Items]
Financial liabilities
Financial Liabilities at Fair Value Through Profit or Loss [Member] | Fixed Interest Rate [Member]
Statement Line Items [Line Items]
Financial liabilities

Financial Risk Management - S_5

Financial Risk Management - Schedule of Liquidity Risk (Details) (20-F) - AUD ($)	Jun. 30, 2019	Jun. 30, 2018
Disclosure of detailed information about financial instruments [line items]
Financial assets	$ 3,003,963	$ 5,791,923
Financial liabilities	1,005,308	945,130
Net maturity	(1,998,655)	4,846,793
Credit Card Facility [Member] | Liquidity Risk [Member]
Disclosure of detailed information about financial instruments [line items]
Facility limit	95,714
Amount used	(6,516)
Amount available	89,198
Trade and Other Payables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,005,308	945,130
Not Later Than Six Months [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	3,003,963	5,791,923
Financial liabilities	1,005,308	945,130
Net maturity	(1,998,655)	4,846,793
Not Later Than Six Months [Member] | Trade and Other Payables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,005,308	945,130
Later Than Six Months and Not Later Than One Year [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Financial liabilities
Net maturity
Later Than Six Months and Not Later Than One Year [Member] | Trade and Other Payables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities
Later Than One Year and Not Later Than Five Years [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Financial liabilities
Net maturity
Later Than One Year and Not Later Than Five Years [Member] | Trade and Other Payables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities
Later Than Five Years [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Financial liabilities
Net maturity
Later Than Five Years [Member] | Trade and Other Payables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities
Cash At Bank / On Hand [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	2,131,741	5,487,035
Cash At Bank / On Hand [Member] | Not Later Than Six Months [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	2,131,741	5,487,035
Cash At Bank / On Hand [Member] | Later Than Six Months and Not Later Than One Year [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Cash At Bank / On Hand [Member] | Later Than One Year and Not Later Than Five Years [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Cash At Bank / On Hand [Member] | Later Than Five Years [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Trade and Other Receivables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	818,766	301,383
Trade and Other Receivables [Member] | Not Later Than Six Months [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	818,766	301,383
Trade and Other Receivables [Member] | Later Than Six Months and Not Later Than One Year [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Trade and Other Receivables [Member] | Later Than One Year and Not Later Than Five Years [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Trade and Other Receivables [Member] | Later Than Five Years [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Performance Bond and Deposits [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	53,456	3,505
Performance Bond and Deposits [Member] | Not Later Than Six Months [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	53,456	3,505
Performance Bond and Deposits [Member] | Later Than Six Months and Not Later Than One Year [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Performance Bond and Deposits [Member] | Later Than One Year and Not Later Than Five Years [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets
Performance Bond and Deposits [Member] | Later Than Five Years [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) (20-F)	Sep. 23, 2019	Aug. 15, 2019shares	Aug. 14, 2019shares
Collaboration Agreement With Translational Genomics Research Institute Tgen Of Phoenix Arizona USA [Member]
Statement Line Items [Line Items]
Period for collaboration agreement	3 years
Major ordinary share transactions [member]
Statement Line Items [Line Items]
Number of shares representing one share of ADS		600	150
Reverse split ratio		4